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THESIS SUMMARY 
Systemic sclerosis is a connective tissue disease of unknown 
aetiology, characterized by extensive vascular damage and an increased 
deposition of collagen. In addition, various immunological 
abnormalities have also been described in patients with the disease. 
This thesis has provided strong evidence in support of an 
immunologically mediated vascular pathogenesis in systemic sclerosis. 
This has been demonstrated by the occurrence of cytotoxicity of human 
vascular endothelial cells following co-culture with patient sera and 
normal peripheral blood mononuclear cells. Further characterization 
of the serum factor capable of causing endothelial cytotoxicity 
revealed that the responsible serum factor was monomeric IgG and was 
capable of binding to vascular endothelial cells, findings which are 
consistent with the cytotoxic factor being an antibody directed 
against the vascular endothelium. 
Further in vi vo evidence of endothelial cell damage was 
demonstrated by the occurrence of elevated plasma levels of von 
Willebrand factor antigen in patients with systemic sclerosis. In 
addition, the presence of immune abnormalities including a high 
incidence of immune complexes and the occurrence of anticardiolipin 
antibodies was shown, thus emphasizing the autoimmune nature of 
systemic sclerosis. 
Finally, prostacyclin production by cultured vascular 
endothelial cells was investigated, during both 15 minute and 72 hour 
exposure to sera from patients with systemic sclerosis. In contrast 
to previous studies, no significant changes were detected between 
patient and control sera in their effect on endothelial cell 
prostacyclin release. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 
1.1.1 
Systemic sclerosis 
History 
Systemic sclerosis is a disorder characterized by increased 
deposition of collagen in the skin and viscera, including the kidney, 
lungs, heart and gastro-intestinal tract. This developing fibrosis is 
associated with a widespread vasculopathy. Systemic sclerosis may 
exist in a mild form, but progressive visceral involvement, resulting 
in cardiac failure, hypertension, renal disease, pulmonary 
complications and intestinal malabsorption can develop (Rodnan 1979). 
The first convincing description of systemic sclerosis was 
published by Carlo Curzio in 1753. By 1837 there were eight such 
cases in the literature and the condition was termed "Sclerodermie". 
In 1898 Osler wrote "Scleroderma is one of the most terrible of human 
ills. Like Tithanus to wither slowly, and like him to be beaten down 
and maimed and wasted until one is literally a mummy, encased in an 
evershrinking, slowly contracting skin of steel, is a fate not 
pictured in any tragedy, ancient or modern." 
Although many patients were known to die soon after the onset of 
skin changes, the systemic nature of the disease was not appreciated 
until the twentieth century. Eventually, it was generally confirmed 
that scleroderma was the clinical manifestation of a systemic disease, 
and in 1945 Goetz proposed that the term scleroderma be replaced with 
progressive systemic sclerosis (PSS). Many authors, however, have 
chosen to use the term "generalized scleroderma" or "systemic 
sclerosis" (SS) because the course of the disease may show a variable 
pattern and is not necessarily progressive in all cases. While some 
patients show a rapid progressive decline once visceral involvement 
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occurs, other cases show remission of certain components of the 
disease, eg Raynaud's phenomenon, whilst other organs are uninvolved, 
remain stable or progress (LeRoy 1981). 
1.1.2 Epidemiology 
Systemic sclerosis is an uncommon disease with an incidence of 
4.5-12 new cases per million population per year (Kurland et al 1969; 
Medsger & Masi 1971, 1979). The female to male ratio in systemic 
sclerosis is about 3:1. and the average age of onset is 40.3 years, 
with 85% of cases occurring between 20-60 years (Medsger 1985; Gonzale 
1959). Significant racial differences have not been observed and 
different geographical regions do not show an altered incidence of 
systemic sclerosis. (Medsger and Masi 1971; 1978). Reports of familial 
systemic sclerosis remain limited and there is insufficient evidence 
to determine whether systemic sclerosis is an inheritable disorder 
(Medsger 1985). 
Various conflicting reports have been published regarding 
associations between systemic sclerosis and HLA system antigens. There 
appear to be weak associations which may reflect a correlation with 
progression rather than susceptibility to systemic sclerosis (Black et 
al 1985a). The discrepancies noted in such studies may be due to 
regional and/or ethnic differences in patient populations. 
1.1.3 Clinical and pathological features of systemic sclerosis 
1.1.3.1 General 
Patients with systemic sclerosis show fibrosis, atrophy, 
inflammation and vascular defects as principle pathological features 
(Campbell and LeRoy 1975). The fibrosis may be diffuse or patchy, with 
atrophy occurring as an end stage process. Perivascular mononuclear 
inflammatory infiltrates are frequently observed early on in the 
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disease and the vascular lesion has been described as the major 
determinant of patient survival (Norton and Nardo 1970; D'Angelo et al 
1969). 
Most patients with systemic sclerosis present with either 
Raynaud's phenomenon or thickening of the skin on the hands or 
fingers. Raynauds's phenomenon, which consists of episodic digital 
ischaemia provoked by cold and emotion, is seen in approximately 90% 
of patients with systemic sclerosis and may antedate other features by 
months or years (Rodnan 1963). Patients may also present with 
rheumatic complaints with pain and stiffness of the joints and 
muscles, whilst others may develop myositis or visceral 
manifestations. 
1.1.3.2 Cutaneous Involvement (Plates 1, 2, 3 & 4) 
Three stages of cutaneous involvement can be seen in systemic 
sclerosis: (1) oedematous; (2) indurative and sclerotic; and (3) 
atrophic. In the oedematous phase, the skin appears taut and the 
fingers "sausage like". Next, in the indurative phase, the skin 
becomes hard and stiff and bound to the underlying structures. These 
changes may appear in the fingers, dorsa of the hands, forearms, face 
and sometimes the trunk. Finally in the atrophic phase, involved 
fingers become fixed in a claw-like position, and facial telangectasia 
may appear. Eventually, about 3-15 years after the onset of systemic 
sclerosis, the involved dermis may begin to soften and become pliable. 
1.1.3.3 Visceral Involvement 
The Kidney 
Renal disease and hypertension are the major causes of death in 
patients with systemic sclerosis. Renal involvement usually follows 
earlier cutaneous abnormalities. Its presentation may take several 
forms, such as the onset of malignant hypertension followed by acute 
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Plate 1 
The face in systemic sclerosis showing restriction of the mouth 
opening, with the development of radial furrowing and a beak-like 
nose. 
Plate 2 
The hands in systemic sclerosis, showing acrosclerotic changes, 
areas of depigmentation and an ulcerated calcinotic lesion. 
Plate 3 
The hands in systemic sclerosis showing acrosclerotic changes 
and digital ischaemia with resulting absorption of terminal phalanges 
and the loss of digits from previous gangrene. 
loss of renal function and often death within one month (Scleroderma 
Renal Crisis). A second group may show progressive renal failure 
occurring over several months, and a third presentation may be with 
proteinuria and the development of azotaemia. Pathological findings 
in "Scleroderma Kidney" include focal vascular lesions consisting of 
intimal hyperplasia and fibrinoid necrosis of the interlobular and 
smaller arteries. 
The Lung (Plates 5 & 6) 
Pulmonary involvement is frequently seen in patients with 
systemic sclerosis. Abnormal pulmonary function tests and 
radiographic evidence of fibrosis usually precede dyspnoea. Faulty 
gas exchange as revealed by an abnormal carbon monoxide transfer 
factor, together with a decrease in vital and total lung capacity, due 
to fibrosis, may occur. The commonest histological findings are 
interstitial fibrosis and thickening of the alveolar septa, as well as 
pulmonary vascular lesions. 
The Heart 
Myocardial fibrosis and characteristic arterial lesions are the 
principle features of sclerodermatous involvement of the heart with 
resulting ECG abnormalities, arrhythmias and conduction disturbances 
and in severe cases, left ventricular failure. Accompanying pulmonary 
arteriolar lesions and fibrosis can place an added burden on the right 
ventricle leading to the development of cor pulmonale. Pericarditis 
with effusion has also been reported. 
The Gastro-Intestinal Tract (Plate 7) 
Oesophageal involvement and dysfunction is very common in 
systemic sclerosis. Diminished or absent peristalsis due to collagen 
deposition in the lamina propria and submucosa with atrophy of the 
muscularis leads to dysphagia with heartburn. Similar involvement of 
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Plate 4 
Skin in systemic sclerosis. The dermis is thickened due to 
excessive collagen deposition and a small artery in the subcutaneous 
tissues shows sub-intimal proliferative changes. 
Haemotoxylin and eosin x 40 
Plate 5 
Lung in systemic sclerosis. Thickening of the inter alveolar 
septa due to excessive collagen deposition. A pulmonary artery shows 
marked sub-intimal proliferation. 
Haematoxylin and eosin x 60 
Plate 6 Chest xray from a patient with systemic sclerosis showing 
reticular shadowing in the lower part of the lung fields, due to 
pulmonary fibrosis. 
Plate 7 
Barium follow through examination in a patient with systemic 
sclerosis and malabsorption, showing multiple areas of stricture 
formation (and saculation) in the small bowel, due to sclerodermatous 
involvement. 
the remainder of the gastro-intestinal tract may produce symptoms of 
bloating with alternating constipation and diarrhoea. Small bowel 
involvement can lead to bacterial colonisation and overgrowth which 
may contribute to malabsorption. 
1.1.3._ Vascular Involvement (Plate 8) 
Raynaud's phenomenon and telangiectasia are the most obvious 
clinical features of the extensive vascular disease found in patients 
with systemic sclerosis. The resulting digital ischaemia may lead to 
areas of infarction in the finger tips with atrophy, recurrent 
infections and even gangrene. 
Pathologically, the smaller arteries of 150-500 F diameter, show 
the major abnormalities, whilst the large and medium sized are less 
involved (Campbell and LeRoy 1975; Norton and Nardo 1970). The major 
abolition is thickening of the sUb-intimal layer of arterioles, 
leading to narrowing or occlusion of the lumen. The internal elastic 
lamina remains intact and the media is relatively normal or slightly 
thin. The adventitia possesses a fibrous cuff around the artery, in 
which mononuclear cell infiltrates may be seen (Campbell and LeRoy 
1975). 
These charac t eris t ic vas cular abnormali ties of su bint imal 
sclerosis and fibrinoid deposits are most frequently described in the 
pulmonary, renal and digital arteries and arterioles, but are not 
confined to these areas and have been reported in almost every part of 
the arterial bed. As these vascular lesions have not been restricted 
necessarily to areas of fibrosis, some authors have suggested that 
they represent the earliest lesion, preceeding the development of 
sclerosis (Beigelman et al 1953; Campbell and LeRoy 1975; Norton and 
Nardo 1970; Jayson 1983,1984; Postlethai te and Kang 1984). The 
occurrence of Raynaud's phenomenon months or years before the onset of 
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Plate 8 
Artery in systemic sclerosis showing sUb-intimal proliferation 
resulting in marked reduction of the lumen. 
Haemotoxylin and eosin x 100 
other clinical features adds further evidence in favour of the 
vascular bed being the primary site of injury in systemic sclerosis. 
Fibrosis could then occur as a result of alterations induced during 
vascular damage. 
The capillary bed is also widely affected in systemic sclerosis. 
Using in vivo capillary microscopy, Maricq et al (1980) observed 
enlarged and deformed capillary loops, surrounded by relatively 
avascular areas, in the nailfolds of 82% of patients with systemic 
sclerosis. Capillary numbers are severely reduced, resulting in 
extreme devascularisation. (Statham and Rowell 1986; Ranft et al 
1987; Wong et al 1988). The remaining capillaries become dilated with 
thickened walls and endothelial cells may become swollen or necrotic. 
Electron microscopic studies of normal skeletal muscle in 
patients with systemic sclerosis have also revealed marked capillary 
basement membrane changes as well as a decrease in the number of 
capillaries (Norton et al 1968). Thickening and multilayering of 
capillary basement membranes was also noted in electron micrographs of 
labial salivary gland and skin biopsies (Camilleri et al 1984; 
Fleischmajer et al 1976). 
In addition to morphological defects , patients with systemic 
sclerosis also exhibit functional abnormalities of the vascular 
system. These have been demonstrated by arteriography, capillary blood 
flow studies, radioactive tracer clearance, calorific heat loss and 
studies of tissue oxygenation (Maricq 1988). 
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1.2 The pathogenesis of systemic sclerosis 
The pathogenesis of systemic sclerosis is poorly defined. 
However, immunological, and vascular abnormalities with altered 
regulation of fibroblast function could be important. It is probable 
that no single factor accounts for all the features of this disorder 
and evidence will be presented showing that considerable interaction 
between these three areas is involved in the pathogenesis of systemic 
sclerosis. 
1.2.1 Connective tissue involvement 
In considering the pathogenesis of systemic sclerosis, the role 
of connective tissue must not be omitted. Systemic sclerosis is a 
disease which is characterised by over-production of collagen. This 
process results in the deposition of dense acellular connective tissue 
which irreversibly impairs the function of involved organs. The 
structure and function of connective tissue is determined by proteins 
such as collagen, fibronectin and proteoglycans, and the cells 
producing these substances. The synthesis, degradation and deposition 
of these proteins is altered in systemic sclerosis, but whether this 
occurs as a primary or secondary disease process is unresolved. 
Accelerated in vitro growth of normal and scleroderma fibroblasts 
by a mitogenic factor present in the sera of patients with systemic 
sclerosis has been described (Potter et al 1985). In addition, an 
increase in the biosynthetic activity of fibroblasts associated with 
sclerodermatous lesions has been shown to result in increased 
production of collagen and glycosaminoglycans (Buckingham et al 1985). 
The presence of activated cells synthesising connective tissue 
may be due to direct stimulation of cells in the area of the lesion. 
Alternatively, chronic suppression of less active cells may occur, 
resulting in "selective" accumulation of more actively synthetic 
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cells. In favour of this second hypothesis, Kahaleh and LeRoy (1986) 
showed the selective appearance, in vi tro, of a high collagen 
producing subset of fibroblasts as a result of prolonged culture in 
sera from patients with systemic sclerosis. Thus they deduced that a 
mitogenic factor in these sera may alter the phenotype of fibroblasts, 
resulting in the appearance of a population of fibroblasts producing 
high amounts of collagen. 
As well as increased production of collagen, a decrease in its 
breakdown, for example by collagenase, may occur in systemic sclerosis 
(Brady 1975). In addition, reduced production of inhibitory mediators 
may allow mitogenic factors to induce unrestricted fibroblast 
proliferation (Duncan et al 1984). 
Various substances, such as lymphokines, monokines and various 
platelet derived factors, have been shown to stimulate fibroblast 
proliferation. Thus, vascular endothelial cell damage, however 
produced, could result in platelet aggregation following the exposure 
of collagen in damaged vessel walls. The resulting release of 
platelet derived factors could then act on the exposed subendothelium 
and initiate fibroblast proliferation with an increase in collagen 
biosynthesis, leading to fibrosis. Transforming Growth Factor ~ 
(TGF~) is released during thrombin induced degranulation of platelets 
(Assoian and Sporn 1986) and has been shown to stimulate collagen and 
fibronectin formation in cultures of fibroblasts (Roberts et al 1986; 
Ignotz & Massague 1986). In addition, TGFp is a chemoattractant for 
human monocytes and has been shown to stimulate production, by 
monocytes, of biologically active mediators which enhance fibroblast 
growth (Wahl et al 1987). Tumour Necrosis Factor ex (TNFoc.) has also 
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been shown to stimulate the growth of cultured fibroblasts and can 
stimulate endothelial cells to produce Interleukin 1 which can also 
act as a fibroblast mitogen (Nawroth et al 1986; Schmidt et al 1982). 
Thus it appears that there is a complex interplay between several 
different cell types and their secretory products, disturbances of 
which,for example by endothelial cell injury, could lead to the 
fibrosis which is such a characteristic feature of systemic sclerosis. 
1.2.2 Immune pathogenesis 
An immune basis for the pathogenesis of systemic sclerosis is 
suggested by the occurrence of features shared with other diseases of 
autoimmune aetiology. Thus, occasionally, systemic sclerosis may show 
"overlap" or clinical association with SLE, polymyositis, or Sjogren's 
syndrome (Tuffanelli & Winkelmann 1962). Marked autoanti body 
formation and abnormalities of cell-mediated immunity are features of 
all these diseases and are also prevalent in systemic sclerosis 
(Maddison 1988; Postlethwaite & Kang 1988). 
The appearance of scleroderma-like skin disease in some 
recipients of HLA-identical allogeneic bone marrow transplants with 
graft-versus-host disease, would suggest that systemic sclerosis may 
be an autoimmune dis ease (Clements et al 1985) • Patients wi th 
graft-versus-host disease show many cutaneous, pulmonary, renal, 
musculoskeletal and vascular abnormalities which are strikingly 
similar to those seen in systemic sclerosis (Clements et al 1985; 
Herzog et al 1980). Graft-versus-host disease, whether in the human 
transplantation patient, or when experimentally induced in the rat, 
thus offers a model for the further investigation of the immune 
abnormalities in systemic sclerosis (Stastny et al 1963) 
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The perivascular infiltrates of lymphocytes, plasma cells and 
macrophages frequently found in the skin and other affected tissues 
provide further histological evidence for an immune pathogenesis of 
systemic sclerosis. 
1.2.2.1 Humoral immune abnormalities 
Numerous investigators have demonstrated humoral immune 
abnormalities in systemic sclerosis. These include the presence of 
hypergammaglobulinemia, cryoglobulinemia, a wide range of autoan-
tibodies including, antinuclear and antinucleolar antibodies, 
rheumatoid factor, antibodies directed against collagen, mitochondria, 
lymphocytes and endothelium, and, in addition, raised levels of 
circulating immune complexes (Bernstein et al 1982; Rodnan 1979; 
Mackel et al 1982; Fregeau et al 1988; Pruzanski et al 1982; Hashemi 
et al 1987 & Hughes et al 1983) 
(i) Autoantibodies 
It has long been recognised that anti-nuclear antibodies are 
present in the sera of patients with systemic sclerosis. The reported 
frequencies have shown a wide range from 40-90% (Tan 1982). These 
variations are probably due to the use of different methods of 
detection. In more recent studies, the use of cultured cells as 
substrates and the avoidance of certain fixatives such as methanol and 
ethanol, has revealed that anti-nuclear antibodies occur in 
approximately 95% of patients with systemic sclerosis (Bernstein et al 
1982; Moroi et al 1980) 
Bernstein et al (1982) have demonstrated, by indirect immuno-
flourescence, anti-nuclear and/or anti-nucleolar antibodies in the 
sera of 97% of patients with systemic sclerosis, using cultured HEP-2 
cells as substrate. As in SLE, various flourescent patterns can be 
seen, reflecting the diversity of anti-nuclear antibodies present. 
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Typical nuclear staining patterns in systemic sclerosis are 
centromere, fine and coarse speckles, diffusely grainy, homogeneous 
and nuclear dots. Three nucleolar staining patterns occur:- speckled; 
homogeneous; and clumpy; (Bernstein et al 1982). 
The centromere pattern of staining is present in 31% of patients 
with systemic sclerosis (Moroi et al 1980). The responsible 
autoantibody has been shown, by immuno-electron microscopy, to be 
reactive with the inner and outer plates of the kinetochore (Brenner 
et al 1981). Clinical studies have revealed that the antikinetochore 
antibody occurs in patients with the CREST syndrome, characterised by 
calcinosis, Raynaud's phenomenon, eosophageal dysmotility, 
sclerodactly and telangiectasia (Steen et al 1984; Fritzler et al 
1980; Chen et al 1985). 
The use of rabbi t and calf thymus extracts and immunodiffusion 
analysis has lead to the identification of various precipitating 
antibodies in systemic sclerosis. Douvas et al (1979) showed that 
precipitating antibodies to a 70,000 Kd soluble extractable nuclear 
antigen known as ScI 70, are highly specific for systemic sclerosis. 
However, this antibody is only present in 20-25% of patients with 
systemic sclerosis, and it correlates with the diffusely grainy 
pattern of nucleoplasmic staining. The Scl-70 antigen has since been 
shown, by using SDS PAGE and immunoblotting with anti Scl-70 positive 
sera, to be topoisomerase 1, with a molecular weight of 100,000 Kd 
(Shero 1987). 
Antibodies to Scl-70 are more frequent in patients with diffuse 
systemic sclerosis than those with the CREST syndrome, and they appear 
to identify those patients with more severe skin, joint and lung 
involvement (Powell et al 1984). Livingston et al (1987), 
demonstrated the occurrence of Scl-70 in patients with generalised 
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disease and they showed an association between HLA-DR2 and Scl-70 
positive patients, suggesting a genetic-serologic clinical subset of 
patients. 
In addition to Scl-70 and antikinetochore antibodies which are 
specific for systemic sclerosis, other precipitating antibodies may 
occur in this disease. Anti RNP, anti Ro and anti La, which may 
commonly occur in SLE, may also be seen in patients with systemic 
sclerosis (Harmon 1985; Bernstein et al 1984). Patients with systemic 
sclerosis/polymyosi tis overlap syndromes show various specific 
autoantibody systems, including anti Ku and PM-ScI (Mimori et al 1981; 
Reichlin et al 1985). These and other antigen-antibody systems 
occurring in overlap syndromes await biochemical characterisation 
(Maddison 1988) 
Auto-antibodies directed against other antigens have also been 
detected in patients with systemic sclerosis and antibodies to type I, 
III and IV collagen have been detected (Mackel et al 1982, Black et al 
1985b). In addition, antibodies directed against smooth muscle cells 
and cell surface and nuclear antigens on cultured rat embryonic 
fibroblasts have also been detected (Kitridou et al 1974, Brentnall et 
al 1982). Furthermore, recent studies have produced evidence that the 
sera of patients with systemic sclerosis also contain antiendothelial 
cell antibodies (Hashemi et al 1987; Baguley et al 1987a ; Byron et al 
1987) 
Thus, it is evident that considerable reactivity towards 
autologous cellular antigens occurs in systemic sclerosis. Although 
the cause of the vascular damage present in systemic sclerosis is 
unknown, it is possible to hypothesize that an antibody response 
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towards autologous endothelium may be partly responsible. Exposure of 
the basement membrane following endothelial injury could then initiate 
a further antibody response to autologous collagen. 
(ii) Immune Complexes 
Immune Complexes are formed by the non-covalent binding of 
antigen and antibody. They are normally cleared from the circulation 
either by interaction with Fc Receptors on circulating or organ 
associated phagocytic cells, or via activation of the complement 
system, followed by their phagocytic removal. Complexes which are not 
removed from the circulation may deposit on vessel walls, activate 
various effector systems and subsequently induce tissue damage. 
Immune complexes have been reported in many connective tissue 
diseases including SLE and Sjogrens syndrome and immune complex 
deposits have been described in scleroderma kidney (McGiven et al 
1971). The presence of variable levels of circulating immune complexes 
in patients with systemic sclerosis has been demonstrated by numerous 
authors. This variability has been explained by the use of different 
immune complex assays, which detect complexes by different physical or 
immunological properties (Siminovich et al 1982). For instance the 
Raji cell method detects immune complexes which will bind to Fc 
receptors on the Raji cells whereas the C1q binding assay detects 
complexes containing immunoglobulin which is capable of fixing 
complement. Thus, in any study on the levels of circulating immune 
complexes, it is important that several different assay systems are 
employed in the determination. However, an alternative explanation for 
widely varying results may be differences in the patient sub-groups 
studied (French et al 1985). 
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Low levels of immune complexes have been reported by various 
authors. Siminovich et al (1982), using fluid and solid phase C1q 
binding assays, C1 activation and the fluid phase conglutin assay, 
detected immune complexes in only six out of forty one patients with 
systemic sclerosis. In a smaller study of eight patients, SoIling et 
al (1979), tested C1q binding, polyethylene glycol precipitable light 
chain determinants and a complement consumption assay. They showed 
only one patient to be positive in any two of the three assays. 
O'Loughlin et al (1980), found no evidence of elevated immune 
complexes in ten patients with systemic sclerosis using the C1q 
binding method. 
In contrast to these studies, high levels of circulating immune 
complexes have been demonstrated when generally larger samples have 
been investigated. An early study by Pisko et al (1979), using the 
Raji cell radio immunoassay, showed that seven of sixteen patients had 
elevated levels of circulating immune complexes. Swierczynska et al 
(1984), using an immunoelectrophoretic method of determination, showed 
that eighteen of twenty nine of patients with systemic sclerosis had 
elevated levels of immune complexes. 
Later studies have combined various methods of immune complex 
determination. Cunningham et al ( 1980) used fi ve different 
methods: decreased haemolytic complement, C1q precipitins, 
cryoglobulins, Raji cell radioimmunoassay and C1q binding. Twelve of 
twenty patients (60%) showed immune complexes by at least one method 
of determination. Similar levels of immune complexes were demonstrated 
by Hughes et al (1983) using fluid phase C1q binding, K cell 
inhibition and Raji cell radioimmunoassay. Twenty of thirty four 
(58.5%) showed a positive result in one or more tests. Chen et al 
(1984) studied forty one patients with systemic sclerosis and found 
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that nineteen (46%) showed immune complexes by either C1q or Protein A 
binding assays. A large study of ninety two patients with systemic 
sclerosis was carried out by Seibold et al (1982). Abnormal results 
were found in forty three patients (47%), using Raji cell radio-
immunoassay, agarose gel electrophoresis and C1q binding assays. 
Haustein and Herman (1985) examined seventy four patients for 
circulating immune complexes by polyethylene glycol precipitation and 
C1q binding, 31% of patients were again positive in both tests. 
The Raji cell determination for immune complexes has produced the 
largest number of positive tests: Haustein and Herman (1985) 78%; 
Seiebold et al (1982) 72%; Pisko et al (1979) 44%; Cunningham et al 
( 1 980) 55%; and Hug he set al (1 9 8 3 ) 38% • It is possible that 
antilymphocytic antibody can give rise to false positive results in 
the Raji cell radioimmunoassay (Anderson & Stillman 1980). However, 
other methods of immune complex determination in which the presence 
of anti lymphocytic antibodies will not produce false positive 
results, have shown significantly elevated levels of circulating 
immune complexes in patients with systemic sclerosis. 
Several authors have reported an association between organ 
involvement and the presence of circulating immune complexes. An 
association between elevated immune complexes and abnormal 
echocardiograms was found by Pisko et al (1979). Hughes et al (1983) 
demonstrated that the presence of immune complexes in patients with 
systemic sclerosis correlated with extensive visceral involvement and 
Siminovich et al (1982) showed that there was a significant 
correlation between immune complexes and lung involvement in systemic 
sclerosis. This pulmonary association was also noted by Seibold et al 
(1982). The immune complex positive patients studied by Chen et al 
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(1984) had higher frequencies of kidney, heart and muscle involvement 
and digital ulceration, compared to those with no detectable immune 
complexes. 
Thus, there is good evidence that patients with systemic 
sclerosis have increased levels of circulating immune complexes, which 
may well be formed by the union of autoantibodies and released 
cellular antigens. A relationship between immune complexes and 
precipitating antibodies to ScI 70, nRNP, Ro and La in the sera of 
patients with systemic sclerosis has been demonstrated (French et al 
1985). The relevance of these immune complexes to the pathogenesis of 
systemic sclerosis remains unclear. However, there is evidence that 
they may be deposited in the walls of diseased blood vessels, and they 
also have the potential to interact with Fc receptors on platelets and 
effector cells (Penttinen 1977). Hence, immune complexes may be 
partly responsible for some of the pathological features of systemic 
sclerosis. 
(iii) Cytokines 
In addition to the direct effect of the cells of the immune 
system, various cytokines secreted from these cells may playa vital 
role in the pathogenesis of systemic sclerosis. Mononuclear cell 
infiltrates are frequently seen in the skin and it is possible 
therefore that monokines and lymphokines released during cell mediated 
immune reactions may be important in the fibrotic processes occuring 
at these sites in patients with systemic sclerosis. In addition, 
antigen or mitogen stimulation of mononuclear cells may release 
monokines and lymphokines which have been shown to be capable of 
modulating fibroblast function, such as collagen and collagenase 
production and fibroblast chemotaxis. 
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Postlethwaite and Kang (1985) have described a lymphocyte derived 
chemotactic factor for fibroblasts, and a mononuclear cell derived 
mitogenic factor for fibroblasts. In addition, these authors have 
demonstrated that Interleukin-1 from monocytes stimulates collagenase 
production and that fibroblast derived collagen production can be 
stimulated by a lymphokine. Further support for this concept has been 
presented by Perlish and Fleischmajer (1985) who showed that normal 
cultured fibroblasts showed increased synthesis of collagen following 
exposure to mononuclear cells from patients with systemic sclerosis. 
Such an effect was not seen with mononuclear cells obtained from 
normal and control donors. 
More recent studies have shown a decreased production of 
Interleukin-1 by peripheral blood mononuclear cells of patients with 
systemic sclerosis compared to those from normal controls (Whicher et 
al 1986, Sandborg et al 1986). Sandborg et al have also demonstrated 
increased production, by mononuclear cells in systemic sclerosis, of 
an interleukin-1 inhibitor which has fibroblast stimulating activity. 
The precise mechanisms involved in cytokine regulation of the 
cellular immune system and their effect on fibroblast activities 
remain unresolved. Further investigation is required before their 
role in the fibroblast proliferation and excess collagen production 
seen in patients with systemic sclerosis can be defined. However, it 
appears likely that cytokines contr ibute in some way to the 
pathogenesis of this disease. 
1.2.2.2 Cellular immune abnormalities 
As cellular immune abnormalities are common in SLE and other 
autoimmune diseases, several investigators have studied the cellular 
immune system in patients with systemic sclerosis. Thus, it has been 
found that patients have decreased numbers of peripheral T lymphocytes 
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but normal levels of circulating B lymphocytes (Hughes et al 1976; 
Bakke et al 1985). The reason for the reduction in T cell number 
remains unknown, but may be due to the accumulation of these cells in 
the skin and viscera, especially in perivascular areas (Whiteside et 
al 1985a). 
Functional activities of T cells from patients with systemic 
sclerosis have also been studied, often with conflicting results. T 
cell responses to phytohaemagluttinin have been reported as depressed 
(Hughes et al 1977) and normal (Alarcon-Segovia et el 1985; Whiteside 
et al 1985b). These discrepancies are probably due to the purity of 
cell preparations and variations in the patient populations studied. 
Immunoregulatory function has also been studied in these 
patients, by measuring T Helper and T Suppressor cell functions. T 
Helper cell function has been shown to be elevated in studies 
utilising pokeweed mitogen stimulated B cells (Alarcon-Segovia 1985). 
This may be due to a decrease in suppressor cell numbers, as is 
suggested by studies which have used monoclonal antibodies directed 
against the CD4 and CD8 markers of T helper and T suppressor/cytotoxic 
cells (Whiteside et al 1983; Keystone et al 1982). However the use of 
these markers to distinguish helper and suppressor populations of T 
cells remains controversial. 
Patients with systemic sclerosis have been shown to have cellular 
immunity to various autoantigens including collagen, fibroblasts and 
muscle cells and other undefined antigens. A proliferative response 
of lymphocytes from patients with systemic sclerosis has been 
demonstrated following exposure to connective tissue, muscle, skin, 
and normal human and chick type I collagen (Currie et al 1970; Kondo 
et al 1979; Stuart et al 1976). Furthermore, lymphocytes from 
patients with systemic sclerosis have been found to be cytotoxic to 
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cultured fibroblasts, epithelial cells and myocytes (Currie et al 
1970). However, Kondo et al (1979) f 
ailed to confirm these 
observations. Wright and colleagues also showed no cytotoxicity 
against epithelial and fibroblastic cell lines. These authors studied 
spontaneous and phytohaemogluttinin induced cytotoxicity and observed 
a decrease in cytotoxicity against Chang liver cells which correlated 
with disease severity (Wright 1979 & Wright et al 1978 1979 1982) 
. , , , . 
However, of greater pathological interest is the ADCC produced by 
normal human peripheral blood mononuclear cells in the presence of 
sera obtained from patients with systemic sclerosis. This type of 
cytotoxicity has been demonstrated against target cells obtained from 
various cell lines, and more recently against vascular endothelium, 
with sera from patients with both systemic sclerosis and SLE (Penning 
et al 1983, 1984a, 1984b, 1984c, 1985; Wright et al 1983). It is 
likely that this mechanism is responsible for some of the vascular 
damage which occurs in patients with systemic sclerosis. In this 
thesis the ADCC against vascular endothelium, occurring in patients 
with systemic sclerosis, will be further characterised with the aim of 
identifying the serum factor responsible for inducing cytotoxicity. 
In addition to abnormalities of mononuclear cell mediated 
immunity, recent work has suggested that polymorphonuclear neutrophils 
may playa role in the pathogenic mechanisms occurring in systemic 
sclerosis. Oxygen radicals released from stimulated neutrophils have 
been shown to damage the vascular endothelium in vitro (Weiss et al 
1981; Sacks et al 1978; Varani et al 1985). Maslen et al (1987) have 
demonstrated that "resting" neutrophils from patients with systemic 
sclerosis secrete increased levels of peroxide in vitro, compared to 
normal control cells. An increase in the basal chemiluminmescence 
activity of neutrophils from patients with systemic sclerosis has also 
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been shown (Czirjak et al 1987). It is possible, therefore, that the 
impaired function of neutrophils thus demonstrated in patients with 
systemic sclerosis could give rise to some of the vascular damage that 
is a prominent feature of this disease. In addition, neutrophils 
possess receptors for the Fc region of IgG and therefore could act as 
effector cells mediating tissue damage by ADCC. 
1.2.3 The vascular hypothesis as a pathogenic mechanism 
Vascular abnormalities are a prominent feature in the pathology 
of systemic sclerosis. It is well established that proliferative 
intimal arterial lesions and obliterative microvascular defects are 
common in the disease. The distinctive vascular pathology occurring in 
systemic sclerosis, together with the frequent occurrence of peri-
vascular mononuclear infiltrates, have lead several authors to 
hypothesise that the vascular system is the primary site of injury in 
systemic sclerosis (Campbell and LeRoy 1975; Norton and Nardo 1970). 
Further support of this hypothesis comes from the frequent early 
occurrence of Raynaud's phenomenon in up to 98% of patients with 
systemic sclerosis (Rodnan 1963; Rowell 1988). 
Numerous authors have looked for evidence of vascular dysfunction 
in systemic sclerosis. Most of these studies have been directed 
towards the vascular endothelium. Endothelial cell damage, and 
defects in the production and release of various endothelial cell 
products, such as von Willebrand factor antigen and prostacyclin, are 
possible indicators of mechanisms giving rise to vascular injury in 
systemic sclerosis. 
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1.2.3.1 Von Willebrand factor antigen and its related activities 
Von Willebrand factor antigen is produced by endothelial cells 
and elevated levels of this factor have been proposed as a marker of 
endothelial cell damage (Woolf et al 1987; Nusinow et al 1984). Raised 
plasma levels have been demonstrated following vascular injury and in 
a variety of clinical conditions often in association with vascular 
disease. These diseases include diabetes mellitus with proliferative 
retinopathy, severe atherosclerosis, and renal failure (Coller et al 
1978; Green et al 1978; Warrel et al 1979). 
Raised circulating levels of von Willebrand factor antigen have 
been observed in patients with systemic sclerosis, as has ristocetin 
co-factor, which is the functionally active component of Factor VIII 
(Kahaleh et al 1981; Pagano et al 1986; Lee et al 1985). However, it 
has been suggested that von Willebrand Factor antigen may participate 
in acute phase resposes so great care is needed in interpreting 
studies based solely on measurements of the factor VIII complex alone 
(Paleolog et al 1987). 
1.2.3.2 Disorders of the coagulation system 
Abnormalities of the coagulation system may well playa role in 
the development of lesions in systemic sclerosis. Endothelial cell 
damage, however it is caused, may be one factor leading to platelet 
aggregation, through the exposure of collagen in blood vessel walls. 
This would result in the release of ~ thromboglobulin, transforming 
growth factor ~ and serotonin, which would then be free to act on the 
exposed subendothelium. In addition, arachidonic acid, cAMP and 
endoperoxides may also be released following platelet degranulation 
and these could be utilised in the production of prostacyclin by 
endothelial cells. Increased circulating levels of platelet 
aggregates and ~ thromboglobulin have been detected in patients with 
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systemic sclerosis, confirming some degree of in vivo platelet 
activation (Kahaleh et al 1982). P Thromboglobulin has been shown to 
inhibit the production of prostacyclin in cultured bovine endothelium 
(Hope et al 1979). Since prostacyclin is a potent platelet 
disaggregating agent, inhibition of its release could further 
contribute to the vascular endothelial cell dysfunction occurring in 
patients with systemic sclerosis. 
In add it ion, plasminogen ac ti va tor, a subs tance which is 
important in the initiation of fibrinolysis, is derived mainly from 
vascular endothelial cells. Endothelial cell damage may therefore be 
followed by a fall in plasminogen activator levels and a corresponding 
reduction in fibrinolysis leading to fibrin deposition. Impairment of 
fibrinolysis has been demonstrated in patients with systemic sclerosis 
by measurements of the euglobulin clot lysis time (Holland & Jayson 
1985; Kahaleh & Leroy 1985). Prolongation of this time indicates a 
decrease in fibrinolytic activity, and possibly reflects a reduction 
in the release of plasminogen activator. Holland & Jayson (1985) also 
showed increased levels of plasma fibrinogen in patients with systemic 
sclerosis. Thus, impairments of the fibrinolytic system in systemic 
sclerosis offers additional indirect support for the occurrence of 
vascular endothelial damage in the pathogenesis of this disease. 
1.2.3.3 Endothelial cell injury 
The widespread occurrence of vascular lesions in patients with 
systemic sclerosis, together with ultrastructural studies of affected 
endothelium, showing swelling, separation of endothelial cell tight 
junctions and detachment of cells, has led many authors to examine the 
effect of sera from patients on endothelial cell growth and viability 
in vitro. 
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Kahaleh et al (1978,1979) were the first investigators to 
describe specific endothelial cell cytotoxic activity, as assessed by 
depressed tritiated thymidine incorporation and a dye exclusion 
microcytotoxicity assay. This in vitro endothelial cell injury was 
blocked by protease inhibitors, and immunoglobulin and complement did 
not appear to be essential for its activity. Levels of Kahaleh's 
endothelial cell specific cytotoxic activity fluctuated and did not 
always correlate with disease activity. Furthermore, when serum from 
one patient was tested on endothelial cells derived from eight 
different primary cultures, the degree of inhibition of tritiated 
thymidine uptake varied from 10-91 % indicating differences in 
endothelial cell susceptibility to this toxic factor. A more recent 
report by Kahaleh et al (1988) describes the presence of lymphotoxin 
in the sera of some patients with systemic sclerosis, and they suggest 
that endothelial cell injury may be mediated by activated T 
lymphocytes through the production of lymphotoxin. 
Since this original report, various authors have carried out 
similar studies with conflicting results. Shanahan and Korn (1982) 
found that serum-mediated endothelial cell cytotoxicity occurred in 
only 7% of twenty eight sera from patients with systemic sclerosis, 
shown by an inhibition of tritiated thymidine incorporation, or 
51chromium release, in cultured human umbilical vein endothelial 
cells. These authors also found that cytotoxicity of endothelial 
cells occurred in other connective tissue diseases such as SLE and 
rheumatoid arthritis, and it lacked specificity in that it also 
occurred with fibroblasts. A similar lack of target cell specificity 
was observed by Cohen at al (1983) who showed that 40% of sera from 
patients with systemic sclerosis were cytotoxic towards pulmonary 
arterial and human umbilical vein endothelial cells, foreskin 
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fibroblasts and neuroblastoma cells. Meyer et al (1983) also 
described lack of disease and target cell specificity by the cytotoxic 
factor occurring in the sera of patients with systemic sclerosis which 
was originally described as being specific for endothelial cells 
(Kahaleh et al 1978,1979). Cohen et al (1983) demonstrated inhibition 
of tritiated thymidine incorporation in fibroblast as well as human 
umbilical vein endothelial cell cultures, by sera from seven of thirty 
patients with systemic sclerosis. The cytotoxic serum factor was also 
demonstrated in patients with SLE, mixed connective tissue disease, 
Raynaud's phenomenon and rheumatoid arthritis. A more recent report by 
Deicher et al (1987) descri bed a small molecular weight endothelial 
cell cytotoxic activity in the sera of patients with systemic 
sclerosis, which consisted of leukotriene B4 bound to a 5 kd carrier. 
These authors have since described an endothelial cytotoxic factor 
which was capable of reducing endothelial cell migra tion and 
fibronectin production in vitro, and when the factor was injected into 
rabbits it caused a significant increase in serum levels of von 
Willebrand factor antigen (Drenk & Deicher 1988). However, Summers et 
al (1984) found no evidence of cytotoxicity in sera from patients with 
systemic sclerosis, using both tritiated thymidine incorporation and 
cellular ATP levels to assess cell growth. These conflicting 
observations have been put into context by a more recent suggestion 
that the cytotoxic factor may be an artifact produced by the oxidation 
of lipoproteins occurring during the storage of serum (Blake 1985). 
In contrast to any possible protease dependent serum-mediated 
endothelial cell cytotoxicity, Penning et al (1984a,b) reported that 
IgG containing fractions of sera from patients with systemic sclerosis 
were capable of producing cytotoxicity of cultured human umbilical 
vein endothelial cells, when co-cultured with normal peripheral blood 
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mononuclear cells. Cytotoxicity of this nature, which was first 
described by Moller in 1965, is known as antibody dependent cellular 
cytotoxicity (ADCC). The ADCC described by Penning et al (1984a) 
tended to occur in patients with both circulating immune complexes and 
antibodies to nuclear and cytoplasmic antigens, and it correlated with 
extensive visceral disease. 
Further evidence suggesting the occurrence of immune mediated 
vascular damage in systemic sclerosis, is the recent finding of 
antibodies directed against the vascular endothelium. These 
antibodies have been detected by various techniques in patients with 
various autoimmune diseases, including systemic sclerosis and SLE, and 
it is possible that they may be responsible for the ADCC reported by 
Penning et al (1984a). Cormane et al (1979) eluted antiendothelial 
cell antibodies from the circulating lymphocytes of patients with 
systemic sclerosis and immunoblotting techniques have revealed 
reactivity against endothelial cell nuclei in the sera of 22% of these 
patients (Alderuccio et al 1986). More recently, antiendothelial cell 
antibodies have been detected in the sera of patients with systemic 
sclerosis by an enzyme linked immunoabsorbent assay (ELISA) (Hashemi 
al 1987; Baguley et al 1987a; and Byron et al 1987). In addition, 
antiendothelial cell antibodies have also been detected in sera from 
patients with SLE (Shingu & Hurd 1981; LeRoux et al 1986; Cines et al 
1984). 
Thus it is well established that antiendothelial cell antibodies 
occur in autoimmune disease and it is possible that they may play an 
important role in the pathogenesis of the vascular lesions of systemic 
sclerosis. 
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1 • 3 SUllllllary 
Although the pathogenesis of systemic sclerosis is undefined, a 
vast amount of evidence suggests that interaction of immunological 
abnormalities with the vascular system is important in producing the 
fibrosis which is such a prominent feature of the disease. 
Whilst cellular immune abnormalities have been demonstrated in 
systemic sclerosis, their role in the pathogenesis of the disease is 
unclear. However, the vascular lesion occurring in systemic sclerosis 
is a prominent feature and is likely to result from endothelial cell 
damage. Various humoral abnormalities occurring in systemic sclerosis 
could be responsible for this endothelial cell damage. A diversity of 
autoanti bodies and elevated levels of immune complexes are known to 
occur in this disease. Both autoantibodies, especially antiendothelial 
cell antibodies, and immune complexes could initiate endothelial cell 
damage, either by activation of the complement system, or by 
interaction with Fc receptor bearing cells to produce ADCC. 
Endothelial cell damage, however it is caused, would result in 
exposure of collagen in the subendothelium, which could then initiate 
platelet activation and aggregation. Moreover, altered endothelial 
cell metabolism due to cell damage could cause an inbalance of 
prostacyclin levels which would predispose to further aggregation of 
platelets. Following aggregation, factors of platelet origin would be 
able to act on the exposed subendothelium to initiate fibrosis. In 
addition, other substances such as cytokines, released from 
perivascular infiltrates, could also be important in stimulating the 
fibrosis found in systemic sclerosis. 
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1.4 Systemic lupus erythematosus 
In this thesis, SLE will be studied in parallel with systemic 
sclerosis as an additional disease group. Klemperer et al (1942) 
originally classified SLE and systemic sclerosis together as diffuse 
collagen diseases. These two diseases frequently show over lap 
features and common clinical manifestations, such as fibrinoid 
necrosis in blood vessels and the frequent involvement of internal 
organs. They also show similar immunological abnormalities with a 
high incidence of both autoantibodies of various types, and 
circulating immune complexes. While SLE has been described as "the 
autoimmune disease par excellence" (Burnet 1976) evidence has 
accumulated in the last ten years that systemic sclerosis has as 
florid immunological abnormalities comparable with those occurring in 
SLE. 
It is possible therefore, that common pathogenic mechanisms may 
be responsible for some of the shared features of the two diseases, a 
possibility that provides a case for studying systemic sclerosis and 
SLE in parallel. 
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1.5 Aims of the present study 
Systemic sclerosis is a connective tissue disease characterised 
by extensive vascular damage (Norton & Nardo 1970). The endothelium 
has been described as grossly abnormal in patients with systemic 
sclerosis, at sites of vascular lesions and endothelial cells may 
appear thickened and separated from one another with a decrease in 
sites of cell to cell contact. In addition, some blood vessels may 
exhibit areas which have been totally denuded of endothelial cells. 
In addition to the occurrence of vascular defects in patients 
with systemic sclerosis, various immunological abnormalities have also 
been reported. These include abnormalities in the cellular immune 
system, and the occurrence of immune complexes and autoantibodies 
(Maddison 1988; Postlethwaite & Kang 1988). Systemic sclerosis 
therefore shows many of the features exhibited by the related 
autoimmune connective tissue disease of SLE, in which pathogenic 
mechanisms are clearly defined. 
The aim of this study, therefore, was to determine possible ways 
in which endothelial damage might be produced and thus lead to the 
development of vascular disease in systemic sclerosis. 
In this study, ADCC of endothelial cells was investigated in an 
in vitro system, to confirm the previous findings of Penning et al 
(1983, 1984a, 1984b). It is likely that ADCC may be an important 
pathogenic mechanism accounting for the vasculopathy observed in 
patients with systemic sclerosis. Further characterisation of the 
ADCC mediating serum factor was then carried out and linked with 
experiments to determine if an antibody directed against the 
endothelium was responsible for mediating ADCC in patients with 
systemic sclerosis. 
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To confirm the occurrence of endothelial damage, in vivo plasma 
levels of von Willebrand factor antigen, which is released by damaged 
endothelium, were determined in patients with systemic sclerosis 
(Woolf et al 1987; Nusinow et al 1984). 
In addition, the presence of other autoimmune phenomenon capable 
of affecting endothelium, ie circulating immune complexes and 
anticardiolipin antibodies have been investigated. Both these 
immunological abnormalities are found in patients with SLE and their 
occurrence in systemic sclerosis would further emphasize the 
autoimmune nature of this disease. 
Finally, the synthesis of prostacyclin by cultured endothelial 
cells, following incubation with sera from patients with systemic 
sclerosis was investigated to determine if a prostacyclin imbalance 
might be responsible for the increase in platelet activation which has 
been shown to occur in patients with systemic sclerosis. 
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CHAPTER 2 
VASCULAR ENDOTHELIAL CELL CULTURE 
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2.1 
2.1.1 
Materials 
Sterilization procedures 
All tissue culture procedures were performed in a class II 
laminar flow microbiological safety cabinet. Aseptic technique was 
observed for all manoeuvres. All glassware, water, gelatin solutions, 
millipore filters and Gilson pipette tips were sterilized by 
autoclaving for 20 minutes, at 1200 C and 15 psi. Pasteur pipettes and 
instruments were sterilized by heat treatment at 1600 C for 120 
minutes. Heat sensitive solutions such as sodium bicarbonate and 
collagenase were sterilized by passage through a millipore filter, 
0.22 pm pore size. Culture media were sterility tested prior to use 
by placing 1ml into 10mls thioglycolate solution and incubating the 
mixture at 370 C for 24 hours. 
2.1.2 Glass distilled water 
All reagents and media for tissue culture use were made up in 
"Ultra Pure" water. Glass distilled water was purified in an Elga 
water purification system and sterilized by autoclaving. 
2.1.3 Tissue culture media 
Minimum Essential Medium (MEM) used for the collection of cords 
was obtained in the "AUTOPOW" form and made up as follows:-
MEM (AUTOPOW) 
Ultra Pure Water 
Sodium Bicarbonate (22g/l) 
1 M HEPES Buffer 
Penici~lin 
Streptomycin 
Fungizone 
105 
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9.59g 
940ml 
40ml 
20ml 
units 
100mg 
2.5mg 
M199 for the culture of human umbilical vein endothelial cells 
was obtained as a 10X concentrate and made up as fOllows:-
2.1.4 
M199 ( 10X concentrate) 
Ultra Pure Water 
Sodium Bicarbonate (22g/l) 
L-Glutamine (200mM) 
Penicillin 
Streptomycin 
Fungizone 
Conditioned medium 
105 
100ml 
790ml 
100ml 
10ml 
units 
100mg 
2.5mg 
B16 conditioned medium was used as a growth supplement for human 
umbilical vein endothelial cells grown in T75 flasks. A mouse 
melanoma cell line (B16) was grown in T75 flasks and fed every three 
days with M199 and 10% foetal calf serum. The spent medium was 
harvested, filtered and stored at -40oC. 
2.1.5 Normal human serum 
Normal human AB serum used for the growth of human umbilical 
vein endothelial cells was obtained at monthly intervals from the 
Blood Transfusion Service, Sheffield. Clotted blood was separated 
aseptically and the serum was heat inactivated at 56°C for 45 minutes. 
Serum was stored at -BOoC in 5ml aliquots. 
2.1.6 Tissue culture ware 
All tissue culture ware used for the growth of human umbilical 
vein endothelial cells was of tissue culture grade. Primary cultures 
were grown in T25 and T75 Nunc flasks. Cytotoxicity assays were 
performed in Nunc 96 well flat bottomed microtitre plates. For 
prostacyclin assays, Falcon 16mm, 24 well plates were used. 
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All tissue culture ware was gelatin coated prior to use. 15, 5, 
0.5 and 0.1 ml of 0.2% gelatin was added to each T75 or T25 flask, 
and each well of 24 or 96 well plates respectively, and left to coat 
at 40 c overnight. Excess gelatin solution was rinsed out with M199 
immediately before use. 
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2.2 
2.2.1 
Methods 
The isolation and culture of human umbilical vein endothelial 
cells 
Umbilical cords from normal vaginal deliveries were placed into 
sterile bottles, containing 150ml MEM, immediately following delivery. 
Cords were stored at 40 C for up to 24 hours prior to use. 
Umbilical cords of less than 20cm were discarded. Clamped ends 
and traumatised regions of the cord were cut off and any excess blood 
remaining was removed by gently massaging the cord along its length. 
The vein was cannulated with a 14G plastic cannula, and firmly secured 
with a silk ligature. The vein was washed free of any remaining blood 
by perfusing with M199 until all traces of blood had been removed. The 
uncannulated end of the cord was then ligated and a stopper was 
secured in place over the cannula. 
The vein was then inflated with a 0.2% solution of type IV 
collagenase in M199, and was incubated for ten minutes at 370 C in a 
humidified atmosphere of 95% air, 5% carbon dioxide. The digested 
layer of endothelial cells was collected into sterile universal 
containers and a further 10-15 ml of M199 was flushed through the vein 
to collect any dislodged cells. The resulting cell suspension was 
centrifuged at 500g for five minutes at 20 oC. The cell pellet was 
resuspended in M199 and washed twice. Finally, the endothelial cells 
were suspended in either 5 or 20 mls M199 containing 20% normal human 
AB serum and placed in a T25 or T75 flask. The human umbilical vein 
endothelial cells were cultured in a Flow incubator, at 370 C in a 
humidified atmosphere of 95% air, 5% carbon dioxide. 
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Twenty four hours after isolation, the human umbilical vein 
endothelial cells were fed with M199 and 20% AB normal human serum and 
were then fed every two days until they reached confluence. Human 
umbilical vein endothelial cells grown in T75 flasks were supplemented 
with 20% B16 conditioned medium. 
2.2.2 Passaging of human umbilical vein endothelial cells 
Once the human umbilical vein endothelial cell monolayer had 
reached confluence, the cells were passaged and plated out at the 
required cell density. The intact cell monolayer was washed once with 
M199 and then incubated with a 0.2% solution of type IA collagenase in 
M199 for 10 minutes at 37°C. The human umbilical vein endothelial 
cells became detached from the substratum in clumps and were dispersed 
to a single cell suspension by treating the spun cell pellet with 
0.025% EDTA in PBS for 10 minutes at 37 oc. Following this second 
digestion, the cells were centrifuged at 500g for five minutes and 
washed twice with M199 containing 10% AB normal human serum, to 
inhibit further enzyme action. The human umbilical vein endothelial 
cells were counted and tested for viability using a trypan blue dye 
exclusion test. Cell number was corrected to the required density and 
the suspension seeded into 96 or 24 well plates. 
2.2.3 Culture of human umbilical artery endothelial cells 
The isolation of umbilical artery endothelial cells was 
performed as for the isolation of vein endothelial cells, with the 
cannulation of an artery in place of the vein. 
Isolates obtained from umbilical arteries were seeded into 
gelatin coated T25 flasks, and fed with M199 supplemented with 20% 
normal human AB serum and 20% B16 conditioned medium. Passaging of 
arterial endothelial cells was identical to the method for venous 
endothelial cells. 
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Identi~ication of human umbilical endothelial cells 
Staining for von Willebrand factor antigen 
Identification of endothelial cells in culture was carried out 
by staining for von Willebrand factor antigen by the direct 
immuno-peroxi dase method. Primary cuI tures of human umbil ical 
endothelial cells were passaged and seeded onto gelatin coated plastic 
cover slips situated in the wells of 24 well plates. When confluent, 
the endothelial cells were fixed in ice cold ethanol for 10 minutes. 
Then the coverslips were mounted on glass slides with DPX mountant, 
and the cells were rehydrated with PBS. Peroxidase labelled anti 
human von Willebrand factor antigen antibody was diluted 1/25 with PBS 
and the endothelial cell mono layers on coverslips were coated with 
this antibody and incubated for one hour in a humidified chamber at 
room temperature. Following this incubation the monolayers were 
washed three times with PBS with a five minute incubation at each 
wash. Following the third wash, the substrate, diaminobenzidine (DAB), 
was made up in PBS at 1mg/ml and 1ul of hydrogen peroxide (30%) added 
i mm e d i ate I y p rio r to use. The endothelial cell monolayers on 
coverslips were then incubated for ten minutes with the substrate and 
hydrogen peroxide. Control coverslips on which cells were incubated 
with peroxidase labelled rabbit anti-mouse immunoglobulin in place of 
von Willebrand factor antigen antibody, and DAB alone were also set 
up. After incubation with the substrate the monolayers were washed 
once with PBS and then counterstained with haematoxylin by immersion 
for ten minutes followed by rinsing in tap water. Finally, the 
endothelial cell monolayers on coverslips were dehydrated in ethanol 
then xylene and remounted on glass slides with DPX mountant. 
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2.3 
2.3.1 
Results 
In vitro growth of human uabilical endothelial cells 
Primary cultures of human umbilical endothelial cells were 
established from the majority of umbilical cords processed. However, 
some cultures failed to become established and reach confluence. Cord 
length appeared to be a factor determining the successful growth of 
human umbilical vein endothelial cells. Insufficient cells were 
isolated from shorter cord lengths and the resulting plating density 
was too low for successful growth of human umbilical endothelial cells 
under these conditions. 
2.3.2 In vitro morphology of bu.an umbilical endothelial cells 
Freshly isolat ed human umbi lical vein endothelial cells 
occurred as small clusters of cells, which rapidly attached to the 
vessel SUbstratum. Small colonies of cells were visible ~preading out 
over the surface of the vessel soon after the initial attachment. 
These small colonies increased in size as the cells multiplied. Such 
growing endothelial cells were of uniform appearance with an elongated 
shape. Each cell possessed a single nucleus containing prominent 
nucleoli, with surrounding peripheral cytoplasm (plate 9). By 
approximately four days, depending upon the initial plating density, a 
confluent monolayer of human umbilical vein endothelial cells was 
obtained (plate 10). Confluent monolayers consisted of closely 
opposed polygonal shaped cells, which had stopped dividing, and 
overlapping of cells was not observed. Contamination of cultures with 
other cell types was rarely noticed. However, any cultures containing 
small numbers of fibroblasts were discarded. 
Arterial endothelial cell isolates from umbilical cords appeared 
as clumps of cells similar to those obtained from umbilical cord 
veins. The arterial endothelial cells quickly adhered to the 
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Plate 9 
A semi confluent monolayer of a primary culture of human 
umbilical vein endothelial cells. Each cell pocesses a single nucleus 
with several prominent nucleoli. Phase contrast x 200 
Plate 10 
A confluent monolayer of a primary culture of human umbilical 
vein endothelial cells, showing the typical cobblestone appearance and 
contact inhibition. Phase contrast x 200 
substrate and began to divide. However, arterial endothelial cells 
did not take on the elongated appearance shown by venous cells at the 
semi confluent stage. Instead arterial cells remained cobblestone 
morphology throughout their period of growth. Once confluent, 
arterial and venous monolayers exhibited similar morphology. 
Staining for von Willebrand factor antigen 
Human umbilical endothelial cells which had been incubated with 
peroxidase labelled anti human von Willebrand factor antigen, followed 
by substrate and hydrogen peroxide, showed a distinct staining 
pattern. Granular perinuclear staining which is characteristic for 
von Willebrand factor antigen was observed. In contrast, control 
endothelial cells stained with peroxidase labelled rabbit anti-mouse 
immunoglobulin showed no such staining (Plates 11, 12 & 13). 
Prostacyclin production 
Cultures of human umbilical vein endothelial cells consistently 
demonstrated the release of prostacyclin as detected by 
radioimmunoassay of its stable metabolite, 6-keto-PGF1~(see chapter 4). 
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Plate 11 
Immunoperoxidase staining of a monolayer of human umbilical vein 
endothelial cells with peroxidase labelled monospecific antisera 
directed against von Willebrand factor antigen. A dark brown, 
perinuclear granular staining pattern is shown. (x50) 
Plate 12 
. Immunoperoxidase staining of a monolayer of human umbilical vein 
endothelial cells with peroxidase labelled monospecific antisera 
directed against von Willebrand factor antigen. As above, dark brown, 
perinuclear granular staining of the antigen is observed. (x100) 
Plate 13 
Control staining of a monolayer of human umbilical vein 
endothelial cells, with peroxidase labelled rabbit anti-mouse 
immunoglobulin. No dark brown, granular staining is visible. (x100) 

2.4 Discussion 
Endothelial cells line the entire vascular system of the body, 
where they provide a nonthrombogenic surface to which platelets and 
other blood cells will not adhere. Endothelial cells grow as a 
monolayer, both in vitro and in vivo, thus enabling the vessels they 
line to maintain a patent vessel lumen. Various metabolically active 
substances are synthesized and released by endothelial cells, and 
these give them their procoagulant, antiplatelet, anticoagulant and 
fibrinolytic properties (see table 1.). 
It is only since the 1970s that investigators have been able to 
routinely isolate, identify and maintain vascular endothelial cells in 
culture. In the first half of the twentieth century, workers 
unsuccessfully attempted to grow endothelial cells in vitro using the 
technique of cell outgrowths from explants. However, limited cell 
growth and overgrowth by fibroblasts and smooth muscle cells inhibited 
their studies. In 1963 trypsin perfusion of vessels was performed. 
Maruyama (1963) carried out trypsin perfusion of human umbilical cord 
veins, and obtained cells that had the morphological appearance of 
endothelial cells. However, these cells failed to replicate, they 
could not be passaged and they degenerated after 21 days in culture. 
At the same time, Pomerat and Slick (1963) isolated endothelial cells 
from rabbit aortas using trypsin perfusion. Their cells could be 
serially passaged, but later passaged cells had the appearance of 
smooth muscle cells or fibroblasts. The major problems faced by 
workers attempting to culture endothelial cells was overgrowth by 
contaminating smooth muscle cells and fibroblasts, and the positive 
identification of endothelial cells. In 1973, Jaffe et al successfully 
isolated and cultured endothelial cells from human umbilical veins,by 
40 
Table 1 
Molecules involved in haemostasis which are synthesised by human 
umbilical vein endothelial cells (Bull 1988). 
1. Adhesive Proteins 
Von Willebrand factor antigen 
Thrombospondin 
Fibronectin 
Collagens type IV, V? and III 
Sulphated Proteoglycans 
2. Coagulation Proteins 
Von Willebrand factor antigen 
Factor V 
Thrombosplastin 
3. Anti Coagulant Proteins 
Anti thrombin III 
Thrombomodulin 
Protein S 
4. Fibrinolytic Proteins 
Plasminogen activators 
5. Prostaglandins 
Prostacyclin (PGI2) 
Prostaglandin E2 
Prostaglandin F2a 
Thromboxane A2 
Tissue & urokinase type 
perfusion with collagenase. These authors also demonstrated the 
presence of von Willebrand factor antigen on these cells which is now 
widely used as a unique marker for endothelial cells (Jaffe 1973). 
The method of Jaffe et al (1973) for the isolation of human 
umbilical vein endothelial cells involves the use of collagenase 
rather than trypsin. Collagenase selectively digests the collagen 
component of the subendothelial cell basement membrane thus reducing 
contamination by smooth muscle cells and fibroblasts from the internal 
elastic lamina. In addition, collagenase is non-toxic to cells in 
culture. Thus, collagenase offers a more controlled method of 
endothelial cell isolation compared wi th trypsin, which 
nonspecifically digests all protein and may destroy cell surface 
antigens (Ryan & Ryan 1983). 
In addition, in his isolation procedure, Jaffe used undamaged 
sections of cord, which had not been clamped during delivery, as 
these damaged areas of cord were more likely to produce contamination 
by smooth muscle cells and fibroblasts. The method of isolation of 
human umbilical vein endothelial cells originally documented by Jaffe 
has since been adopted by several workers and a technique adapted from 
this method was used in the present study. 0.2% type IV collagenase 
was successfully used for the perfusion, with an incubation period of 
10 minutes at 37oC. This digestion period was used since longer times 
resulted in further digestion of the subendothelial cell layer with an 
increased risk of smooth muscle cell and fibroblast contamination. 
Endothelial cells have also been isolated from bovine aortas 
using a similar technique to that described for human umbilical vein 
endothelial cells (Booyse al 1975). However, cloning techniques are 
required in order to obtain populations of pure bovine aortic 
endothelial cells (Jaffe 1984). Various methods have also been adopted 
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for the culture of endothelial cells from a variety of animals and 
sites, including human iliac arteries; human and bovine pulmonary 
arteries and veins; bovine saphenous veins; porcine aortas,inferior 
vena cava and pulmonary veins; rabbit aortas and marginal vessels of 
the ear; guinea pig aortas and portal veins; and canine jugular veins 
(Jaffe 1984). In addition, several groups have obtained transformed 
endothelial cells. In early studies, various properties of the 
endothelium, such as monolayer morphology, Wiebel-Palade bodies, and 
the synthesis of von Willebrand factor antigen were not retained in 
these transformed cells, and thus they did not provide adequate model 
systems for the study of normal endothelial cell functions. However, a 
recent report by Faller et al (1988) describes the immortalisation of 
human endothelial cells by murine sarcoma viruses, without 
morphological transformation, a technique which could be used in 
future studies. 
More recently, investigators have been attempting to isolate and 
maintain microvessel endothelial cells in vitro. It appears that the 
growth requirements for these cells differ from those of the larger 
arteries and veins and depend upon the site that vessels are obtained 
from. Although some workers have succeeded in isolating human 
microvascular endothelial cells, no major studies have been carried 
out using these cells (Folkman et al 1979; Davison et al 1980, 1981; 
Sherer et al 1980; Marks et al 1985; Vinters et al 1987) 
Systemic sclerosis is a disease which shows marked vascular 
abnormalities. The involved vessels are the smaller arteries and 
arterioles, and the capillary bed. Thus it would perhaps be relevant 
to study the effects of serum from patients with systemic sclerosis on 
capillary endothelium. However, the maintenance of these cells in 
vitro has proved very difficult and contamination with fibroblasts has 
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been a major problem. In this laboratory, attempts have been made 
to culture capillary endothelial cells from human lung, obtained from 
surgical specimens, and human foetal skin, lung and brain. Although 
the isolation of capillary endothelial cells has been achieved from 
these sites, maintenance and growth has been inhibited by the 
contamination of microvessel cultures with fibroblasts. Capillary 
endothelial cells from omental tissue have also been isolated and 
cultured in this laboratory using the method of Kern et al (1983) 
However, we were not satisfied with the endothelial origin of these 
cells and therefore this source was not pursued. 
In this study, endothelial cells were deri ved from human 
umbilical veins. There are various advantages in using umbilical 
cords as a source of endothelial cells. Cords are easily obtained and 
a supply of over 500 umbilical cords was available for this study. 
The vein is an unbranched vessel and is easily cannulated at both 
ends, thus making the flushing through of washing medium, addition of 
enzyme and collection of effluents a relatively easy task. However, 
various uncontrollable foetal and maternal factors may affect the 
growth and biological activity of endothelial cells thus obtained. 
For instance large variations in the production of prostacyclin have 
been recorded from endothelial cells obtained from different cords. 
Factors such as foetal stress, maternal anaesthesia and maternal 
smoking habits may all affect the viability, growth characteristics 
and activity of isolated endothelial cells. Thus, caution must be 
used in making direct comparisons of endothelial cells derived from 
different cords. 
The low mitotic index of human umbilical vein endothelial cells 
in vitro has prevented long term culture of these cells (Maciag et al 
1984). Most workers have been unable to cultivate endothelial cells 
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beyond the second or third passage and later passaged cells appear to 
have lost their functional properties. For example, prostacyclin 
production diminishes when endothelial cells are serially passaged 
(Ager et al 1979). 
Serum is a necessary growth requirement for human umbilical vein 
endothelial cells. Foetal calf serum was used in early studies on the 
growth of human umbilical vein endothelial cells. However, foetal 
calf serum has been shown to cause a relative inhibition of endo-
thelial cell growth (Summers et al 1984) and therefore human serum has 
since been adopted by many investigators and concentrations up to 50% 
have been shown to be mitogenic (Jaffe 1984). In the present study 
20% human AB serum was used for the growth of human umbilical vein 
endothelial cells in vitro as this serum concentration adequately 
supported endothelial cell growth. 
It is widely accepted that human umbilical vein endothelial 
cells are much more fastidious in culture than endothelial cells 
deri ved from large animal vessels. Bovine and porcine aort ic 
endothelial cells can be maintained in vitro for long periods of time 
with relative ease. However this is not true of human umbilical vein 
endothelial cells and therefore workers have been searching for a 
factor, not present in serum, which will support serial passaging of 
human umbilical vein endothelial cells whilst maintaining their in 
vivo characteristics. 
Early studies showed that fibroblast growth factor, derived from 
bovine neural tissue, enhances the proliferation of human umbilical 
vein endothelial cells (Gospodowicz et al 1978). Maciag et al (1979) 
later identified the reactive fraction of fibroblast growth factor 
which causes this stimulation of proliferation, which is known as 
endothelial cell growth factor. The use of endothelial cell growth 
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factor with fibronectin coated plates has enabled workers to maintain 
human umbilical vein endothelial cells in vitro for fifteen to twenty 
one passages or up to twenty seven population doublings. In the 
presence of endothelial cell growth factor the requirement for serum 
is diminished, and Maciag et al (1981) reported the growth of human 
umbilical vein endothelial cells at plating densities as low as 1.25 
cells per square centimeter. Heparin appears to diminish the 
requirement for endothelial cell growth factor (Thornton et al 1983). 
It probably works by stabilising the structure of the endothelial cell 
growth factor molecule. 
It is likely that factors of platelet origin are required for 
endothelial cell growth since serum is a necessary requirement and 
impure preparations of platelet derived growth factor have shown 
proliferative effects on human umbilical vein endothelial cells. 
However, these cells do not possess receptors for platelet derived 
growth factor and further investigation is required before the role of 
this factor in the growth of endothelial cells is known (Heldin et al 
1981; Bowen-Pope & Ross 1982). 
Endothelial cells themselves have been shown to synthesize and 
release growth factors which promote fibroblast and smooth muscle cell 
growth and one of these has been shown to bind to endothelial cell 
surfaces (DiCorleto et al 1983; Gajdusek 1984). However, whether 
endothelial derived growth factor stimulates the proliferation of 
endothelial cells is uncertain. 
In this study, the growth of human umbilical vein endothelial 
cells to first passage was accomplished on gelatin coated plastics, 
with 20% normal human serum, without the addition of growth factors. 
Thus, although it appears that external growth factors are important 
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for the long term propagation of human umbilical vein endothelial 
cells, in short term culture, morphological and functional properties 
can be retained without the addition of such factors. 
In addition to growth factors, it is evident that substances 
produced by endothelial cells and incorporated into their extra 
cellular matrix and subendothelial basement membrane, are important in 
the maintenance of an intact monolayer, and may be important in 
cellular attachment, spreading, migration and proliferation. Hence, 
such sUbstances are often used as substrates to aid the growth of 
endothelial cells in vitro. Elastin, laminin, fibronectin, collagens, 
thrombospondin and sulphated proteoglycans are all synthesized by 
endothelial cells and incorporated into their basement membrane (Bull 
1988). Several of these substances have been used to coat tissue 
culture plastics to facilitate cell growth. 
2.4.1 Identirication o~ human umbilical endothelial cells 
In this study the cri teria used for defining cultures as 
endothelium were:-
1. Morphological appearance at the light microscope level 
2. Positive staining for von Willebrand Factor antigen 
3. The production of prostacyclin 
The simplest way of identifying endothelial cells is by their 
morphological appearance as seen by phase contrast microscopy. In 
culture, human umbilical vein endothelial cells grow as a monolayer of 
closely opposed polygonal shaped cells with an oval, centrally located 
nucleus. The human umbilical vein endothelial cells grown for this 
study possessed this typical "cobblestone" appearance. Once a 
confluent monolayer is obtained endothelial cells in vitro exhibit 
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"de 't" " t t 'h'b't' " nSl y or con ac ln 1 1 lon growth characteristics; ie they 
cease to proliferate once a compact monolayer has been formed. This 
inhibition of proliferation is thought to be due to cell to cell 
contact (Wieser et al 1985). However, the subendothelial cell 
basement membrane may also be important in the control of 
proliferation. 
In contrast to endothelial cells in vitro, fibroblasts differ 
morphologically since they appear as long spindle shaped cells, which 
when confluent grow close together in parallel arrays with whorling 
and multiple overlapping layers. Smooth muscle cells have a typical 
"hill and valley" appearance in vitro, with areas of multiple layers 
of cells interspersed with areas of lower cell density (Jaffe 1984). 
Thus, smooth muscle cells and fibroblasts can be distinguished from 
human umbilical vein endothelial cells by their morphological 
appearance. 
Von Willebrand factor antigen is the major component of the 
factor VIII complex found in plasma. Von Willebrand factor antigen 
may be measured directly or functionally as ristocetin co-factor. 
Since the early 1970s it has been known that endothelial cells contain 
von Willebrand factor antigen. In 1973 Jaffe et al demonstrated its 
synthesis and release by human umbilical vein endothelial cells in 
vitro. Von Willebrand factor antigen is either incorporated into the 
subendothelial cell basement membrane or it is released and complexed 
to factor VIII procoagulant molecules in plasma. Immunoelectron 
microscopic studies have localized von Willebrand factor antigen to 
the Weibel-Palade bodies, which may act as a processing or storage 
site (Wagner et al 1982). Endothelial cells from a variety of sites 
and species have been shown to synthesize and secrete von Willebrand 
factor antigen in vitro, with the exception of porcine endothelial 
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cells. Thus, its detection offers a method for the identification of 
endothelial cells. The positive staining for von Willebrand factor 
antigen has been widely used as a unique marker for endothelial cells 
and was one of the criteria used for the positive identification of 
human umbilical endothelial cells cultured in this study. Human 
umbilical endothelial cells grown in vitro showed characteristic 
granular perinuclear staining when the direct immuno-peroxidase 
technique of staining for von Willebrand factor antigen was carried 
out (Plates 11, 12 & 13). 
Another characteristic of endothelial cells in vitro is the 
synthesis and release of prostacyclin. Prostacyclin is produced by 
endothelial cells following the oxidative reduction of arachidonic 
acid, which is mobilized from membrane phospholipids. It is the most 
potent disaggregator of platelets known and its production by the 
vascular endothelium gives blood vessels their non-thrombogenic 
properties. In this study prostacyclin release by endothelial cells 
in vitro was detected by radioimmunoassay of its stable metabolite, 6 
keto PGF1~. Fibroblasts and smooth muscle cells have also been shown 
to release prostacyclin in vitro (Baenziger et al 1979; Ali et al 
1980). However the levels obtained from these cell types are much 
lower than those produced by endothelial cells. The levels of 
prostacyclin produced by human umbilical vein endothelial cells which 
\ 
were measured in this study were compatible with measurements carried 
out by other workers on similar cells. 
An additional characteristic feature of endothelial cells is the 
presence of Weibel-Palade bodies. First demonstrated by Weibel and 
Palade,these are tubular cytoplasmic organelles which are unique to 
endothelial cells. Identifiable by electron microscopy, these 
structures have been described in endothelial cells derived from a 
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variety of sites and species. Typically, they occur as rod shaped 
cytoplasmic components containing bundles of tubules enclosed by a 
tightly fitting membrane (Weibel and Palade 1964). Various functional 
roles have been suggested for Weibel-Palade bodies, the most recent 
being that they are a site of storage of von Willebrand factor antigen 
(Wagner et al 1982). Although Weibel-Palade bodies may not always be 
seen in cultured endothelial cells, when present they serve as a 
useful marker for this cell type. 
2.4.2 The endothelial cell surrace 
The vascular endothelium provides a vast surface which is in 
contact with all constituents of the blood. Thus, the surface 
antigens expressed on endothelial cells have been extensively studied, 
especially by workers in the field of renal transplantation, since 
vascular lesions are a prominent feature in patients exhibiting 
allograft rejection. 
HLA A,B, and C antigens have all been demonstrated on the 
surface of cultured human umbilical vein endothelial cells (Moraes and 
Stastny 1977; Neppart et al 1984). However, the expression of HLA DR 
antigens on human endothelial cells is less well defined. Using 
eleven different monomorphic monoclonal antibodies against human DR 
antigens, Stastny and Nunez (1984) failed to demonstrate HLA DR 
antigens on human umbilical vein endothelial cells. This failure to 
detect HLA DR antigens on endothelial cells was also reported by 
Neppert et al (1984). However, HLA DR antigens have been 
demonstrated, by immunofluorescent techniques, on capillary walls of 
kidney vessels in glomeruli and around tubuli, but not in the walls of 
larger vessels, and they were not found in the walls of capillaries 
and larger vessels of umbilical cord and placenta (Scott et al 1981). 
In addition, using a complement dependent cytotoxic method of 
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detection, HLA DR antigens have been detected on human umbilical vein 
endothelial cells (Hirschberg et al 1980 and 1984). Thus, it appears 
that endothelial cells from different sites and different sized 
vessels may differ in their expression of HLA DR antigens, and the 
method of detection employed may be critical. In addition, the 
activation state of endothelial cells may be important. For instance, 
Pober et al (1986) demonstrated the inducible expression of HLA DR 
antigens by activated T cells or immune interferon. 
Receptors for the Fc component of immunoglobulin and the 
activated third component of the complement cascade are also inducible 
on cultured bovine aortic endothelial cells. Under "normal" 
conditions, these cells do not possess receptors for Fc and C3 but 
these can be induced following exposure to white cell lysates or 
infection with influenza or cytomegalovirus. (Ryan et al 1981, 1983). 
In addition to HLA antigens, antigens unique to the surface of 
endothelial cells have also been demonstrated. Using an 
immunofluorescent technique, Lindquist and Osterland (1971) showed 
specific staining of vascular endothelium by human sera from patients 
with a variety of diseases including connective tissue diseases. Sera 
from kidney transplant recipients obtained following allograft 
rejection have been shown to react with endothelial cells (Moraes and 
Stastny 1977; Stastny and Nunez 1984; Cerilli et al 1977, Cerilli & 
Brasile 1980). Stastny and Nunez also demonstrated reaction of these 
sera with monocytes, hence the responsible antigens have been termed 
endothelial-monocyte antigens. Antiendothelial cell antibodies have 
also been eluted from lymphoid cell membranes (Cormane et al 1979) and 
sera and IgG from patients with SLE have been shown to bind to human 
umbilical vein endothelial cells (Shingu and Hurd 1981; LeRoux et al 
1986; Cines et al 1984). More recently, using an ELISA, 
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antiendothelial cell antibodies have been detected in the sera of 
patients with systemic sclerosis (Hashemi et al 1987; Baguley et al 
1987a; Byron et al 1987) 
In addition to the expression of surface antigens, endothelial 
cells also exhibit important accessory cell functions. Hirschberg et 
al (1980, 1984) demonstrated that endothelial cells can substitute for 
macrophages as antigen presenting cells to sensitized T lymphocytes 
and this property involves self HLA DR determinants. Endothelial 
cells produce interleukin 1 which is important for the triggering and 
proliferation of T lymphocytes (Miossec et al 1986) 
Thus endothelial cells play an important role in the response of 
the immune system. They have been shown to express molecules of the 
Class II MHC and they exhibit accessory cell functions. In addition, 
endothelial cells produce interleukin 1 in vitro. Hence, as a result 
of these properties and their distribution throughout the blood and 
lymph system, endothelial cells may be involved in various immune 
reactions occurring both in the healthy and diseased individual. 
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CHAPTER 3 
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY 
OF VASCULAR ENDOTHELIAL CELLS IN SYSTEMIC SCLEROSIS 
AND SYSTEMIC LUPUS ERYTHEMATOSUS 
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3.1 Introduction 
Antibody dependent cellular cytotoxicity (ADCC) is an immune 
mechanism in which target cell specific antibody interacts with immune 
effector cells enabling them to mediate target cell lysis. ADCC was 
first described in 1965 by Moller et al and then by Perlmann and 
Perlmann (1970). The latter authors showed lys is of chicken 
erythrocytes in the presence of peripheral blood lymphocytes, and 
target cell specific antisera. Since these initial observations, ADCC 
has been described in a variety of allogeneic and xenogeneic assay 
systems. It is complement independent and occurs at antisera titres 
much lower than those required for complement mediated cytolysis 
(Perlmann and Holm 1969; Perlmann & Perlmann 1970). 
Although ADCC has been recognised for some time, the precise 
nature of the effector cells involved and the mechanism of cytolysis 
are not fully established. However, for effective ADCC there are three 
requirements (Zighelboim and Gale 1974) 
1. An effector cell with a surface receptor, capable of interacting 
effectively with the exposed binding site on the Fc region 
of the antibody molecule (Fc receptor). 
2. Target cell specific antibody. 
3. An intact Fc region of the antibody molecule. 
3.1.1 Errector cell populations in !DCC 
Monocytes, macrophages, polymorphonuclear leukocytes and a 
I t · f lymphocytes have all been shown to heterogenous subpopu a lon 0 
mediate ADCC (Sarmay et al 1985; Ralph 1984; Johnson et al 1985; Shen 
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et al 1987; Richer et al 1983). It appears that the nature of the 
effector cell mediating ADCC may vary with differing target cells 
(Nelson et al 1976; Kovithavongs et al 1975). Different antibodies 
directed against the same target cell may preferentially cause 
activation of different effector cells (Richter et al 1983). The 
concentration of antibody molecules coating the target cell may be 
another determining factor in the nature of the effector cell 
mediating ADCC, as may the class of immunoglobulin (Kurlander et al 
1978; Zoller et al 1983). 
In general, it appears that lymphocytes are most effective at 
mediating ADCC of nucleated targets such as allogeneic lymphocytes and 
tumour cell lines, whereas monocytes are more effective at killing 
anucleated erythrocytes. However chicken erythrocytes, which are 
nucleated, are equally well lysed by monocytes and lymphocytes (Greiss 
1984) • 
The subpopulation of lymphoid cells effective in ADCC make up 
part of the null cell population of lymphocytes. They have been 
classed together with natural killer (NK) cells, and may be the same 
population of cells. These have been termed large granular 
lymphocytes. The ADCC mediating cells have been called killer (K) 
cells and make up approximately 5% of peripheral blood lymphocytes 
(Maclennan et al 1976). They possess receptors for the Fc region of 
immunoglobulin, are non-phagocytic and non-adherent and do not possess 
surface membrane immunoglobulins or receptors for complement 
(Maclennan et a11976; Bean et al 1976). 
In addition to the type of effector cell determining ADCC 
reactions, its level of activation is also important. Various factors 
known to modify biological responses may also alter the effector 
cell's ability to mediate ADCC. For example, 0 interferon has been 
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shown to both inhibit and enhance ADCC by different populations of 
effector cells against various targets (Ortaldo et al 1987; Catalona 
et al 1981). However, ~ interferon and interleukin 1 have both been 
shown to act as potent stimulators of ADCC (Ortaldo et al 1987). It 
is possible that such factors may exert their effects by altering the 
expression of Fc receptors on effector cells as it has recently been 
shown that 0 interferon induces an increase in the expression of FcR1 
and FcR III (see later) on monocytes and neutrophils (Buckle et al 
1988). 
The requirement, in ADCC , for an interaction between target 
specific antibody and the Fc receptor on effector cells is 
demonstrated by the inhibition of ADCC seen in the presence of heat 
aggregated IgG and soluble immune complexes (Panayi et al 1977; Lustig 
and Bianco 1976). Recent studies centred on the nature of the Fc 
receptor have identified three different types, termed FcRI, II and 
III. These different receptors have differing affinities for IgG and 
can be identified with specific monoclonal antibodies. As different 
Fc receptors are present on different effector cells, the type of 
receptor involved in ADCC depends on the nature of the effector cell 
in the system under study. Gergely (1988) demonstrated the occurrence 
of FcRIII on human K cells. He also examined the IgG domain specific 
sites on this receptor which are important in ADCC. The FcRIII on K 
cells is shown to have a CH2 and CH3 domain specific binding site. The 
CH2 specific site is important both in receptor binding of antibody 
and mediating target cell destruction, whilst the CH3 specific site 
only has antibody binding capability (Sarmay et al 1985; Gergely 
1988). ADCC induced by monocytes, however, has been shown to occur via 
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FcR1 (Shen et al 1986). Further work is required before the precise 
antibody binding sites on the Fc receptors of effector cells can be 
determined for all ADCC reactions. 
3.1.2 Antibody nature in !DCC 
Early studies demonstrating ADCC involved antibody of IgG class 
as the sensitizing agent (Maclennan et al 1969). Further 
investigation of the role of antibodies of the IgM class as mediators 
of ADCC have, however, produced conflicting results. ADCC by IgM 
antibodies has not been demonstrated against human erythrocytes and 
chicken erythrocytes (Holm et al 1974; Richer et al 1983; Lustig and 
Bianco 1976). However, IgM induced ADCC has been detected in a 
systems using human effector cells and sheep erythrocytes as target 
cells (Fuson and Lamon 1977). In a comparison of IgM and IgG induced 
cytotoxici ty, Fuson et al (1978) showed that pre-incubation of 
lymphocytes with antibody facilitated IgM induced ADCC, but had 
little effect on ADCC mediated by IgG. In contrast, these authors 
showed that cytotoxicity produced by freshly isolated peripheral blood 
lymphocytes against IgM sensitized target cells was significantly 
lower than that produced by IgG sensitized target cells. 
Zoller et al (1982) also demonstrated IgM mediated ADCC with 
highly purified monoclonal antibodies against sheep erythrocytes by 
murine and human effector cells, but found that much greater 
concentrations of antibody of IgM class were necessary to induce ADCC 
than were required with IgG antibody. In a later study, these authors 
studied the nature of the effector cells mediating ADCC induced by 
antibodies of the IgG and IgM classes against sheep erythrocyte target 
cells (Zoller et al 1983). Although the populations of effector cells 
mediating ADCC by the two different classes appeared to overlap, they 
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differed in their relative killing capacity. Although a 10x greater 
IgM concentration was used compared to the IgG class antibody, a lower 
percentage of targets coated with IgM were killed. 
It appears that although the antibody class mediating ADCC is 
mainly IgG, IgM has also been shown to be capable of inducing this 
type of killing. However, the concentration of antibody required in 
IgM induced ADCC is much higher and the killing is less efficient. It 
is also possible that different populations of effector cells may be 
used in ADCC induced by IgG and IgM classes of antibody. 
In systems where IgG acts as the class of antibody capable of 
mediating ADCC, the effect of antibody subclass has also been 
investigated. Early studies measured the inhibition of an ADCC system 
by the various IgG subclasses, on the assumption that should a 
particular subclass inhibit ADCC, then antibodies of the same subclass 
are those mediating ADCC. Inhibition of lysis of human and chicken 
erythrocytes by human effector cells has been shown with IgG1 and 
IgG3, but not with IgG2 and IgG4 subclasses of antibody (Holm et al 
1974; Spiegelberg et al 1976; Urbaniak & Greiss 1980). In a study 
where IgG monoclonal antibodies against various murine cell surface 
antigens were examined in ADCC reactions with human effector cells, 
IgG antibody of the IgG2a and IgG3 subclasses was the most effective 
in mediating lysis, while IgG2b and IgG1 were less and least effective 
respectively (Sears and Christiaansen 1985). However, different 
monoclonal antibodies of the same subclass showed large variations in 
their ability to induce ADCC, thus implicating the importance of other 
factors such as antibody affinity towards the target cell. This is 
illustrated by a recent study by Gergely (1988) which revealed that 
although the IgG1 and IgG3 subclasses of antibody both bound to the Fc 
receptors on human K cells, only the IgG1 subclass was capable of 
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mediating lysis of human erythrocytes by K cells. IgG of different 
subclasses has been shown to exhibit variable binding affinities for 
FcRI, the order of binding being IgG1>IgG3>IgG4»IgG2 (Unkeless et al 
1988). Thus the differing abilities of the various subclasses to 
mediate ADCC may be due to the variability in their binding affinities 
for Fc receptors. 
Thus it appears that several factors influence ADCC reactions. 
These include the type of effector cell, its state of activation and 
the number and type of Fc receptors expressed. Antibody class and 
su bc lass and its affini ty towards the target ce 11 may al so be 
important factors. The target cell and its susceptibility to lysis is 
also an important controlling factor. For instance, the density and 
distribution of target cell surface antigens may affect antibody 
binding and the nature of the effector cell capable of mediating lysis 
and the degree of lysis. Interspecies variations are also important 
factors. Differences in ADCC have been shown when target cells, 
antibodies and effector cells from different species are tested 
(Zigelboim and Gale 1974). Thus, it is of crucial importance that 
homologous systems are used in the study of ADCC in human disease 
(Urbaniak 1978). 
3.1.3 Mechanisms occurring in !DCC 
The mechanisms occurring in K cell mediated ADCC remain 
undefined. However, it is possible that specific antibody must first 
combine with the appropriate antigen on the target cell before 
combining with Fc receptors on effector cells. Thus, the target cell 
specific antibody acts as a bridge allowing cytolytic cells bearing Fc 
receptors, to recognize and lyse target cells. Once the effector cell 
has bound to the target cell by way of Fc receptor binding to target 
cell bound antibody, it becomes activated and ready for the delivery 
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of its lethal hit, i.e. it becomes programmed for target cell lysis. 
Following the activation process, target cell destruction ensues. The 
steps involving programming for lysis and target cell death were 
originally thought to be similar for both K cell mediated ADCC and 
lysis by cytotoxic T lymphocytes and NK cells (Sears and Christiaansen 
1985). However, recent work has shown that although the perforin 
pathway of cell lysis (see below) is calcium dependent, many cytotoxic 
T lymphocytes remain cytotoxic even in calcium free conditions, thus 
indicating another or other mechanisms of cytolysis which are calcium 
independent (Young and Liu 1988b; Clark 1988). 
The perforin mechanism of cytolysis occurs following conjugation 
between target and effector cells. The latter undergo cytoplasmic 
rearrangement resulting in secretion of a pore forming protein, called 
perforin, or cytolysin, which is present in granules. Perforin 
monomers released from these granules polymerise to produce tubular 
complexes which then insert into the target cell membrane, forming 
channels which are a necessary component of the lethal hit. Channel 
formation by these perforin monomers is not enough to kill the target 
cell, although it is not known whether soluble lytic factors from 
effector cells enter target cells by way of these membrane channels. 
However, the mode of target cell death occurring in ADCC appears 
to involve the mechanism of apoptosis rather than necrosis, which 
occurs in complement mediated lysis (Duvall and Wyllie 1986). 
Apoptosis involves early degradation of nuclear material with distinct 
patterns of DNA fragmentation (Cohen et al 1985). The effector cells 
appear to be "immune" to their own cytolytic mediators and may 
possibly kill more than one target cell. However, other experiments 
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have suggested that under certain circumstances, cytotoxic T 
lymphocytes are equally susceptible to lysis when recognised by other 
cytotoxic T lymphocytes as targets (Young and Liu 1988a). 
In contrast to the above mechanism of ADCC involving recognition 
of target cells via specific antibody previously bound to the target 
cell surface, is a mechanism involving "arming" of effector cells, 
thus rendering them cytotoxic to target cells. Greenberg and Shen 
(1973) demonstrated effector cell binding of preformed complexes of 
antibody and target cell antigen via Fc receptors. They suggest that, 
providing excess antibody is present in the complex, the effector cell 
will acquire specificity through free binding sites on the antibodies 
in the complex, thereby allowing specific recognition of target cell 
antigen, followed by specific cytotoxicity. 
3.1.4 ADCC and its role in disease states 
Although there is no firm evidence that ADCC occurs in vivo, 
various roles have been proposed for this potentially important immune 
mechanism, including immunological responses towards tumours and 
virally infected cells (Sears and Christiaansen 1985; Gonik et al 
1985). ADCC of vascular endothelial cells has also been implicated in 
allograft rejection and, with relevance to this study, could be one of 
the immunological mechanisms functioning in autoimmune diseases 
(Hirschberg et al 1975) 
The pathological features of many autoimmune diseases could well 
be mediated, at least in part, by ADCC. Some of the various 
autoanti bodies found in autoimmune diseases may be capable of 
interacting with a patient's K cell population to produce autologous 
tissue injury. A number of reports have demonstrated a factor, 
present in the serum of patients with autoimmune diseases, capable of 
mediating ADCC of various target cells when co-cultured with effector 
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cells from normal human donors. Thus, IgG from patients with 
rheumatoid arthritis has produced ADCC of Chang liver target cells 
(MacLennan et al 1969; Panayi 1976). In another study, IgG anti-DNA 
antibodies from patients with SLE caused destruction of DNA coated 
chicken erythrocytes by normal lymphocytes (Quismorio et al 1976). 
Norris et al (1984) showed ADCC of nonhistone nuclear antigen coated 
target cells induced by autoantibodies such as RNP,Sm and SS/A Ro from 
patients with SLE. In addition, ADCC towards human target cells by 
normal human peripheral blood mononuclear cells in the presence of 
sera from patients with SLE and systemic sclerosis, has been 
demonstrated by Penning et al (1983, 1984a, 1984b, 1984c, 1985) and 
Wright et al (1983) and will be further characterised in this study. 
In further support of ADCC as a pathogenic mechanism occurring in 
autoimmune diseases, is the occurrence of perivascular mononuclear 
cell infiltrates in the blood vessels of these patients (Campbell & 
LeRoy 1975). These occur in regions of tissue damage and it is 
feasible that autoantibodies and mononuclear cells could interact at 
these sites and thus inflict tissue injury by ADCC. 
Although a number of studies have demonstrated ADCC mediated by 
sera from patients with various autoimmune diseases, reduced ADCC 
against Chang liver cells has also been reported by the effector cell 
populations obtained from these patients (Wright et al 1979; Cooper et 
al 1978). However, Cooper et al (1978) failed to show a reduction in 
ADCC against chicken erythrocytes by effector cells from the same 
patients, thus indicating a different population of effector cells 
mediating ADCC against the 2 different targets. Other workers have, 
however, demonstrated reduced ADCC towards antibody coated chicken 
erythrocytes by effector cells from patients with SLE compared with 
those obtained from normal controls (Feldmann et al 1976). In another 
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study, sera from patients with SLE were shown to suppress ADCC towards 
sensitised chicken erythrocytes, compared with sera from normal 
controls (Zvalfler & Bluestein 1979). The suppressive activity was 
shown to co-elute with IgG and the authors suggested that the 
suppression of ADCC was due to a direct effect of antibody combining 
with membrane antigens of the effector cell population. 
Thus, the reduced levels of ADCC reported by various authors in 
autoimmune diseases, could be caused either by blocking of effector 
cell Fc receptors, by antibody or immune complexes, or by a 
generalised suppression of cellular immunity occuring in these 
patients. Alternatively, the effector cells mediating ADCC could be 
sequestered in tissues as a result of their involvement in damaged 
tissue, thereby depleting the circulating blood of this population of 
cells 
3.1.5 In vitro measurement or cytotoxicity 
The detection, characterisation and quantitation of ADCC can only 
be carried out in vitro. Various methods have been employed in the 
measurement of cytotoxicity. These involve either visual methods, 
where target cell damage is assessed microscopically, or biochemical 
or radioisotope based techniques. 
Visual determinations of cytotoxicity, which usually involve cell 
counting, can be criticised in that they are very subjective. A 
biochemical marker, the release of lactate dehydrogenase, acts as a 
sensitive indicator of cell lysis, and its measurement can be used in 
a more objective assessment of cytotoxicity. However, in this study, 
cytotoxicity was measured by radioisotopic release from prelabelled 
target cells. A radioisotope is easily measured, it is released in a 
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soluble form by lysed cells and it is easily separated from residual 
cells and cell debris. Thus, radioisotopes offer an excellent method 
for the measurement of cytotoxicity. 
Several radioisotopes have been utilised in cytotoxicity assays. 
There are several requirements for an isotope used in such studies: 
1. The isotope should show minimal toxicity towards both target and 
effector cell populations. 
2. The isotope should be evenly distributed among target cells, 
regardless of their metabolic activity or stage in the cell 
cycle. 
3. The release of isotope into the supernatant should only occur 
following irreversible damage to the labelled cell. 
4. The isotope should be rapidly and readily released by target 
cells. 
5. Once released, isotope should not be reutilised by target 
or effector cells. 
51Chromium matches these requirements and hence was used for 
target cell labelling in this study. 51Chromium has been widely used 
as a routine label in studies of the survival of erythrocytes in 
patients with haemolytic disease. In 1961 Goodman showed that 
51chromium release could serve as a precise indicator of antibody and 
complement induced lysis of nucleated cells. This work was confirmed 
by Sanderson (1965) and Wigzel (1965). Later, 51 chromium was used as 
63 
a label for the determination of cell mediated lysis of cultured cells 
in monolayer (Holm and Perlmann 1967). As a result of these initial 
observations, 51 chromium has been widely used in target cell labelling 
in cytotoxicity assays. 
Chromium 
51chromate. 
labelling is usually carried out using sodium 
The chromate ion 51CrO will passively diffuse into the 
cell cytoplasm where it is non-covalently bound to proteins and other 
cell constituents. Generally the label is retained within the target 
cells, with only about 15-30% spontaneous release, during a 24 hour 
culture period. Most of this probably comes from spontaneously 
damaged or dying cells (Holm & Perlmann 1967). However, once the 
cells are lysed, >90% of the total radioactivity is released (Holm and 
Perlmann 1967). In addition to its relatively low spontaneous 
release, 51 chromium is non-toxic to target and effector cells even at 
the high concentrations used in cytotoxicity assays. 
One of the principle features of 51chromium is that released 
label from lysed target cells is not reused (Holm & Perlmann 1967; 
Bunting et al 1963). The reason for this is uncertain but two possible 
explanations have been put forward. The first suggests that the 
hexavalent ion 51Cr04 is reduced to trivalent 51Cr03 which cannot 
traverse the cell membrane (Rajam and Jackson 1958). The second 
explanation suggests that 51 chromium is released from target cells in 
a stable form, covalently bound to small protein fragments to which 
cell membranes are impermeable (Ronai 1969). 
Thus 51 chromium is commonly used for in vi tro studies of 
cytotoxicity. It is ideally suited for this use because of its low 
toxicity, low levels of spontaneous release and its rapid uptake and 
release by target cells. 51Chromium is incorporated via passive 
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diffusion and therefore its uptake is not dependent upon cellular 
metabolic activity. Finally, released 51 chromium is not reused by 
target or effector cells. 
Hence, 51 c hromium offers a very sensitive index of cell damage 
and was used in this study to measure the direct serum cytotoxicity 
and ADCC of human umbilical vein endothelial cells caused by sera from 
patients with systemic sclerosis and SLE. 
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3.2 
3.2.1 
Materials and methods 
Patient and control groups 
Systemic sclerosis 
48 patients with systemic sclerosis (39 women; 9 men; mean age 
(+SD) 54.5+15.8 years) were investigated for the ability of their 
sera to produce cytotoxicity of vascular endothelial cells, either 
directly or in co-culture with peripheral blood mononuclear cells. 
Raynaud's phenomenon and acrosclerosis were constant features in all 
the patients who had been investigated by a standard protocol (Table 
2) which enabled points to be awarded for cutaneous and visceral 
involvement and so produce a disease score for each patient(see 
appendix IV). On this basis, the patients were sub-divided into 
categories of "severe disease" (disease score) 6; 19 women; 4 men; 
mean age (+SD) 57.4+16.9 years) and "mild disease" (disease score ~ 5; 
21 women; 4 men; mean age (+SD) 52.0+ 14.6 years). 5 of these 
patients were being treated with prednisolone, supplemented in 3 cases 
(all with "severe disease") with azathioprine. Nifedipine and 
captopril were used to treat an additional 9 and 8 patients 
respectively. Non of the patients were receiving treatment with 
penicillamine. 
Systemic lupus erythematosus 
49 patients with SLE (41 women; 8 men; mean age (+SD) 44.1+13.6) 
years were similarly examined for the ability of their sera to cause 
cytotoxicity of vascular endothelial cells either directly or 
indirectly. The principle clinical features of these patients, who 
all had positive tests for antinuclear and anti DNA antibodies, are 
shown in appendix V. All but one of these patients were being treated 
with prednisolone the dose ranging from 2.5mg to 30mg daily. In 
addition, 12 patients were receiving further treatment with 
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Table 2 
Criteria of systemic involvement in patients with Systemic 
Sclerosis. 
System involved 
Skin 
Gut 
Lungs 
Heart 
Kidneys 
Other 
Criteria 
Sclerosis - Face 
Hands 
Trunk 
Radiological changes 
Radiological changes &/or 
Disease score 
(points alloted) 
for involvement) 
1 
1 
1 
3 
abnormal CO transfer factor 3 
ECG changes 
Proteinuria &/or 
creatinine clearance 
<60 ml/min 
Sjogren's syndrome, 
Polymyositis 
3 
3 
3 
azathiaprine, 4 with cyclophosphamide, 8 with warfarin and 4 with 
chloroquine. 
Normal controls 
The control group consisted of 44 normal healthy adults, 34 
women; 10 men; mean age (+SD) 36.3+11.2 years. 
3.2.2 Serum samples 
Serum samples were obtained from blood which was collected by 
venepuncture and allowed to clot at 37 0 C, to avoid the loss of 
cryoprecipitable proteins. The blood was centrifuged at 1,500g for 20 
minutes at 37°C , the serum removed aseptically and aliquoted into 
sterile glass bijoux. Serum samples were stored at -BOoC and were not 
reused once thawed. 
3.2.3 Isolation of effector cell populations for use in ADCC assays 
For ADCC assays effector cells were obtained from one control 
donor (CH) for all assays, to minimize any variation that could arise 
between different donors. 
To determine the viability of isolated effector cells, a trypan 
blue dye exclusion test was carried out. 10 pI of 0.4% trypan blue was 
gently mixed with 40 pI peripheral blood mononuclear cells in M199 
and an aliquot of this was placed in a haemocytometer. The number 
and viability of effector cell populations was then determined under a 
light microscope. Populations of effector cells with viability <90% 
were discarded. 
3.2.3.1 Peripheral blood mononuclear cells 
Mononuclear cells have a lower density than erythrocytes and 
granulocyes and remain at the top of a separation fluid with a density 
of 1.077 g/ml, following centrifugation of whole blood (Boyum 196B). 
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Procedure 
Effector cells for use in ADCC assays were obtained from 
heparinised (20 units/ml of preservative free heparin) peripheral 
blood, collected by venepuncture with a wide bore (19G) needle. 5ml 
heparinised blood was diluted with an equal quantity of sterile PBS 
and was then layered onto 10ml "Lymphoprep" separation fluid in a 
glass universal container. This preparation was then centrifuged at 
1000g for 20 minutes at 20oC. The resulting separated peripheral 
blood mononuclear cells were present as a visible band of cells at the 
sample/medium interface. These cells were carefully aspirated from 
the interface using a glass pasteur pipette. The peripheral blood 
mononuclear cells were then washed in M199 and centrifuged at 500g for 
10 minutes at 20o C. Following this first wash, the peripheral blood 
mononuclear cells were twice washed in M199 and centrifuged at 350g 
for 5 minutes. Finally, the peripheral blood mononuclear cells were 
resuspended in HEPES buffered M199, counted and tested for viability 
using a trypan blue dye exclusion test. The cell suspension was 
adjusted to the required concentration with HEPES buffered M199. For 
ADCC assays the peripheral blood mononuclear cells were used at a 
concentration of 2.5x106 viable cells/mI. 
3.2.3.2 Monocytes 
The average density of monocytes is lower than that of 
lymphocytes, but because the densities of the two cell types overlap, 
separation using a density gradient results in cross contamination of 
the two different populations of cells. However, if the osmolality of 
the gradient medium is appropriately adjusted whilst the density is 
kept constant, as in "Nycodenz monocytes", the separation of monocytes 
from lymphocytes can be achieved. If the osmolality is increased, the 
° d °ty Lymphocytes are cells expel water, shrink and increase ln enSl • 
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more sensitive than monocytes in this respect, and will therefore 
sediment further during centrifugation, resulting in a band of 
monocytes at the top of the gradient. 
Procedure 
Blood was collected by venepuncture and 9ml was placed into a 
glass universal containing 1ml 2.7% w/v EDTA (pH 7.4). 3ml of this 
was layered onto 3ml "Nycodenz monocytes" and the preparation was 
centrifuged for 15 minutes at 600g and 20oC. The resulting band of 
monocytes at the sample/medium interface were harvested using a glass 
pasteur pipette and washed three times with M199. The final monocyte 
suspension was counted and tested for viability, then adjusted to 2.5 
x 10 5 cells/mI. The purity of monocyte preparations were assessed 
using the non-specific esterase method, which specifically stains 
monocytes (Yam et al 1971). 
3.2.3.3 Monocyte depletion 
Two methods, which use ei ther the adherent or phagocytic 
properties of monocytes, were employed to deplete these cells from 
peripheral blood mononuclear effector cell populations. 
1. Adherence to Plastic 
This method removes all adherent cells from the effector cell 
population. A suspension of peripheral blood mononuclear cells in 
10ml M199 was incubated in a T75 flask for 60 minutes at 37oC. 
Non-adherent cells were vigorously washed from the flask with M199 and 
centrifuged for 5 minutes at 350g. The adherent cell depleted 
preparation of peripheral blood mononuclear cells was counted, tested 
for viabili ty and resuspended in M199 at the appropriate cell 
concentration. 
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2. Treatment with Carbonyl Iron Powder. 
This method removes actively phagocytic and adherent cells. 
Peripheral blood mononuclear cells were incubated for 30 minutes at 
37 0 C on 90mm petri dishes in 10ml M199, containing 10mg carbonyl iron 
powder. The non-adherent cells were vigorously washed off the petri 
dish with M199. The resulting preparation of non-adherent cells , 
which included macrophages containing phagocytosed carbonyl iron 
particles, was layered onto "lymphoprep" and centrifuged at 1000g for 
20 minutes at 20 oC. While macrophages containing ingested carbonyl 
iron particles sedimented through the separation gradient, the 
phagocyte depleted cells which formed a band at the interface were 
collected, washed and resuspended in M199. 
3.2.4 51Cbromium release cytotoxicity assays 
51Chromium release assays were used in this study to measure the 
cytotoxicity of human venous or arterial umbilical endothelial cells 
caused by sera from patients with systemic sclerosis and SLE, either 
alone or in conjunction with peripheral blood mononuclear cells. 
Cytotoxicity assays were performed in situ in microtitre plates 
using human venous or arterial endothelial cells, at first passage, 
as target cells. Endothelial cells were seeded at 10,000 cell/well 
into flat-bottomed, gelatin coated 96 well microtitre plates, and 
incubated at 370 C in a humidified atmosphere of 5% C02/95% air. After 
48 hours the human umbilical vein endothelial cells were confluent and 
ready for radiolabelling prior to their use as target cells in 
cytotoxicity assays 
3.2.4.1 Radiolabelling of endothelial cell monolayers 
100pl M199 + 20% normal human AB serum containing 0.5 pci 
51 chromium, in the form of sodium chromate, was added to each well 
which contained a confluent monolayer of endothelial cells. The 
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microtitre plate was then incubated at 370 C in a humidified atmosphere 
of 5% C02 /95% air, for a further 18 hours. After this labelling period 
the medium above the endothelial cell monolayer was discarded and the 
cells were carefully washed 3 times to remove any excess 51 chromium. 
3.2.4.2 Assay conditions 
Triplicate assay wells were set up for each particular set of 
conditions and the final volume in each well was adjusted to 200pl 
with HEPES buffered M199. 
Control conditions for each individual assay consisted of:-
1. Baseline or spontaneous 51 chromium release 
M199+ 5% normal human AB serum. 
2. Maximal 51 chromium release 
100pl saponin and 100pl M199. 
3. Spontaneous cell mediated cytotoxicity (NK activity) 
M199 + 5% normal human AB serum and 2.5x10 5 peripheral blood 
mononuclear cells 
The test wells consisted of 
1. Direct serum induced cytotoxicity 
2. 
M199 + 5% test serum 
Antibody dependent cellular cytotoxicity 
M199 + 5% test serum + 2.5x10 5 peripheral 
cells 
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blood mononuclear 
Once all the control and test wells were set up, the microtitre 
plate was incubated for 18 hours at 37oC. Following incubation, the 
microtitre plate was centrifuged at 200g for 10 minutes at 150C and 
100yl supernatant was transferred from each well to a supernatant 
tube. 100pl formic acid was then added to each well and the contents 
of each well were transferred to a residue tube (each well being 
scraped to assure the total removal and transfer of all cellular 
material). 
The supernatant and residue tubes were then counted in pairs for 
4 minutes/tube, in an Intertechnique CG 30 gamma spectrometer. The 
spectrometer was equipped with an Epson RX-80 computer, programmed to 
calculate the percentage 51 c hromium release and the percentage 
specific cytotoxicity (see below) 
3.2.4.3 Calculation of cytotoxicity 
The percentage 51 c hromium release (CR) and the percentage 
specific cytotoxicity (SC) were calculated by the method of Gale and 
McLennan (1976):-
(supernatant cpm - bg) x 2 
%51 Cr Release = -------------------------------------------- x 100 
(supernatant cpm - bg) + (residual cpm - BG) 
Where cpm = counts per minute 
bg = back ground cpm 
The percentage specific cytotoxicity (% SC) was determined to 
o 0 0 b lOne and maximal isotopic compensate for interassay varlatlon ln ase 1 
release:-
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(Experimental % 51Cr release - baseline % 51Cr release) 
% SC = 
------------------------------------------------------- x 100 
(Maximal % 51Cr release - baseline % 51Cr release) 
For each serum tested in ADCC assays the" 
, excess percentage 
specific cytotoxicity" (excess % SC) d was etermined from the 
percentage specific cytotoxicity of the serum only tubes and the 
percentage specific cytotoxicity of the serum + peripheral blood 
mononuclear cell co-culture tubes:-
Excess % sc = [%SC (S+PBM)] - [%SC (S) + %SC (PBM)] 
Where S = serum 
PBM = peripheral blood mononuclear cells 
3.2.4.4 Statistical analysis of data 
Levels of "excess % specific cytotoxicity" obtained in patient 
and control groups were statistically compared using the Wilcoxon 
Mann-Whi tney test (Seigel et al 1956). In addition, as 95% of sera 
from controls produced levels of "excess % specific cytotoxicity" ~8%, 
levels of "excess % specific cytotoxicity" >10% were considered to be 
"positive" values. Further statistical analysis of the proportions of 
sera from patients and controls producing "excess % specific 
cytotoxicity" of >10% was then also made, using the chi-squared test 
for association (Norusis 1988). 
3.2.4.5 Cytotoxicity in the presence of a source of complement 
In addition to direct serum induced cytotoxicity with 5% serum 
and ADCC studies, experiments were carried out to determine the 
effects of 20% serum on cultured human umbilical vein endothelial 
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cells, either alone or in the presence of a source of complement 
(normal rabbit serum). Control wells were set up as previously 
described and test wells consisted of :_ 
1. M199 + 20% test serum 
2. M199 + 20% tes t serum + 12.5% normal rabbit serum 
3.2.5 Pre-incubation studies 
Pre-incubation studies were performed with human umbilical vein 
endothelial cells to determine whether the factor, present in patient 
serum, capable of mediating ADCC would preferentially bind to target 
and/or effector cells. These pre-incubation studies were performed in 
conjunction with a standard direct serum induced cytotoxicity and ADCC 
test, ie for one particular serum, all these tests were carried out on 
human umbilical vein endothelial cells derived from a single cord 
3.2.5.1 Serum pre-incubation or target cells 
Confluent human umbilical vein endothelial cell mono layers in 
microti tre plates were labelled wi th 51 chromium as previously 
described. Following the 18 hour labelling period, the microtitre 
wells for preincubation were washed once with HEPES buffered M199. For 
each particular serum under observation, 6 wells were pre-incubated, 
with 5% test serum in M199, for 1 hour at 37 0 C in a humidified 
atmosphere of 5% C02/95% air. Following this pre-incubation period, 
the endothelial cell monolayers were washed 3 times with HEPES 
buffered M199. 3 of the wells were set up to test for any direct 
cytotoxic effects. To these wells, 5% normal human AB serum in HEPES 
buffered M199 was added. 
ADCC. To these wells, 
The other 3 wells were set up to test for 
5% normal human AB serum and 2. 5x 1 05 
peripheral blood mononuclear cells in HEPES buffered M199 were added. 
The necessary controls, ie baseline, maximal 51chromium release and 
spontaneous cell mediated cytotoxicity were also set up in triplicate. 
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The microtitre plate was then incubated for a further 18 hours at 370 C 
and processed as outlined previously. 
3.2.5.2 Serum pre-incubation of effector cells 
Peripheral blood mononuclear cells were isolated as previously 
described. Following the third wash, they were counted, tested for 
viability and resuspended at 2.5x10 6 viable cells / ml, in HEPES 
buffered M199. 5% test sera was then added to 2.5x106 peripheral 
blood mononuclear cells and the volume adjusted to 2ml with HEPES 
buffered M199. This mixture was then incubated for 1 hour at 370 C in 
a humidified atmosphere with 5% CO 2/air and gentle mixing every 20 
minutes. Following this pre-incubation period, the peripheral blood 
mononuclear cells were washed with M199. The resuspended cells were 
counted and the concentration re-adjusted to 2.5x10 6 viable cells / 
mI. These preincubated peripheral blood mononuclear cells were then 
cultured with 51chromium labelled human umbilical vein endothelial 
cells with 5% normal human AB serum in microtitre plates and the assay 
performed as usual. 
3.2.6 Serum titration studies 
In order to determine the lowest dilution of serum at which ADCC 
could be detected, the serum of a patient with SLE and 2 patients 
with systemic sclerosis, who had previously consistently demonstrated 
cytotoxicity against human umbilical vein endothelial cells in 
co-culture studies, were titrated down to one part serum in one 
million parts M199. Triplicate assay wells were set up and 10 pI of 
the following dilutions of serum, 5% normal human AB serum and M199 
were added. The various dilutions of serum were tested both alone and 
in the presence of peripheral blood mononuclear cells. The dilutions 
of serum tested in co-culture studies were :- 1, 1/2, 1/5, 1/10, 
1/102, 1/103, 1/104 , 1/105, 1/10 6• 
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3.2.7 Column chromatography of serum samples 
Column chromatography was performed on serum samples by gel 
filtration on an "ULTROGEL" column, using PBS (pH 7.2). An upward 
flow of 20ml per hour was maintained with a peristaltic pump, and 
separation was performed at 4oC. 3ml of serum was separated and 
fractions of 7ml were collected following passage through a UV monitor 
measuring optical density at 280nm. The fractions were then pooled to 
give 10 pooled fractions covering the elution profile as shown in fig 
1 • 
The pooled fractions were then concentrated to a volume of 1ml 
using an "Amicon" concentrator with a membrane of 30,000 MW cut off 
and a maximum operating pressure of 70 psi. Concentrated fractions 
were then aliquoted and stored at -40oC prior to use. In cytotoxicity 
assays, 20 pI of each pooled fraction was used per well together with 
10 pI normal human AB serum. 
The presence of IgG and IgM in the pooled fractions were 
determined by double and radial immunodiffusion (see appendices I & 
II) • 
3.2.8 Isolation of IgG from serum samples 
The isolation of IgG from patient and control sera was performed 
by the techniques of ion exchange chromatography and affini ty 
chromatography. 
3.2.8.1 Ion exchange chromatography 
Principle 
In ion exchange chromatography, proteins bind electrostatically 
to an ion exchange matrix which has an opposite charge to the protein. 
The affinity of the protein for the exchanger depends upon its charge 
b d substances are washed from the exchanger using a density, and un oun 
column volume of starting buffer. The bound protein is eluted by 
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Figure 1 
A typical elution profile of serum following passage through an 
ULROGEL column, showing the 10 pooled fractions which were 
concentrated prior to use in ADCC assays. 
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either increasing the ionic strength, or else by altering the pH of 
the buffer. An eluting buffer of increasing ionic strength causes 
competition between buffer ions and proteins for the charged groups on 
the ion exchanger. If the pH is altered, then when the isoelectric 
point of the bound protein is reached, its net charge becomes zero and 
it no longer binds to the exchanger. 
Procedure 
An anion exchanger (DEAE cellulose) was used in this study for 
the separation of serum immunoglobulins. 1ml serum, to be separated, 
was dialysed against 20mM phosphate buffer (pH 8.0) with three 
changes of buffer. The dialysed sample was then loaded onto the ion 
exchange column and approximately 30, 10ml fractions were eluted with 
20mM phosphate buffer. Under these conditions, the IgG elutes 
straight through and all other serum components bind to the column. 
The bound protein was eluted wi th 30, 10ml fractions of 200mM 
phosphate buffer (pH 8.0). The column was re-equilibrated to 20mM 
prior to the next separation. 
The IgG containing fractions were detected by UV absorbance at 
280nm. The pooled fractions were then dialysed against 3 changes of 
PBS and concentrated to a volume of 1ml in an "AMICON" concentrator , 
with a membrane of 30,000 MW cut off and a maximum operating pressure 
of 70 p.s.i. IgG preparations were aliquoted and stored at -40oC 
prior to use. IgG content was determined by radial immunodiffusion 
(see Appendix II ). For cytotoxicity assays, the amount of IgG / well 
was 0.1 mg (which is equivalent to 10 pI of 10 mg/ml). 
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3.2.8.2 Affinity chromatography 
Principle 
Affinity chromatography is a form of adsorption chromatography 
in which the molecule to be purified is specifically and reversibly 
adsorbed to a specific ligand which is immobilised on an insoluble 
support, such as sepharose. For the isolation of IgG from serum, the 
ligand is staphylococcal protein A. IgG binds to this via its Fc 
receptors and all other serum components will pass through the 
affinity column, bound IgG is subsequently eluted. Protein A binds 
human IgG of subclasses 1,2 and 4 but not 3 (Hudson & Hay 1980) 
Procedure 
The staphylococcal protein A / sepharose column was washed with 
about 20ml stripping buffer (0.1M sodium ethanoate pH 5.0) and was 
then equilibrated with 20ml 10 mM Tris buffer (pH 7.4). Following 
equilibration, the serum sample to be separated was loaded onto the 
column and the unbound serum components were eluted with a further 20 
ml of Tris buffer. The IgG remaining bound to the column was then 
eluted with 0.1 M glycine buffer (pH adjusted to 3.0 with HCI). The 
IgG containing fractions were determined by absorbance at 280 nm and 
fractions were pooled and dialysed with three changes of PBS, then 
concentrated to 1 ml in an Amicon concentrator, and the IgG content 
determined as previously described. IgG was aliquoted and stored at 
-40oC. 
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3.3 Results 
3.3.1 Basic parameters of the assays 
3.3.1.1 Baseline 51chromium release 
The baseline or spontaneous 51 c hromium release from cultured 
human umbilical vein endothelial cells, occurring over 18 hours, was 
24.37% + 0.36% (mean + SEM; n = 126 experiments). From cultured 
arterial endothelial cells, the baseline 51 chromium release was 25.74% 
+ 1.97% (mean + SEM; n = 4 experiments. 
3.3.1.2 Maximal 51chromium release 
The maximal 51 chromium release determined by the addition of 
saponin, was 94.48% + 0.33% (mean + SEM; n = 126 experiments) from 
human umbilical vein endothelial cells, and 87.91% + 4.26% (mean + 
SEM; n = 4 experiments) from arterial endothelial cells. 
3.3.1.3 Spontaneous cell mediated cytotoxicity 
The specific cytotoxicity caused by spontaneous cell mediated 
cytotoxicity, following co-culture with normal human peripheral blood 
mononuclear cells and human umbilical vein endothelial cells, was 
13.16% + 0.59% (mean+ SEM; n = 89 experiments). For arterial 
endothelial cells the spontaneous cell mediated cytotoxicity was 
13.94% + 2.18% (mean + SEM; n = 4 experiments). 
3.3.1.4 Effector donor variation 
Peripheral blood mononuclear cells derived from different donors 
showed varying levels of spontaneous cell mediated cytotoxicity (table 
3). For routine use, peripheral blood mononuclear cells obtained from 
a single control donor (CH) were used. 
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Table 3 
Percentage specific cytotoxici ty (SC) f h o uman umbilical vein 
endothelial cells due to spontaneous cell mediated cytotoxicity 
produced by peripheral blood mononuclear cells obtained from different 
donors. 
Donor 
PH 
NL 
JM 
CH 
%SC (mean + SEM) 
16.21 + 1.79 
19.44 
18.77 
13.16 + 0.59 
3.3.1.5 Effector cell to target cell ratio 
n(expts) 
4 
2 
2 
89 
In co-culture studies, the level of cytotoxicity increased as 
the number of effector cells increased (see fig 2). For routine use 
2.5 x 105 peripheral blood mononuclear cells per well were used as 
the best compromise between adequate levels of cytotoxicity and 
availability of the effector cells. 
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Figure 2 Excess % specific cytotoxicity of human umbilical vein 
endothelial cells produced by co-culture with increasing amounts of 
normal peripheral blood mononuclear cells and serum from a patient 
with systemic sclerosis which had previously exhibited ADCC of human 
umbilical vein endothelial cells. 
3.3.1.6 Serua concentration causing maximal ADCC 
In preliminary ADCC assays, serum was added at a concentration 
of 5%. To determine if this was the optimal amount of serum required 
for maximal ADCC to occur, se~um t t" 
L concen ra lons ranging from 2.5% to 
50% were tested in co-culture experiments with 2.5 x 105 peripheral 
blood mononuclear cells / well. The results are illustrated in fig 3. 
A serum concentration of 5% was maintained for future routine 
testing, since maximal ADCC was observed with this concentration. 
3.3.1.1 Intra and inter assay variation 
Intra-assay variation observed in ADCC assays was low. In a 
series of 12 baseline release wells within the same assay, the value 
of 51 c hromium release was 20.24% + 0.36% (mean + SEM) with a 
coefficient of variation of 6.69%. 
However, inter-assay variation was much wider. The baseline 
51 c hromium release showed a coefficient of variation of 16.68% (n=126 
experiments) and an even wider variation was observed between values 
of spontaneous cell mediated cytotoxicity derived from assays 
performed on separate occasions, the coefficient of variation being 
42.16% (n=89 experiments). 
3.3.2 Clinical studies 
3.3.2.1 Errect or co-culture or human umbilical vein endothelial 
cells with serum and peripheral blood mononuclear cells 
In this study, 48 patients with systemic sclerosis were examined 
for cytotoxicity against cultured human umbilical vein endothelial 
cells by co-culture with patient sera and normal human peripheral 
blood mononuclear cells. Sera derived from 10 of 48 patients 
demonstrated "excess % specific cytotoxicity" of )10%; ie 
approximately 20% of patients with systemic sclerosis exhibited ADCC 
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Figure 3 
The effect of varying the % concentration of added serum, on the 
excess % specific cytotoxicity of human umbilical vein endothelial 
cells produced by co-culture with normal peripheral blood mononuclear 
cells and serum from a patients with systemic sclerosis. 
against cultured human umbilical vein endothelial cells (see fig 4). 
All 48 patients were serially examined and successive bleeds were 
performed on 3-10 occasions over a period of 2 years. Of the 10 
patients exhibiting ADCC, 7 showed cytotoxicity for each successive 
bleed, whereas in 3 patients, the cytotoxic effect was not observed in 
later bleeds. 
In contrast to the above results obtained from patients with 
systemic sclerosis, only 2 out of 44 sera obtained from normal control 
donors showed "excess % specific cytotoxicity" of >10%. ie <5% of sera 
from normal control donors exhibited ADCC against cultured human 
umbilical vein endothelial cells (see fig 4). 
When the levels of "excess % specific cytotoxicity" obtained 
following co-culture of sera from patients with systemic sclerosis and 
normal controls, were statistically compared using the Wilcoxon 
Mann-Whitney test, no significant difference was observed (p = 0.075) 
due to the disproportionately large number of nil values in both 
groups. However, when a comparison of the proportion of sera from 
patients with systemic sclerosis demonstrating "excess % specific 
cytotoxicity" of >10% was statistically compared to the proportion of 
control sera demonstrating "excess % specific cytotoxicity" of >10% a 
significant difference between the 2 populations was observed 
(p <0.025). 
In addition to the group of patients with systemic sclerosis 49 
patients with SLE were also observed for their effects on the 
cytotoxicity of human umbilical vein endothelial cells following 
co-culture with patient serum and normal peripheral blood mononuclear 
cells. 7 patients with SLE exhibited increases in "excess % specific 
cytotoxicity"of >10%. ie 14% of patients with SLE exhibited ADCC 
against cultured human umbilical vein endothelial cells (see fig 4). 
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Figure 4 Excess % specific Cytotoxici ty of human umbilical vein 
endothelial cells produced by co-culture with normal peripheral blood 
mononuclear cells and sera from patients with Systemic sclerosis and 
SLE or normal controls. 
When studied serially, 4 patients showed cytotoxic effects when up to 
14 successive bleeds were tested. 2 patients were not tested on more 
than one occasion and in one patient the cytotoxic effect was no 
longer demonstrated by serum obtained from successive bleeds. When 
compared using both statistical tests, the SLE and control groups did 
not differ significantly. 
Comment 
Sera from approximately 20% of patients with systemic sclerosis 
and 14% patients with SLE demonstrated enhanced cytotoxicity of 
cultured human umbilical vein endothelial cells following co-culture 
with normal human peripheral blood mononuclear cells. The majority of 
these patients also exhibited enhanced cytotoxicity when examined 
serially over a period of 2 years. In contrast, <5% of sera from 
normal control donors exhibited cytotoxicity against human umbilical 
vein endothelial cells. 
3.3.2.2 Errect or co-culture or human umbilical artery endothelial 
cells with serum and peripheral blood mononuclear cells 
28 patients with systemic sclerosis were examined for 
cytotoxicity against arterial endothelial cells following co-culture 
with sera and normal peripheral blood mononuclear cells. Sera from 6 
patients exhibited ADCC; ie approximately 20% of patients with 
systemic sclerosis showed cytotoxicity towards cultured arterial 
endothelial cells following co-culture with normal peripheral blood 
mononuclear cells (see fig 5). However, the levels of "excess % 
specific cytotoxicity" of arterial endothelial cells obtained 
following co-culture with sera from patients with systemic sclerosis 
and normal controls, were not significantly different as determined by 
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Figure 5 ExcesS % specific cytotoxicity of human umbilical artery 
endothelial cells produced by co-culture with normal peripheral blood 
mononuclear cells and sera from patients with systemic sclerosis or 
normal controls. 
the Wilcoxon Mann-Whitney and chi-squared tests. 
Sera from 3 patients that had previously demonstrated ADCC 
against venous endothelial cells failed to cause cytotoxicity of 
arterial targets. These 3 sera correlated with those those which had 
lost ADCC activity in serial bleeds. In addition, 6 sera derived from 
patients with SLE which had previously shown ADCC towards human 
umbilical vein endothelial cells were also tested for their effect 
against cultured arterial endothelial cells. 5 of the 6 sera once 
more, showed "excess % specific cytotoxicity" of )10%. In contrast, 
only 1 of 18 sera derived from normal control donors showed enhanced 
cytotoxicity towards arterial endothelial cells. The results obtained 
following the co-culture of human umbilical artery endothelial cells 
with serum from patients with systemic sclerosis and normal peripheral 
blood mononuclear cells are summarized in fig 5. 
Comment 
Approximately 20% of sera derived from patients with systemic 
sclerosis were cytotoxic towards cultured human arterial endothelial 
cells following co-cuI ture with normal human peripheral blood 
mononuclear cells. These sera were also cytotoxic against human 
umbilical vein endothelial cells. 
3.3.2.3 Direct serum induced cytotoxicity of human umbilical 
endothelial cells 
All the serum samples tested in co-culture with peripheral blood 
mononuclear cells and either venous or arterial cells were also 
examined for a direct serum induced cytotoxicity against the same 
targets. No evidence of venouS or arterial endothelial cell 
84 
cytotoxicity was found with 5% serum from patients with systemic 
sclerosis or SLE. 
Further studies were carried out, in 19 patients with systemic 
sclerosis, 15 patients with SLE and 19 normal controls, to determine 
the effects of 20% serum on cultured venous endothelial cells either 
alone or in the presence of normal rabbit serum as a source of 
complement. Once again, no increase in 51 chromium release was observed 
following exposure to 20% serum either alone or with added complement. 
Comment 
No evidence of direct serum induced cytotoxicity of venous or 
arterial endothelial cells was demonstrated by 5% sera obtained from 
patients with systemic sclerosis and SLE. In addition, cytotoxicity 
against venous endothelium by 20% serum, either alone or in the 
presence of complement, was not detected. 
3.3.2.4 Effect of serum pre-incubation with target ce1ls 
No increase in "excess % specific cytotoxicity" was observed 
following the pre-incubation of human umbilical vein endothelial cells 
with serum from normal control donors. However, when endothelial 
cells were pre-incubated with sera from patients with systemic 
sclerosis, 7 sera consistently demonstrated increased "excess % 
specific cytotoxicity" of )10%. These sera had previously produced 
cytotoxicity against against human umbilical vein endothelial cells by 
co-culture with peripheral blood mononuclear cells. Sera from 3 
patients with systemic sclerosis, which had previously produced ADCC, 
did not produce cytotoxicity following pre-incubation with target 
cells. These samples correlated with those which had lost ADCC 
activity in serial bleeds. In addition, 3 sera derived from patients 
with SLE also produced cytotoxicity following pre-incubation of target 
cells. (see fig 6 and table 4) 
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The effect of serum pre-incubation of target cells on the excess 
% specific cytotoxicity of human umbilical vein endothelial cells 
produced by co-culture with normal human peripheral blood mononuclear 
cells and sera from 10 patients with systemic sclerosis, who had 
previously demonstrated enhanced cytotoxicity of endothelial cells in 
co-culture experiments. 
Table 4 
The effect,on endothelial cytotoxicity, of pre-incubating target and 
effector cells with sera from patients with systemic sclerosis capable 
of producing ADCC of human umbilical vein endothelial cells. 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
(+) = "Excess 
(-) = "Excess 
Target cell 
pre-incubation 
Effector cell 
pre-incubation 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
% specific cytotoxicity > 10 
% specific cytotoxicity < 10 
Co-culture (target 
& effector cells) 
+ 
+ (-)* 
+ 
+ (-)* 
+ 
+ 
+ 
+ 
+ (-)* 
+ 
which have lost cytotoxic activity in successive (*) = Serum samples 
bleeds 
....... 
3.3.2.5 Errect or serum pre-incubation with errector cells 
Sera from 10 patients with systemic sclerosis which had 
previously produced cytotoxicity in co-culture experiments were also 
examined in studies in which the effector cells were pre-incubated 
with serum. In contrast to pre-incubation with target cells, only one 
serum showed enhanced cytotoxicity of venous endothelium following 
preincubation with effector cells. (see fig 7 and table 4) 
Comment 
These results established that the cytotoxicity inducing factor 
present in the sera of patients with systemic sclerosis was capable of 
binding to human umbilical vein endothelial cells; a finding 
consistent with it being an antibody directed against the vascular 
endothelium. In the one patient that binding to effector cells 
occurred a different factor, such as fragments of IgG or a cytokine, 
may be involved. 
3.3.2.6 Errect or serum titration 
The effects of serial dilutions of serum from 1 patient with 
SLE and 2 patients with systemic sclerosis in co-culture experiments 
are illustrated in fig B. Enhanced cytotoxicity was observed with 
serum dilutions up to 1/106 with serum from the patient with SLE. ie 
cytotoxicity of human umbilical vein endothelial cells following 
co-culture with peripheral blood mononuclear cells was observed with 
serum concentrations as low as 5x10-6 %. Serum from patients with 
systemic sclerosis exhibited "excess % specific cytotoxicity"of )10% 
when serum was diluted 1/10 and 1/2, ie 0.5% and 2.5% final 
concentration. 
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The effect of serum pre-incubation of effector cells, on the 
excess % specific cytotoxicity of human umbilical vein endothelial 
cells produced by co-culture with normal peripheral blood mononuclear 
cells and sera from 10 patients with systemic sclerosis, who had 
previously demonstrated enhanced cytotoxicity of endothelial cells in 
co-culture experiments. 
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Figure 8 
The effect of serum dilution, on the excess % specific 
cytotoxicity of human umbilical vein endothelial cells produced by 
co-culture with normal peripheral blood mononuclear cells and sera 
from 1 patient with SLE (a), and 2 patients with systemic sclerosis (b,c). 
Comment 
Enhanced cytotoxicity towards cultured human umbilical vein 
endothelial cells following co-culture with serum and peripheral blood 
mononuclear cells was observed with serum dilutions as low as 1/10 6• 
This observation is consistent with the view that the mechanism of 
cytotoxicity occurring in co-culture experiments is ADCC since very 
low titres of antibody are sufficient to produce this type of 
cytotoxicity. In addition, these results indicate variable titres of 
the antibody mediating ADCC of endothelial cells, which could be 
responsible for the fluctuating results obtained in the serial 
studies. 
3.3.2.1 Errect or depletion or errector cell populations for use in 
co-culture studies with human uabilical vein endothelial 
cells 
Adherence to plastic 
The effect of the plastic adherence depletion of effector cells 
on "excess % specific cytotoxicity" following co-culture with sera 
from patients with systemic sclerosis and cultured human umbilical 
vein endothelial cells is shown in fig 9. An enhanced cytotoxicity 
was observed in 6 of the 7 cases. 
Comment 
The enhanced cytotoxicity observed in these 6 cases implied the 
enrichment of the remaining population of effector cells following 
adherent cell depletion, and indicate that the population of effector 
cells mediating cytotoxicity against human umbilical vein endothelial 
cells was non-adherent. 
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Figure 9 
The effect of adherent cell depletion on the excess % specific 
cytotoxicity of human umbilical vein endothelial cells produced by 
co-cuI ture wi th normal peripheral blood mononuclear cells and sera 
from 7 patients with systemic sclerosis. 
Treatment with carbonyl iron powder 
The effect of depletion of peripheral blood mononuclear cells by 
treatment with carbo I iron ny powder on "excess % specific 
cytotoxicity" following co-culture with sera derived from patients 
with systemic sclerosis is illustrated in fig 10. In all 3 cases, 
enhanced cytotoxicity was observed. 
Comment 
These results again suggested that the population of effector 
cells causing cytotoxicity was non-adherent and also non-phagocytic. 
3.3.2.8 Errect or pure monocytes as efrector cells co-culture studies 
with human uabilical vein endothelial cells 
When monocytes were isolated, and used at a concentration of 2.5 
x 10 4 cells / well, as effector cells in co-culture studies with sera 
from patients with systemic sclerosis and human umbilical vein 
endothelial cells, the "excess % specific cytotoxicity" was zero for 
each sera examined (see fig 11). 
Comment 
These results confirmed those of the adherence depletion and 
phagocytosis studies, and provided firm evidence that monocytes were 
not the responsible effector cells mediating cytotoxicity towards 
human umbilical vein endothelial cells in co-culture studies. 
3.3.2.9 Errect or column chromatography or sera for use in co-culture 
studies with human uabilical vein endothelial cells 
The results of ULTROGEL fractionation of sera capable of inducing 
enhanced cytotoxicity of human umbilical vein endothelial cells 
following co-culture with normal human peripheral blood mononuclear 
cells are shown in figs 12, 13, 14, 15 & 16. Sera from 4 patients 
with systemic sclerosis and from one patient with SLE (Fig 15) were 
fractionated and 10 pooled fractions collected. The IgG levels were 
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Figure 10 
The effect of carbonyl iron depletion on the excess % specific 
cytotoxicity of human umbilical vein endothelial cells produced by 
co-cuI ture wi th normal peripheral blood mononuclear cells and sera 
from 3 patients with systemic sclerosis. 
~ 
~ a_ 
(.) a-
X 
0 
...., 
0 
~ 
~ 
(.) 
(.) a_ 
.... 
. -(.) 
Q) 
c. 
(J) 
oQ 
(J) 
(J) 
Cl) 
CJ 
>< 
W 
Figure 11 
30 
20 
10 
o , 
Peripheral blood 
mononuclear cells 
I , 
Monocytes 
The effect of pure monocytes as effector cells, on the excess % 
specific cytotoxicity of human umbilical vein endothelial cells 
produced by co-culture with normal peripheral blood mononuclear cells 
and sera from 3 patients with systemic sclerosis. 
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Figure 12 
Excess % specific cytotoxicity C __ ) of human umbilical vein 
endothelial cells p'oduced by co-culture with normal peripheral "blood 
mononuclear cells and pooled ULTROGEL fractions of sera from a patient 
with systemic sclerosis. The IgG content of each fraction is also 
illustrated C •• ). 
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Figure 13 
Excess % specific cytotoxici ty ( ) of human umbilical vein 
endothelial cells produced by co-culture with normal peripheral blood 
mononuclear cells and pooled ULTROGEL fractions of sera from a patient 
with systemic sclerosis. The IgG content of each fraction is also 
illustrated ( •• ). 
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Figure 14 
Excess % specific cytotoxicity ( ) of human umbilical vein 
endothelial cells produced by co-culture with normal peripheral blood 
mononuclear cells and pooled ULTROGEL fractions of sera from a patient 
with systemic sclerosis. The IgG content of each fraction is also 
illustrated ( •• ). 
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Figure 15 
Excess % specific cytotoxicity ( __ ) of human umbilical vein 
endothelial cells produced by co-culture with normal peripheral blood 
mononuclear cells and pooled ULTROGEL fractions of sera from a patient 
with systemic sclerosis. The IgG content of each fraction is also 
illustrated ( •• ). 
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Figure 16 
Excess % specific cytotoxicity ( __ ) of human umbilical vein 
endothelial cells produced by co-culture with normal peripheral blood 
mononuclear cells and pooled ULTROGEL fractions of sera from a patient 
with systemic sclerosis. The IgG content of each fraction is also 
illustrated ( •• ). 
determined for each fraction and these are also illustrated in figs 
12-16. The "excess % specific cytotoxicity" produced by the fractions 
correlated with the IgG levels present in these fractions for 4 of the 
5 fractionated sera. In one case, the elevated "excess % specific 
cytotoxicity" continued in fractions beyond the peak of IgG (Fig 16). 
Further fractionation of different bleeds obtained from this patient 
were carried out and the same effect was observed on 3 separate 
occasions. (This serum was the only one capable of sensi tizing 
effector cells in pre-incubation studies.) In addition to the 
fractionation of patient sera, serum samples obtained from normal 
controls were also fractionated in the same way. None of these 
fractions produced ADCC of endothelial cells. 
Comment 
ULTROGEL fractionation of sera capable of inducing cytotoxicity 
against human umbilical vein endothelial cells demonstrated that the 
cytotoxicity-inducing activity paralleled the IgG content of 
fractions and was consistent with the idea that the factor was an 
antibody directed against the vascular endothelium. 
3.3.2.10 Effect of IgG preparations in co-culture studies witb bu.an 
umbilical vein endotbelial cells 
In addition to the fractionation of sera using ULTROGEL column 
chromatography, IgG was also prepared, by DEAE-sepharose and 
staphylococcal protein A column chromatography, and the resulting 
samples of IgG were tested in co-culture studies with human umbilical 
vein endothelial target cells. The results obtained are shown in table 
5. 
As illustrated, 7 of 10 patients who had previously exhibited 
enhanced cytotoxicity of human umbilical vein endothelial cells, also 
demonstrated cytotoxicity by IgG preparations obtained by DEAE 
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Table 5 
The effect, on endothelial cytotoxicity, of IgG prepared by DEAE 
sepharose and Staphylococcal protein A column chromatography, from 
sera of patients with systemic sclerosis capable of producing ADCC of 
human umbilical vein endothelial cells. 
Patient DEAE Protein A 
1 
2 + + 
3 + 
4 + 
5 + + 
6 
7 + 
8 + 
9 
10 + 
(+) = "Excess % specific cytotoxicity" > 10 
(_) = "Excess % specific cytotoxicity" < 10 
Co-culture (serum 
& effector cells) 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
separation. 3 sera were also separated on a protein A column and the 
IgG obtained tested in co-culture experiments. 2 of the 3 showed 
"excess % specific cytotoxicity of >10%. IgG preparations were also 
prepared from 9 normal control sera, and these all failed to produce 
ADCC of cultured endothelial cells. 
Comment 
These results provided further evidence that the serum factor 
causing enhanced cytotoxicity of human umbilical vein endothelial 
cells in co-culture with peripheral blood mononuclear cells was an 
antibody of the IgG class. 
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3.4 Discussion 
3.4. 1 Basic parameters of the assays 
3.1(.1.1 Baseline and maximal 51 chromilDl release 
The spontaneous release of 51 c hromium from labelled cells in 
vi tro is known as the baseline 51 chromium release. It is mainly the 
result of target cell death occurring during the incubation period. 
The rate of 51 chromium release occurring spontaneously varies 
considerably with different cell types, and target cells showing high 
baseline values may not be used in such assays. The mean baseline 
release from human umbilical vein endothelial cells observed in this 
study was 24.37% over the 18 hour incubation period. Variation was 
observed between individual assays with extreme values of 16.59% and 
32.96%. This variation is probably due to the robustness and 
variability of endothelial cell cultures derived from different 
donors. Clearly, the number of target cells spontaneously dying over 
18 hours may vary from culture to culture. 
Values for baseline release reported by other authors compare 
favorably with the value obtained in this study, and values of 
spontaneous 51 c hromium release of 15-30% have been previously been 
described (Perlmann and Holm 1969). 
The mean value obtained in this study for maximal 51 chromium 
release was 94.48%. This figure represents the total amount of 
51 c hromium released from targets following cellular lysis. A value 
<100% is usually obtained due to the fact that a small amount of label 
remains bound to cell debris following lysis, and hence is not 
released into the supernatant (Heberman et al 1976). Previously 
reported values for maximal release of 51 chromium from dead cells are 
in the range of 80-95% (Wigzell 1965; Holm and Perlmann 1967) 
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3.-.1.2 Spontaneous cell mediated cytotoIicity 
Spontaneous cell mediated cytotoxicity is the process of 
destruction of target cells by normal lymphocytes in the absence of 
any sensitizing agent. The responsible effector cells are natural 
killer (NK) cells, ie cells which can spontaneously kill certain 
susceptible target cells in a manner which is not MHC restricted. NK 
cells possess receptors for the Fc region of IgG and hence may also be 
capable of mediating ADCC. In fact NK cells and K cells may consist of 
the same, or an overlapping sub-population of cells within the 
peripheral blood mononuclear cell population. 
The specificity of lysis by NK cells is demonstrated by the fact 
that some targets are resistant to killing by NK cells. It is not 
known, however, whether susceptible cells share a common determinant 
or whether multiple subsets of NK cells exist, all with different 
target cell specificities. 
In this study, the mean value obtained for spontaneous cell 
mediated cytotoxicity towards cultured human umbilical vein endo-
thelial cells was 13.16% specific cytotoxicity. Although in general 
there was good correlation in the levels of spontaneous cytotoxicity 
between assays (as illustrated by a SEM of 0.59%) occasional large 
fluctuations were observed. The reasons for these variations is 
uncertain. However, one possible explanation for this variability 
could be that altered ratios of different subpopulations of effector 
cells are isolated on each occasion. Each assay was performed on 
endothelial cells derived from a different umbilical cord. It is also 
possible, therefore, that variations in the susceptibility to lysis of 
endothelial cells obtained in this way, may be an additional factor 
accounting for the wide range of values obtained for spontaneous cell 
mediated cytotoxicity. A particular determinant on the target cell 
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surface may determine whether cellular lysis by NK cells occurs. 
Thus, the absence or presence of such a determinant, or its altered 
frequency or distribution, may result in the exhibition of differing 
susceptibilities to lysis of endothelial cells obtained from different 
donors. 
3.-.1.3 E~~ector cell donor variation 
The spontaneous cell mediated cytotoxicity observed with 
effector cells obtained from different donors, showed little 
variation. The observed variation may be due to higher numbers of 
competent cytotoxicity mediating cells occurring in the effector cell 
population. In order to eliminate any variation arising from different 
effector cell donors, a single donor (CH) was used for all routine 
studies. 
3._.1.- E~~ector cell to target cell ratio 
The number of cells capable of mediating ADCC wi thin the 
mononuclear population is likely to be very small (Maclennan et al 
1976). Hence there is a requirement for an excess of effector cells 
in order that significant target cell lysis may occur. To determine 
the optimal number of peripheral blood mononuclear cells to use in 
°t ADCC p~oduced by varying numbers of effector cytotoxiCl Y assays, ~ 
cells, in combination with a standard number of target cells, was 
assessed. 
The results obtained showed that, for a given number of target 
cells, ADCC increased as the number of effector cells increased, an 
effect which began to plateau when the number of peripheral blood 
mononuclear cells per well was 5x105. 
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Maximal ADCC was observed when the number of peripheral blood 
mononuclear cells per well was 5-10x105. The yield of peripheral blood 
mononuclear cells obtained in these studies prohibited the use of this 
amount of effector cells and so, as a compromise, the number of 
effector cells used was 2.5x105 per well. 
3.11.1.5 Intra and inter assay variation 
In the present study, the intra-assay variation observed between 
triplicate assay wells was relatively low and the values obtained for 
baseline 51 c hromium release were relatively consistent between 
successive assays. Hence, cytotoxicity assays were performed with 
reproducible accuracy. However, some what greater levels of variation 
were observed between values of spontaneous cell mediated cytotoxicity 
which were obtained in assays performed on separate occasions. In 
addition, the levels of ADCC obtained for a particular serum sample 
tested on separate occasions was variable. This type of variation is 
not due to any controllable factor, and is an inherent problem in 
cytotoxicity assays of this nature. 
A major source of this inherent variability could be the number 
of competent effector cells present in any particular sample. A 
different composition in the effector cell population may arise from 
alterations in the way in which peripheral blood mononuclear cells 
recirculate between the blood and tissues, in vivo. Blood collected 
on different occasions may contain different amounts of the various 
subpopulations of effector cells (Frietas & Desousa 1976). In 
addition to the composition of the effector cell population, and the 
nature of the cells present, the activation state of these cells may 
be important in determining the level of spontaneous cell mediated 
cytotoxicity (Ralph 1984). 
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The various values obtained for the "excess % specific 
cytotoxicity" following co-culture of target and effector cells and an 
individual serum sample may also be a result of the different 
composition of effector cell populations. The number and distribution 
of Fc receptors may be another important factor, as discussed earlier 
in the introduction to this chapter. 
Target cell heterogeneity could be another factor responsible 
for this inherent variability. The variation in values obtained for 
spontaneous cell mediated cytotoxicity may be explained by differing 
frequencies of the target cell surface determinants responsible for 
inducing NK cell mediated cytotoxicity. Target cell heterogeneity 
could also be an important factor in determining levels of ADCC. 
Cell surface antigens involved in the binding of specific antibody, 
may be present at different densities on human umbilical vein 
endothelial cells obtained from different umbilical cords. Such a 
variation in specific antigen densities could be yet another important 
factor accounting for the variable levels of ADCC observed. 
3.4.2 Clinical studies 
3.4.2.1 Co-culture studies 
Investigations concerning the possibility of ADCC as a 
pathogenic mechanism in human autoimmune diseases remains limited. The 
probable reason for the small number of such studies is the complex 
nature of ADCC assays, which require the co-culture of two separate 
populations of cells. However, IgG from patients with rheumatoid 
arthritis, capable of enhancing cytotoxicity towards chang liver cells 
in co-culture studies has been described (Maclennan et al 1969; Panayi 
1976). In addition, antilymphocytic antibodies from patients with 
h to l'nduce ADCC (Kumagi et al 1981). Penning et al SLE have been sown 
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(1984a) described a serum factor in 18% of patients with systemic 
sclerosis and 45% of patients with SLE, that was capable of enhancing 
the cytotoxicity of a variety of established human target cells when 
co-cultured with normal human peripheral blood mononuclear cells. 
More relevant to what may occur in vivo, however, is the use of 
primary cultures of vascular endothelial cells as targets. The 
endothelium is in intimate contact with both the sensitizing antibody 
and circulating effector K cells, and thus could readily become a 
target in vivo. Moreover, the use of vascular endothelium as a target 
in ADCC assays is particularly relevant in systemic sclerosis, since 
vascular lesions are a major feature of the disease. 
In this study, endothelial cells were isolated and grown in 
vitro for use as target cells in cytotoxicity assays. Serum from 
approximately 20% of patients with systemic sclerosis showed enhanced 
cytotoxicity of both venous and arterial endothelium, following 
co-culture with normal human peripheral blood mononuclear cells. In 
addition, 14% of serum from patients with SLE showed a similar 
enhancement of cytotoxicity against human umbilical vein endothelial 
cells. 
Similar results were obtained by Penning et al (1984a, 1984b, 
1985) who showed enhanced cytotoxicity of human umbilical vein 
endothelial cells following co-culture with peripheral blood 
mononuclear cells by sera obtained from 25% and 9% of patients with 
systemic sclerosis and SLE respectively. 
The present study has established, through the use of IgG 
preparations obtained by the methods of ion exchange and affinity 
chromatography, that IgG is the serum factor responsible for mediating 
this ADCC of vascular endothelial cells. Further confirmation was 
provided by column chromatography which revealed that the responsible 
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serum factors causing cytotoxicity were confined to IgG containing 
fractions. However, the fractionation of serum obtained from one 
patient showed that cytotoxicity continued beyond the IgG containing 
fractions. In this patient it is possible that IgG fragments may also 
be responsible for mediating ADCC. It is interesting to note, that 
serum obtained from this patient was the only serum which caused 
cytotoxicity following preincubation of effector cells. In all other 
sera examined, no such effect was observed. A possible explanation for 
this effect is that immunoglobulin fragments may be capable of 
"arming" K cells in a manner similar to that described by Greenberg & 
Shen (1973). Alternatively, a non-immunoglobulin serum component, 
such as a cytokine, may have caused the activation of peripheral blood 
mononuclear cells during the preincubation period. 
The majority of sera which demonstrated ADCC of cultured human 
umbilical vein endothelial cells, were capable of binding to target 
cells, and enhanced cytotoxicity of these cells was observed following 
preincubation of the target cell monolayer. These results indicate 
that the IgG capable of mediating ADCC, binds to the target cell prior 
to the occurrence of cellular lysis. This evidence supports the idea 
that the serum factor is an antibody directed against the vascular 
endothelium. Antiendothelial cell antibodies have previously been 
described by alternative methods, such as ELISA, and have been 
demonstrated in patients with systemic sclerosis, with an incidence 
similar to that of the ADCC found in this study (Hashemi et al 1987; 
Baguley et al 1987a; Byron et al 1987). It thus seems probable that 
ADCC of human umbilical vein endothelial cells demonstrated in this 
study was mediated by antiendothelial cell antibodies. 
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In addition to cytotoxicity towards cultured human umbilical 
vein endothelial cells, this study has also demonstrated a similar 
cytotoxicity towards human umbilical arterial endothelial cells. Sera 
obtained from patients with both systemic sclerosis and SLE, that 
produced enhanced cytotoxicity of venous endothelial cells, also 
caused enhanced cytotoxicity of arterial endothelial cells. It has 
been suggested that endothelial cells of venous and arterial origin 
exhibit different cell surface molecules. However, the antiendo-
thelial cell antibody that is present in the sera of patients with 
systemic sclerosis and SLE and which mediates ADCC must, on the 
evidence of these results, be directed against an antigen common to 
the surface of both venous and arterial human umbilical endothelium. 
The demonstration of ADCC against arterial target cells is of 
major pathological significance, as the characteristic vascular lesion 
of systemic sclerosis principally affects arteries. Although the 
observations made in this study occurred in vitro, it is also possible 
that a similar cytotoxic mechanism could also occur in vivo, if 
arterial endothelial cells exhibit the same antigenic determinants as 
the cultured endothelial cells used in this study. The vascular 
defects which are a common feature of systemic sclerosis could thus be 
explained by an antibody directed against the vascular endothelium, 
which is capable of binding to endothelial cells. K cells could then 
mediate endothelial cell lysis by binding to antibody via their Fc 
receptors, and thus contribute to the development of the vascular 
lesions which are characteristic of the disorder. 
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3.4.2.2 Direct seru. induced cytotoxicity of hu.an u.bilical 
endothelial cells 
One of the pathogenic mechanisms that was initially proposed for 
systemic sclerosis was the presence of a circulating factor directly 
cytotoxic for vascular endothelium. The first investigators to 
describe such a circulating endothelial cell specific cytotoxic factor 
were Kahaleh et al (1978, 1979) who reported that sera from 60% of 
patients with systemic sclerosis caused diminished 3H thymidine 
incorporation by cultured human umbilical vein endothelial cells. 
Cohen et al (1983) later reported a similar cytotoxic factor in the 
sera of patients with systemic sclerosis, but they failed to show 
specificity towards endothelial cells. Shanahan and Korn (1982) also 
showed a lack of target cell specificity and in addition, they found 
cytotoxic activity in sera from patients with other connective tissue 
diseases, an observation which was also reported by Meyer et al 
(1983). 
In contrast to these reports, this study has failed to 
demonstrate any direct serum induced cytotoxicity of endothelial cells 
by sera from patients with systemic sclerosis. This observation is, 
however, supported by the work of Summers et al (1984) who also failed 
to demonstrate the presence of an endothelial cytotoxic factor in 
sera obtained from patients with systemic sclerosis. 
The conflicting observations reported in the present study may 
be explained by the different types of assays used in the assessment 
of cytotoxicity. The work of Kahaleh et al (1978, 1979); Cohen et al 
(1983) and Shanahan and Korn (1982) was carried out using 3H thymidine 
incorporation studies, whereas the experiments performed in this study 
involved 51 chromium release assays for the assessment of endothelial 
cell cytotoxicity. The former assay gives an indication of cell 
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growth by measuring DNA synthesis, whereas 51 chromium release assays 
measure cellular lysis. It is possible that the earlier reports in 
fact described an endothelial cell growth inhibitory factor as opposed 
to a cytotoxic factor. Penning (1984a) also demonstrated the absence 
of an endothelial cytotoxic factor in the sera of patients with 
systemic sclerosis as assessed by 51 chromium release. However when 
these sera were tested in 3H thymidine uptake studies, inhibition of 
uptake was revealed. 
Variations in the patient subpopulations studied may be another 
factor explaining the conflicting reports on direct serum induced 
endothelial cell cytotoxicity. Previous investigators have shown an 
incidence of serum cytotoxic factor in patients with systemic 
sclerosis that has varied from 60% to 7% (Kahaleh et al 1979; 
Shanahan and Korn 1982; Cohen et al 1983). It is possible therefore, 
that different sub-populations of patients, showing differing degrees 
of severity of disease, may be a cause for the varying and conflicting 
incidence of this serum induced cytotoxicity. Finally, it has been 
proposed that the endothelial cell cytotoxic factor may be an artifact 
produced by oxidation occurring during the storage of serum (Blake et 
al 1985); an explanation that would also explain the conflicting 
results obtained in the earlier studies. All serum samples obtained 
for the present study were treated in a standard manner, stored at 
-80 oc and thawed samples were not reused. In addition, all new serum 
samples were tested prior to long periods of storage to minimize the 
development of oxidative artifacts. 
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3.4.2.3 Serua titration studies 
One of the features characteristic of ADCC is the fact that very 
low titres of antibody are capable of producing this type of 
cytotoxicity. The amount of antibody capable of mediating ADCC is 
much lower than that required to produce complement mediated lysis 
(Perlmann & Holm 1969; Perlmann & Perlmann 1970). 
Serum dilutions were carried out in the present study and 1:2; 
1:10; and 1:10 6 were the lowest serum dilutions capable of mediating 
cytotoxicity by the 3 different sera investigated. The varying titres 
of serum required for ADCC to occur wi th samples deri ved from 
patients, may be due to different amounts of specific antibody present 
in the serum sample. In addition antibody affinity may be important. 
High affinity antibody may allow greater numbers of effector cells to 
participate in ADCC, since more antibody will bind to antigenic 
determinants on target cells, and hence more Fc si tes will be 
available for effector cell binding. Differences in affinity may be 
due to different antibody subclasses taking part in the ADCC reaction, 
and the involvement of different Fc receptors which show varying 
binding affinities for IgG (Hogg, 1988). 
However, the amount of serum required to mediate ADCC was low, 
providing further evidence that the mode of cytotoxicity is probably 
ADCC. In addition, heat inactivation of test serum did not cause a 
decrease in ADCC (data not presented) thus further eliminating the 
possibility of complement mediated lysis. 
3.4.2.4 Errector cell populations 
The nature of the effector cell mediating ADCC may be variable. 
It appears that the nature of the target cell, and the sensitizing 
antibody are important factors, as discussed in the introduction to 
this chapter. The major effector cell capable of mediating ADCC is 
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thought to be the K cell, an Fc receptor bearing, non-thymus dependent 
lymphocyte (Bean et al 1976). However, monocytes, poymorphonuclear 
neutrophils and macrophages have also been shown to mediate ADCC in 
some in vitro systems (Richter et al 1983; Shen et al 1987; Ralph 
1984; Johnson et al 1985). In this study, depletion studies were 
performed in an attempt to determine the nature of the effector cells 
mediating the ADCC of vascular endothelium. Preparations of 
peripheral blood mononuclear cells were depleted by plastic adherence, 
or phagocytosis of carbonyl iron, and the remaining purified cell 
preparations were then used in cytotoxicity assays. 
Following the adherent cell depletion of peripheral blood 
mononuclear cells by incubation on plastic petri dishes, a rise in 
ADCC was observed. This effect was also seen following treatment of 
peripheral blood mononuclear cells with carbonyl iron. These results 
indicate that the effector cells responsible for mediating the ADCC 
described in this study, were unlikely to be macrophages or monocytes. 
In order to obtain further proof that monocytes were not capable 
of mediating ADCC, pure preparations of this cell type were isolated 
from a suspension of peripheral blood mononuclear cells. These were 
then used as effector cells in ADCC assays. No cytotoxicity was 
detected, adding further evidence that monocytes were not the effector 
cells required for ADCC to occur in the assay system under 
observation. In addition, pure polymorphonuclear neutrophils were 
isolated and in preliminary experiments, these cells also failed to 
produce ADCC of cultured endothelial cells (data not presented). 
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Hence the effector cells responsible for mediating the ADCC of 
vascular endothelium, which have previously been described as non-B, 
non-T and to possess Fc receptors (Penning 1984a), are neither plastic 
adherent nor phagocytic, and are unlikely, therefore, to be either 
monocytes or macrophages. 
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CHAPTER 4 
PROSTACYCLIN SYNTHESIS BY HUMAN 
UMBILICAL VEIN ENDOTHELIAL CELLS 
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4.1 
11.1.1 
Introduction 
The discovery of prostacyclin 
In 1975 Moncada and colleagues discovered a sUbstance in the 
vessel wall which they called PGX and which was later termed 
prostacyclin or PGI2 (Moncada et al 1976a). These workers discovered 
that this compound relaxed vascular strips in vitro and acted as a 
very potent inhibitor of platelet aggregation. Further 
characterization of this compound showed that it caused vasodilation 
in vivo, was the most potent inhibitor of platelet aggregation known 
and possessed antithrombotic properties (Armstrong et al 1977; Higgs 
et al 1978; Ubatuba et al 1979). 
4.1.2 Sites of synthesis of prostacyclin 
Early studies of prostacyclin were performed on arterial 
micro somes prepared from homogenates of whole arterial walls (Bunting 
et al 1976) or with arterial and venous strips (Raz et al 1977; 
Johnson et al 1976). Moncada and co-workers (1977) demonstrated the 
differential formation of prostacyclin in the layers of rabbit aorta, 
the intimal layer being the major site of synthesis, with the media 
and adventitia showing progressively diminishing synthetic capacity. 
Weksler et al (1977) were the first to demonstrate the synthesis 
of prostacyclin from human umbilical vein and bovine aortic 
endothelial cells in vitro. Other types of endothelial cells have 
since been shown to produce prostacyclin in vitro, including porcine 
endothelial cells and also microvascular endothelial cells (McIntyre 
et al 1978; Gerritsen 1987). However, whereas prostacyclin is the 
major product of arachidonic acid metabolism in endothelial cells 
derived from large blood vessels, a study performed by Charo et al 
(1984) demonstrated that cultured endothelial cells derived from 
dermal microvessels in human new born foreskin, release PGF2 and PGE2 
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in greater quantities than PGI2, which was only released in relatively 
small amounts. Although fibroblasts and smooth muscle cells also 
synthesize prostacyclin, the levels of prostacyclin released by 
endothelial cells is much greater (Ali et al 1980; Baenziger et al 
1979). Prostacyclin is also produced by renal glomerular cells, 
gastric mucosal cells, macrophages and mesothelial cells (Hassid et al 
1979; Whittle et al 1980; Humes et al 1977 & Herman et al 1979). 
However, the vascular endothelium appears to be the major site of 
prostacyclin synthesis in the body (Schror 1985). 
4.1.3 Structure of prostacyclin 
Prostacyclin represents a member of the group of compounds known 
as eicosanoids, which includes prostaglandins (PG), thromboxanes (TX), 
leukotrienes (LT) and other oxygenation products of polyunsaturated 
20-carbon unsaturated fatty acids, in particular arachidonic acid. 
The chemical structures of prostacyclin and the stable product of its 
hydrolysis are illustrated in Fig 17. 
4.1.4 Biosynthesis of prostacyclin (Fig 18) 
The initial step in the biosynthesis of prostacyclin involves 
the release of arachidonic acid via the activation of phospholipase 
(primarily phospholipase A2). Arachidonic acid is either derived from 
dietary linoleic acid or is ingested as a constituent of the diet. 
After absorption from the gut, it is esterified and occurs in the body 
as a component of cell membrane phospholipids and other complex 
lipids. 
A wide variety of physical, chemical and hormonal factors may 
activate the enzyme phospholipase A2. 
released they may follow two pathways: 
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The cyclooxygenase pathway, showing the conversion of 
arachidonic acid to prostacyclin. 
The cyclo-oxygenase pathway 
This gives rise to the prostaglandins and thromboxanes. 
The lipo-oxygenase pathway 
This gives rise to the leukotrienes and other unsaturated 
hydroxy acids. 
The pathway followed in vivo varies according to the tissue and 
species. In the cyclo-oxygenase pathway, the first product is an 
unstable cyclic endoperoxide derivative (PGG2) which can proceed 
either spontaneously, or via the action of a peroxidase, to PGH 2• 
PGH2 is the common intermediate for TXA2, PGD2, PGE2, PGF2 and PGI2. 
Prostacyclin synthetase converts PGH2 into prostacyclin, which is 
unstable under physiological conditions and is rapidly hydrolysed to a 
stable compound, 6-keto-PGF1~. 
Various sUbstances act as inhibitors of prostaglandin synthesis, 
such as aspirin and other non-steroidal anti-inflammatory drugs 
(NSAIDS) which are very potent inhibitors. These compounds work by 
preventing the formation of prostaglandin endoperoxides. 
Anti-inflammatory steroids appear to reduce prostaglandin synthesis by 
decreasing the availability of substrate to cyclo-oxygenase, or by 
blocking the efflux of prostaglandins from their site of synthesis. 
The release and metabolism of arachidonic acid can be initiated 
by numerous factors including nerve stimulation, neurotransmitters (eg 
norepinephrine), neuropeptides (eg somatostatin), various hormones (eg 
bradykinin), hyperosmolar solutions and mechanical strain. 
Deformation of the cell membrane, as caused by stretching of a blood 
vessel, for instance during inflation of the lung and contraction of 
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the intestine, may also cause increased prostaglandin formation. In 
addition, so may tissue damage for example by trauma, hypoxia and 
breakdown of lysosomes. 
4.1.5 Metabolism or prostacyclin 
Under physiological conditions of pH and temperature, 
prostacyclin is an unstable molecule, with a half life in the blood of 
3 minutes, due to its rapid hydrolysis to a stable product, 
6-keto-PGF 1 ex. (Gryglewski & Moncada 1987). Circulating levels of 
prostacyclin are low (approximately 0.5 pmol/ml, 18 pg/ml) although 
plasma levels of 6-keto-PGF1~ranging from <50 pg/ml to 300 pg/ml have 
been reported (Haslam & McClenaghan 1981; Greaves & Preston 1982). 
Prostacyclin is more stable at alkaline pH and in the cold. 
Prostacyclin and 6-keto-PGF1~are both enzymatically degraded in 
vivo by 15-0H and 9-0H prostaglandin dehydrogenase and by delta-13,14 
reductase, to yield a 13, 14-dihYdro-15-oxo-PG product which has a 
longer half life (8-16 minutes) in the systemic circulation than the 
primary prostaglandins. 
Unlike PGE1 and PGE2, prostacyclin is not taken up by the lung 
transport system, and is therefore not metabolized by these enzymes, 
following one passage through the circulation. The major clearance 
route is probably via the liver and kidney. There are several urinary 
metabolites of prostacyclin including 2,3-dinor-6-keto-PGF1~and 6,15 
diketo,13,14 dihydro,2-3 dinor PGF1~(Myatt et al 1981). In addition, 
it is possible that prostacyclin and 6-keto-PGF1~ are metabolized by 
blood vessels, platelet and hepatic 9-0H prostaglandin dehydrogenase 
to an active, stable metabolite, 6-keto-PGE1 , thus implying the 
recycling of inactive products (Wong et al 1980). 
Since prostacyclin is not readily inactivated following passage 
through the lungs, it has been described as a circulating hormone 
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(Moncada et al 1978). However, its biological instability suggests 
that it is more likely to act locally. 
4.1.6 Biology of action of prostacyclin 
Prostacyclin is the most potent inhibitor of platelet 
aggregation known. In contrast thromboxane, which is also derived 
from arachidonic acid, exerts opposing effects in that it has potent 
proaggregatory and vasoconstrictor properties. Platelets are the 
major site of synthesis of thromboxane, as endothelial cells are for 
prostacyclin. Thus, a balance between these two substances maintains 
normal blood flow and control of haemostatic responses to injury. (See 
Fig 19). 
The biological effects of prostacyclin are mediated via its 
stimulatory effects on the cellular adenylate cyclase system, with 
resulting elevation in cellular levels of cAMP (Gorman et al 1977; 
Tateson et al 1977). In this respect, prostacyclin is 10x more potent 
a stimulator of platelet cAMP than PGE1 (Gorman et al 1977; Best et al 
1977). In addition, the accumulation of cAMP caused by prostacyclin 
occurs more quickly and is longer lasting than that mediated by PGE1 
(Gorman et al 1977). As well as stimulating levels of cAMP in 
platelets, prostacyclin has also been shown to exhibit this effect in 
endothelial cells (Hopkins & Gorman 1981). When cAMP levels are high, 
prostacyclin production falls thus endothelial cells may regulate 
their biosynthesis of this compound by means of a feedback inhibition 
mechanism. 
The stimulation of cAMP induced by prostacyclin has been studied 
in the platelet. Intracellular Ca 2+ ions are required for 
phospholipase activation, aggregation and the release reaction. The 
formation of thromboxane A2 in activated platelets results in the 
release of Ca2+ from bound intracellular sites. The calcium ions thus 
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The balance between thromboxane A2 and prostacyclin. 
"Thromboxane A2 provokes platelet aggregation and has a 
vasoconstrictor role on smooth muscle (III) in the vessel wall. 
Prostacyclin, a potent inhibitor of platelet aggregation, also 
produces vasodilation in smooth muscles (IV) of the vessel wall." 
(+) = positive influence (-) = negative influence 
SE = subendothelium 
released bind to calmodulin, and this calcium-calmodulin complex 
stimulates phospholipase A2 activity and also activates myosin kinase. 
Myosin is phosphorylated by the active kinase enzyme and is then able 
to interact with actin, resulting in platelet contraction and the 
release reaction (Hathaway & Adelstein 1979). Prostacyclin causes 
elevated levels of cAMP which results in Ca2+ sequestration with a 
resulting fall in phospholipase activation; thus less arachidonic acid 
is available for thromboxane and prostaglandin synthesis. Elevated 
levels of cAMP results in the activation of a cAMP-dependent protein 
kinase that phosphorylates myosin-kinase. Hence myosin phosphor-
ylation decreases, the actin-myosin interaction declines and the 
release reaction is inhibited. Thus prostacyclin is able to inhibit 
platelet activation at various metabolic levels (Weksler 1982). 
Prostacyclin is also able to reduce platelet adhesion. However, 
much greater concentrations of prostacyclin are required for adhesion 
to be inhibited (Moncada et al 1976b). When the vessel is mildly 
injured and the levels of prostacyclin in the vicinity are low, 
platelets will adhere but aggregation will be inhibited. Hence the 
process of wound healing is initiated without thrombus formation. 
Adherent platelets could provide the endothelial cells with endo-
peroxides which could then be used in further synthesis of prost-
acyclin. Experiments have demonstrated that platelet endoperoxides 
are in fact "stolen" by endothelial cells for conversion to pros-
tacyclin (Bunting et al 1976; Moncada et al 1977; Marcus et al 1980; 
Chesterman et al 1986) 
Additional actions of prostacyclin on platelets include the 
prevention of platelet shape change, and inhibition of the expression 
of procoagulant activity (PF3) and fibrinogen receptors (Ehrman & 
Jaffe 1980; Harsfalvi et al 1980; Hawiger et al 1980). Thus platelet 
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aggregation is readily inhibited by prostacyclin. Aggregation induced 
by all known aggregating agents, including thrombin, can be inhibited 
by prostacyclin, as can the secretion of vasoactive mediators which 
are released during aggregation (Bunting et al 1981). 
As well as being capable of preventing platelet aggregation, 
prostacyclin is also able to disaggregate previously clumped 
platelets, both in vitro and in vivo (Ubatuba et al 1979). Pros-
tacyclin inhibits thromboxane generation and the release of platelet 
arachidonic acid via the elevation of cAMP levels. Inhibition of clot 
retraction and a prolonged bleeding time is reported in patients 
receiving prostacyclin infusions (Ubatuba et al 1979; O'Grady et al 
1980). 
Prostacyclin also has vasodilatory properties (Weksler 1982). It 
can affect erythrocyte deformability in patients with systemic 
sclerosis and Raynaud's phenomenon, and via its effects on cAMP, alter 
polymorphonuclear leukocyte functions and adherence to the endothelium 
(Dowd et al 1981; Boxer et al 1980). "Cytoprotective" activity is 
also exhibited by prostacyclin for example its anti-ulcer actions on 
the gastric mucosa (Robert 1979). 
Thus prostacyclin has a diversity of effects on platelets, 
haemostasis and the vascular system. These effects are finely 
balanced with levels of thromboxane, which exerts opposing actions. 
When an inbalance occurs between these 2 compounds, various 
pathological states may follow (see later). 
4.1.7 Regulation of prostacyclin biosynthesis 
Endothelial cells are the major site of prostacyclin synthesis. 
However, the regulation of prostacyclin synthesis by these cells is 
poorly understood, although it appears that a close interaction with 
other cell types and their products is important, in particular with 
111 
platelets and platelet derived sUbstances. 
The rate limiting step in the synthesis of prostacyclin is the 
availability of free sUbstrate. Arachidonic acid present in cultured 
endothelial cells is obtained from plasma or medium and cannot be 
synthesized by endothelial cells (Sivarajan et al 1984; Spector et al 
1981, 1983). However arachidonic acid formed in other cells, for 
example platelets, polymorphonuclear cells and vascular smooth muscle 
cells, may be transferred to endothelial cells for the synthesis of 
prostacyclin (Schror 1985). Thus, an endogenous supply of substrate 
can exist in vivo. Endoperoxides can also be obtained from other cell 
types for the synthesis of prostacyclin, in particular platelet 
derived endoperoxides may be used by endothelial cells in the 
synthesis of prostacyclin (Bunting et al 1976; Moncada et al 1977; 
Marcus et al 1980; Chesterman et al 1986). 
Resting endothelial cells do not synthesize prostacyclin and a 
stimulus is required to initiate a response. The prostacyclin thus 
released is all newly synthesized as it is not stored by endothelial 
cells (Schror 1985) 
Serum and plasma both stimulate prostacyclin release from 
cultured endothelial cells (Seid et al 1983). Serum may affect 
prostacyclin production by providing an exogenous source of 
arachidonic acid, or else by hydrolysing cellular lipids. Factors 
present in serum generated during the clotting process, for example 
platelet derived growth factor, may also be important in inducing the 
synthesis of prostacyclin by endothelial cells (Coughlin et al 1980; 
Seid et al 1983a; Ritter et al 1982; 1983) although this finding has 
been disputed (Callahan et al 1986; Poggi et al 1983). 
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Thrombin was one of the first sUbstances shown to stimulate 
prostacyclin synthesis in cultured endothelial cells (Weksler et al 
1978). These authors proposed that thrombin stimulation of prost-
acyclin may occur in vivo to limit thrombus formation at sites of 
vascular injury. In addition, endothelial cells were shown to become 
refractory to thrombin stimulation (Weksler et al 1978). The 
mechanism of thrombin induced stimulation is unclear. Thrombin 
binding sites have been demonstrated on endothelial cells although the 
nature of these sites has not been established (Awbrey et al 1979). 
Thrombin stimulation of prostacyclin is species dependent and is not 
seen in bovine endothelial cells (Goldsmith et al 1981). 
Various other stimuli may induce the synthesis of prostacyclin 
by cultured endothelial cells, some of which are listed in table 6. 
They include chemical and mechanical mediators, drugs and sublethal 
immunological injury. C5a des arg, leukocytes, C5b-8 activated 
neutrophils and a heterologous antibody towards endothelial cells have 
all been shown to act as stimulators of prostacyclin production 
(Rampart et al 1985; Harlan & Callahan 1984; Goldsmith & McCormick 
1984; Suttorp et al 1987). Interleukin 1, ()( interferon and a 
lymphocyte derived factor have also been shown to induce prostacyclin 
synthesis in cultured endothelial cells, as have endotoxin and phorbol 
diester (Rossi et al 1985). Mechanical stress factors such as those 
induced by blood flow have also been shown to initiate a prostacyclin 
response (Frangos et al 1985; van Grondelle et al 1984; McIntire et al 
1987) • 
Several studies concerned with the production of prostacyclin by 
cultured endothelial cells have presented conflicting data. It 
appears that the endothelial cell donor and the in vitro culture 
conditions used, are important variables. Weksler et al (1977) 
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Table 6 
Exogenous activators of prostacyclin synthesis 
umbilical vein endothelial cells (Bull 1988). 
1. Enzymes 
Trypsin 
Thrombin 
2. Vasoactive pep tides 
Bradykinin 
Angiotensin II 
Histamine 
Adrenaline 
DDAVP 
3. Delayed activators 
Phorbol esters 
Endotoxin 
Interleukin-1 
4. Mechanical stimulus 
Hypoxia 
Physical assault 
Others 
Calcium ionophore A23187 
High density lipoprotein 
Hydrogen peroxide (low concentrations) 
in human 
demonstrated a two-fold increase in prostacyclin production by bovine 
aortic endothelial cells compared with human umbilical vein endo-
thelial cells. Within a particular species, arteries produce greater 
amounts of prostacyclin compared with veins (Johnson 1980). Sex may 
also have an effect , and serial passaging of endothelial cells 
results in a reduction in levels of prostacyclin release (Maggi et al 
1980; Johnson 1980; Goldsmith et al 1984). 
In addition, cell density is also important. Studies have 
demonstrated that prostacyclin production is greatest in the 
exponential phase of growth compared with confluent monolayers of 
human umbilical vein and bovine endothelial cells, and there is a 
fall in prostacyclin levels as the density of cell growth increases 
(Ali et al 1980; Evans et al 1984). However, this has been 
contradicted by Eldor et al (1983) who demonstrated an increased 
capacity to synthesize prostacyclin following the formation of a 
contact inhibited cell monolayer of bovine aortic endothelial cells. 
Arachidonic acid levels in the cell may be important in determining 
the amounts of prostacyclin synthesized, thus the concentration of 
arachidonic acid in the culture medium may be crucial (Spector et al 
1983; Hong et al 1979). 
The various agents capable of stimulating prostacyclin formation 
and release, may act by altering cellular cAMP levels. Catecholamines 
and prostacyclin itself can cause an elevation of cAMP levels, so that 
released prostacyclin could enhance its own synthesis. However, 
increased amounts of cAMP may also inhibit arachidonic acid release 
with a resulting fall in prostacyclin synthesis due to a lack of the 
precursor (Adler et al 1981). Other stimulatory agents may also 
modify endothelial cell cAMP levels. Thus, this mechanism may be a 
common pathway for the control of prostacyclin synthesis. Ca 2+ levels 
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are important in the stimulation of prostacyclin synthesis and a Ca2+ 
influx may occur following the stimulation of endothelial cells 
(Hassid 1982). In addition, prostacyclin production in response to 
serum is inhibited by TMB-8 (an antagonist of intracellular calcium 
mobilisation) and W7, a calmodulin antagonist (Seid et al 1983b). 
However, more work remains to be done in order to fully establish the 
complex mechanisms occurring in the regulation of prostacyclin 
biosynthesis by the vascular endothelium. 
4.1.8 Prostacyclin in Disease States 
Prostacyclin synthesis by vascular tissue may be altered in 
various disease states. A decrease in prostacyclin production is seen 
in diseases characterised by acute or chronic endothelial cell injury, 
or by lipid deposition in the vessel wall. Conversely, increased 
prostacyclin production is associated with diseases where there is a 
bleeding tendency and defective platelet function (Weksler 1982) 
Altered levels of prostacyclin synthesis have been described in 
atherosclerosis, and aortas from atherosclerotic rabbits produce 
enhanced amounts of prostacyclin in vitro (Voss et al 1983). In 
addition, sera from hyperlipidemic subjects caused increased synthesis 
of prostacyclin from cultured human umbilical vein endothelial cells 
(Tremoli et al 1985). Mechanically de-endothelialised rabbit aortas, 
which mimic injured vessels, produce markedly reduced levels of 
prostacyclin, thus indicating the requirement of an intact endothelial 
cell monolayer for prostacyclin synthesis (Eldor et al 1981). 
Prostacyclin production is also altered in diabetes. Johnson et 
al (1979; 1981) reported reduced vascular levels of prostacyclin in 
diabetes, as did Patel et al (1982) who measured the levels of 6-
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keto-PGF 1 ex. in superna tants from cuI tured human umbilical vein 
endothelial cells incubated in the presence of sera from diabetic 
patients. 
Foetal and placental tissues have been shown to generate much 
greater levels of prostacyclin than vessels from normal adul ts 
(Remuzzi et al 1979; Terragno et al 1978; 1979). However, placental 
and foetal vessels obtained during pre-eclampsia and eclampsia produce 
diminished amounts of prostacyclin in vitro (Remuzzi et al 1980a; 
Downing et al 1980) 
Sera from patients with haemolytic uremic syndrome fail to 
stimulate prostacyclin synthesis in cultured endothelial cells to the 
same extent as normal sera (Remuzzi et al 1980b). It has been 
postulated that these sera lack a stimulatory factor for prostacyclin 
synthesis. In patients with thrombotic thrombocytopenic purpura, a 
factor causing endothelial cell damage, which could interfere with 
normal prostacyclin production, has been described (Burns et al 1981). 
Other authors have described an abnormal rate of prostacyclin 
degradation in patients with thrombotic thrombocytopenic purpura (Chen 
et al 1981; Wu et al 1982). In addition, a plasma factor has been 
described in patients with uremia, which stimulates prostacyclin 
synthesis from cultured bovine endothelial cells. 
Nicotine has been shown to alter the production of prostacyclin 
by cultured endothelial cells. In one study by Bull et al (1985) 
prostacyclin synthesis by rat aortic rings was significantly decreased 
after 7 days continuous subcutaneous infusion of nicotine. In 
addition, the synthesis of prostacyclin by cultured endothelial cells 
obtained from placental umbilical cords of mothers who smoked, was 
markedly reduced (Busacca et al 1984) 
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The IgG fraction obtained from plasma containing the lupus 
anticoagulant, was shown to inhibit prostacyclin release by bovine 
endothelial cells and rings of rat aorta (Carreras et al 1981; 1982). 
This patient had experienced recurrent thrombosis and repeated 
spontaneous abortions, although she did not have SLE. However, plasma 
from two patients with SLE were found to inhibit prostacyclin release 
from rabbit aorta (McVerry et al 1980). In another study, cultured 
porcine endothelial cells released less prostacyclin when incubated 
with sera from patients with SLE and systemic sclerosis compared to 
that released following stimulation with normal control sera (Seid et 
al 1982). 
However, reports on altered production of prostacyclin in 
patients with systemic sclerosis remain limited. Belch et al (1984) 
found elevated levels of endogenous 6-keto-PGF1C>(" in 15 patients with 
systemic sclerosis compared with normal controls. Sera from patients 
with systemic sclerosis has been shown to inhibit the synthesis of 
prostacyclin by cultured human umbilical vein endothelial cells 
(Rustin et al 1987a). However, in another study, prostacyclin 
production by cultured endothelial cells was the same following 
incubation with sera from patients with systemic sclerosis and normal 
control sera (Evans et al 1984). Thus, conflicting data exists 
regarding the effects of sera from patients with systemic sclerosis on 
prostacyclin synthesis by cultured endothelial cells. Since pros-
tacyclin production is crucial for the maintenance of vascular 
integrity, further investigations of these serum-induced effects on 
cultured human umbilical vein endothelial cells were performed as an 
additional aspect of this study. 
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4.2 Measurement of prostacyclin levels 
Principle 
Prostacyclin has a very short half life and is rapidly converted 
to a stable metabolite, 6-keto-PGF1~. Thus, for the determination of 
prostacyclin release, 6-keto-PGF 1 t>( was measured by means of a 
radio-immunoassay. Tritiated 6-keto-PGF1~and 6-keto-PGF1~present in 
the sample under analysis, compete for binding sites on antibody 
directed against the 6-keto-PGF 1oc.molecule. Unbound 6-keto-PGF 1CX is 
removed by spining with charcoal, and the amount of labelled 
6-keto-PGF 1 ex. remaining bound to the ant i body is measured by liquid 
scintillation counting. The level of radioactivity is proportional to 
the amount of 6-keto-PGF 10( present in the test sample, and by 
reference to a standard curve, the amount of 6-keto-PGF1~expressed as 
pmol/100 pl can be determined. 
Procedure 
Test samples (1 OOpl) were mixed with an equal volume of 
tritiated 6-keto-PGF1~ and antibody, and incubated for 16-20 hours at 
40 c. Tritiated 6-keto-PGF1o<. was previously diluted in 100)11 tris 
gelatin buffer (pH 7.4) to give approximately 3000 counts per minute, 
and antibody (kindly supplied by Dr M Greaves, Dept Haematology, Royal 
Hallamshire Hospital, Sheffield), was diluted to give 50% binding in 
the absence of unlabelled 6-keto-PGF1~. All assay procedures were 
performed on ice, and duplicate tubes were prepared for each test. A 
reference standard curve was prepared in parallel by the addition of 
0-0.4 pmol/100 pl 6-keto-PGF1~ to 100 pl antibody and labelled 
6-keto-PGF 1« • Non-specific binding was determined in tubes containing 
standard, labelled 6-keto-PGF1~ and tris gelatin buffer in place of 
antibody; and total counts were assessed by the addition of 500 yl 
tris gelatin buffer to 100pl labelled 6-keto-PGF1~. 
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After overnight incubation at 4oC, 300 pI charcoal suspension 
was added to each tube, except those used for determining total 
counts, and mixed. Tubes were then centrifuged at 2000g for 15 
minutes at 40 C. 250 yl supernatant was then transferred to scintillant 
tubes and 2 ml liquid scintillant added. After mixing, samples were 
counted for 5 minutes in an LKB 1217 Rack-Beta liquid scintillation 
counter, equipped with a computer programmed to calculate the 6-
keto-PGF1~content of each sample, by reference to the standard curve. 
Results were expressed as pmol 6-keto-PGF1~/100 ~l. 
Tris gelatin buffer 
4.05g sodium chloride 
0.90g Tris 
0.25g gelatin 
500ml distilled water 
Sodium chloride and Tris in distilled water were heated to 560 C , 
prior to the addition of gelatin. The buffer was then cooled and the 
pH adjusted to 7.4. 
Charcoal suspension 
0.5g bovine serum albumin 
0.5g dextran T 70 
0.6g Norit A charcoal 
The above were made up to 100 ml in tris gelatin buffer, and the 
solution well mixed before use. 
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4.2.1 Characteristics of the radio-tm.unoassay of 6-keto-PGF1~ 
The radio-immunoassay performed in this study for the detection of 
6-keto-PGF1~ had a limit of detection of 50 pg/ml. The intra-assay 
variation between duplicate determinations within a single assay was 
<5%. The inter-assay variation of standard curves was <10% 
(coefficient of variation) [See fig 20J. The cross reactivities of 
the anti-serum to 6-keto-PGF 1 ()l", with available prostaglandins and 
metabolites were the same as those published by Greaves and Preston 
(1982) and are listed in table 7. 
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Table 7 
The cross-reactivity of the antiserum to 6-keto-PGF1ocwith available 
prostaglandins and metabolites, calculated from the mass of pros-
taglandin required to produce 50% displacement of bound 
[3HJ-6-keto-PGF1~from the binding sites (Greaves and Preston 1982) 
6-keto-PGF 1<X 
13,14-dihydro-6-keto-PGF1~ 
PGF1cx 
PGD2 
PGF2a< 
PGE1 
13, 14-dihydro-6, 15-diketo-PGF 1cx 
6,15-diketo-PGF1~ 
13, 14-dihydro-PGF 2o( 
PGA2 
PGA1 
Thromboxane B2 
13, 14-dihydro-PGE 1 
PGB1 
13, 14-dihydro-PGE 2 
13, 14-dihydro-15-keto-PGF 2 0<. 
13, 14-dihydro-15-keto-PGE 1 
Arachidonic acid 
% cross reactivity 
100.000 
1.100 
0.350 
0.250 
0.200 
0.075 
0.075 
0.075 
0.020 
0.015 
0.004 
0.004 
0.004 
0.002 
<0.001 
<0.001 
<0.001 
<0.001 
4.3 E~~ect o~ cell density on prostacyclin release ~roa cultured 
human uabilical vein endothelial cells 
4.3.1 Introchction 
Various authors have demonstrated altered prostacyclin synthesis 
by cultured endothelial cells at different cell densities. However, 
reports of enhanced synthesis during the exponential growth phase (Ali 
et al 1980; Evans et al 1984), have conflicted with the demonstration 
of increased production following the formation of a contact inhibited 
monolayer (Eldor et al 1983). In this study, therefore, experiments 
were performed in an attempt to clarify these discrepant observations. 
Prostacyclin release by human umbilical vein endothelial cells per pg 
protein and per cell was determined over a period of 2-12 days 
following 15 minute exposure to both 20% normal human AB serum and 
M199 alone, and also following 24 hour exposure to 20% normal human AB 
serum. 
4.3.2 Materials and methods 
4.3.2.1 E~~ect o~ protein content on prostacyclin release 
Primary cultures of human umbilical vein endothelial cells were 
isolated and grown to confluence in T25 flasks as previously 
described. The cells were fed at 24 hours and then subsequently at two 
day intervals, with M199 supplemented with 20% normal human AB serum. 
Confluent monolayers of human umbilical vein endothelial cells were 
passaged and seeded into gelatin coated 24 well plates at 4x104 cells 
per well. Endothelial cells were fed daily during cell growth assays, 
which were carried out for 12 days, in order to minimize any effects 
on the synthesis of prostacyclin caused by the depletion of 
precursors, for example arachidonic acid, from the culture medium. 
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At 2, 4, 6, 8, 10 and 12 days, the cell supernatant was removed 
from duplicate wells and retained for analysis of 6-keto-PGF1~content. 
These samples were used in the determination of prostacyclin release 
during the previous 24 hours. In addition a 15 minute incubation with 
either 20% normal human AB serum or M199 alone was also performed in 
duplicate at 2, 4, 6, 8, 10 and 12 days and the cell supernatants 
retained for analysis of 6-keto-PGF1~ content. Supernatant samples 
were stored at -40oC prior to analysis of 6-keto-PGF1~ content. After 
the collection of 24 hour and 15 minute stimulation supernatants, 
human umbilical vein endothelial cells were washed 3 times with PBS 
and 0.25 ml 1N sodium hydroxide was added to each well. Following an 
overnight incubation at 370 C in a humidified atmosphere with 5% C02, 
the contents of each well was removed. These samples were then 
assayed for protein content by the Lowry method (see Appendixm). The 
amount of prostacyclin released, as determined by 6-keto-PGF1~levels, 
was expressed per pg protein. 
4.3.2.2 Errect or cell number on prostacyclin release 
The experiments performed to determine the prostacyclin release 
per cell from cultures of human umbilical vein endothelial cells were 
identical to those carried out to assess the prostacyclin release per 
ug protein. However, prior to the addition of 1N sodium hydroxide, 
cells were counted under a phase contrast microscope equipped with an 
eye piece graticule. Two fields were randomly selected and the number 
of cells in 100 squares were counted. The total number of cells per 
well was determined using the following formula: 
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Total number 
cells/well 
Mean number cells/100 squares 
= -----------------------------
Area of 100 squares 
x Area of well 
The amount of prostacyclin released was expressed per cell. 
4.3.3 Results 
4.3.3.1 Determination or protein 
The protein content of human umbilical vein endothelial cells 
was determined at 2, 4, 6, 8, 10, and 12 days, following an initial 
plating density of 4 x 10 4 cells per well. 10 experiments were 
performed on human umbilical vein endothelial cells derived from 
different umbilical cords. There was a rise in protein content of 
cultures in parallel with cell growth from 4.59 + 1.03 pg (mean + SEM) 
at day 2, to 19.03 + 2.73 pg at day 12 (fig 21). 
4.3.3.2 Errect or protein content on prostacyclin release 
Prostacyclin release per pg protein decreased with increasing 
protein content, following 15 minute stimulation with both 20% normal 
human AB serum (n=10 experiments) and M199 alone (n=5 experiments) 
[figs 22 & 23]. However, the amount of prostacyclin released per pg 
protein was greater from endothelial cells stimulated by 20% serum 
compared with those stimulated by M199 alone. In addition, the 
accumulated release of prostacyclin per pg protein over 24 hours 
showed a similar pattern of production (fig 24). 
The amount of prostacyclin released per ~g protein varied with 
human umbilical vein endothelial cells derived from different 
umbilical cords in both the 15 minute stimulation, and 24 hour 
accumulation experiments. 
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Figure 21 
The protein content (mean + SEM) of human umbilical vein 
endo thelial cells during con tinuous cuI ture for 12 days (n= 1 0 
experiments). 
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Figure 22 
The prostacyclin release / ug protein (mean + SEM) of human 
umbilical vein endothelial cells following stimulation by human AB 
serum for 15 minute periods at intervals during continuous culture for 
12 days (n=10 experiments). 
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Figure 23 
The prostacyclin release / ug protein (mean + SEM) of human 
umbilical vein endothelial cells following stimulation by M199 for 15 
minute periods at intervals during continuous culture for 12 days (n=5 
experiments) • 
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Figure 24 
The cumulative prostacyclin release / ug protein (mean + SEM) of 
human umbilical vein endothelial cells during 24 hour periods at 
intervals during continuous culture for 12 days (n = 5 experiments). 
4.3.3.3 Determination of cell number 
The number of human umbilical vein endothelial cells was 
determined in duplicate wells at 2, 4, 6, 8, 10, and 12 days (n=5 
experiments). An increase in cell number was observed with increasing 
time (fig 25), although the final cell number at day 12 varied 
considerably between cultures obtained from different cords. 
-.3.3.4 Effect of cell number on prostacyclin release 
As in the experiments performed to determine the effect of 
protein content on prostacyclin release, an inverse relationship was 
observed between cell number and prostacyclin release (figs 26 & 27). 
This effect was seen in human umbilical vein endothelial cells during 
15 minute exposure to 20% normal human AB serum (n=5 experiments), and 
in 24 hour accumulation experiments (n=5 experiments). 
Comment 
The protein content and cell number of cultured human umbilical 
vein endothelial cells increased with time. In contrast, the amount 
of prostacyclin released per pg protein and per cell decreased with 
time during both 15 minute exposure to 20% normal human AB serum and 
M199 alone, and following 24 hour incubation. The amount of 
prostacyclin released during 15 minute exposure to 20% serum was 
greater than that released following exposure to M199 alone. In 
addition, there was a large variation in the amount of prostacyclin 
released from human umbilical vein endothelial cells derived from 
different umbilical cords. Also, the rate of increase of protein and 
cell number varied with the different cultures of human umbilical vein 
endothelial cells. 
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Figure 25 
The number (mean + SEM) of human umbilical vein endothelial 
cells at intervals during continuous culture for 12 days (n=5 
experiments). 
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Figure 26 
The prostacyclin release / cell (mean + SEM) from human 
umbilical vein endothelial cells following stimulation by 20% human AB 
serum for 15 minutes at intervals during continuous culture for 12 
days (n=5 experiments). 
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Figure 27 
The continuous prostacyclin release / cell (mean + SEM) from 
human umbilical vein endothelial cells during 24 hour periods at 
intervals during continuous culture for 12 days (n=5 experiments). 
4.3.- Discussion 
4.3.4.1 Errect or cell density on prostacyclin release 
The resul ts obtained from these experiments have clearly 
demonstrated an inverse relationship between cell density and 
prostacyclin release from cultured human umbilical vein endothelial 
cells. This phenomenon was observed when the prostacyclin release 
was expressed as either per pg protein or per cell. In addition, both 
15 minute stimulation of human umbilical vein endothelial cells with 
either 20% normal human serum or M199 alone, and accumulated 24 hour 
release of prostacyclin showed this density dependent phenomenon. 
Thus, one can conclude that actively growing human umbilical vein 
endothelial cells produce increased amounts of prostacyclin compared 
with confluent cell monolayers. 
A similar density dependent release of prostacyclin from 
cultured human umbilical vein endothelial cells was demonstrated by 
Evans et al (1984). These authors analysed spent growth medium 
obtained at 24 hourly intervals and observed a decline in prostacyclin 
content with increasing time without, however, correcting their 
results for cell number or protein content. In addition, Ali et al 
(1980) demonstrated significantly higher production of all prost-
anoids, including prostacyclin, during the exponential growth phase of 
bovine aortic endothelial cells, as compared with confluent mono-
layers. These effects were observed following the initial seeding of 
cells at varying densities. 
In contrast to the results obtained in this study, and those 
demonstrated by Evans et al (1984) and Ali et al (1980), are the 
findings of Eldor et al (1983), who described an increased capacity of 
bovine aortic endothelial cells to synthesize prostacyclin following 
the formation of a contact inhibited cell monolayer. However, these 
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authors determined the stimulated release of prostacyclin per cell 
following exposure to arachidonic acid, which may account for their 
differing results, since arachidonic acid may provide substrate for 
further prostacyclin release, and hence stimulate its production. 
A poss i ble reas on for the decline in prostacyclin release with 
increasing cell density, may be the depletion of available substrate 
for prostacyclin synthesis. Endothelial cells obtain substrate for 
the synthesis of prostacyclin, in the form of arachidonic acid, mainly 
from cell membrane phospholipids. It appears that endothelial cells do 
not synthesize arachidonic acid but must acquire it in a preformed 
state from exogenous sources (Spector et al 1981; Sivarajan et al 
1984). In conditions of high cell density, insufficient arachidonic 
acid may be available in the culture medium for maximum uptake and 
subsequent conversion to prostacyclin to occur. Hong et al (1979) 
analysed the cellular content of arachidonic acid at different growth 
stages of a mouse fibroblast cell line. They showed that the 
arachidonic acid per cell diminished with time and the release of 
prostacyclin from these cells showed a similar rate of decline with 
time. However, feeding the cells with fresh growth medium stimulated 
prostacyclin production. In addition, these authors found that the 
majority of arachidonic and lineoic acid in the culture medium was 
rapidly (within one day) incorporated into cellular phospholipid. The 
results of Eldor et al (1983) who, in contrast to the results obtained 
in this study, demonstrated increased prostacyclin release following 
the formation of a contact inhibited monolayer (by arachidonic acid 
stimulation) could thus be explained, since by supplying an exogenous 
source of substrate, no depletion effects would be likely to occur. 
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In contrast to the above mechanism, it has been suggested that 
arachidonic acid is infrequently rate-limiting (Weksler 1987). 
Instead the release of this substrate may be important. Depletion in 
the culture medium of various growth factors, following an increase in 
cell density, could result in diminished activation of the enzymes 
cyclooxygenase and prostacyclin synthase. Platelet derived growth 
factor and epidermal growth factor have both been found to stimulate 
prostaglandin synthesis in fibroblasts and smooth muscle cells by the 
induction of cyclooxygenase synthesis (Rozengurt et al 1983; Habenicht 
et al 1985). In addition, platelet derived growth factor has been 
shown to stimulate prostacyclin synthesis by bovine aortic 
endothelium, aortic smooth muscle and adrenal capillary endothelium 
(Coughlin et al 1980). However, this observation is somewhat 
controversial since Callahan et al (1986) failed to demonstrate the 
stimulation of prostacyclin synthesis by platelet derived growth 
factor in human umbilical vein and bovine aortic endothelial cells, 
as did Poggi et al (1983). In addition, Heldin et al (1981) and 
Bowen-Pope & Ross (1982) failed to demonstrate the occurrence of 
receptors for platelet derived growth factor on bovine aortic and 
human endothelial cells. However, it is possible that this factor 
could act via a receptor independent mechanism. 
Alternatively, rather than the depletion of stimulatory factors 
of cyclooxygenase and prostacyclin synthase, inhibitory factors may be 
important. As cell density rises, there is a build up of endothelial 
cell metabolites which may exert an inhibition on the release of 
prostacyclin. In support of such a hypothesis, Evans et al (1984) 
showed decreased prostacyclin release from human umbilical vein 
endothelial cells grown in endothelial cell conditioned medium, 
compared with those grown in fresh culture medium. Thus, endothelial 
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cells may exert a negative feedback mechanism on their release of 
prostacyclin. The formation of a contact inhibited cell monolayer by 
human umbilical vein endothelial cells may act as a signal for the 
diminished synthesis of prostacyclin and in this study, a confluent 
monolayer was obtained before the end of the experiments. 
The differences in endothelial cell capacity to synthesize 
prostacyclin at different stages of growth, may serve a physiological 
compensatory mechanism whereby less prostacyclin is released from 
intact vascular endothelium, compared with growing cells following 
localized injury. Such growing cells may enhance repair mechanisms 
and reduce adhesion and thrombosis, by synthesizing increased levels 
of prostacyclin. 
Since the release of prostacyclin varies with stages of cell 
growth and possibly with availability of substrate, studies on 
prostacyclin biosynthesis must be strictly standardized in terms of 
cell density and feeding regimes, in order to reduce any variables 
arising from these factors. In all experiments performed in this 
study, human umbilical vein endothelial cells were seeded at a 
constant initial density and the feeding of cells during experiments 
was carefully controlled. 
4.3._.2 Serua stimulation or prostacyclin release rrom human 
uabilical vein endothelial cells 
In experiments performed to observe the effects of cell density 
on the release of prostacyclin from cultured human umbilical vein 
endothelial cells 15 minute stimulations with either 20% normal human 
serum or M199 alone were employed. The release of prostacyclin was 
much greater following stimulation with 20% normal human serum 
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compared with M199 alone. This effect was also observed in later 
experiments performed to observe the effects of sera from patients 
with systemic sclerosis on the release of prostacyclin. 
The stimulation of prostacyclin release by serum has previously 
been documented (Ritter et al 1982, 1983; Seid et al 1983a). Seid et 
al (1983a) observed that serum stimulated the release of prostacyclin 
from pig aortic endothelial cells to a greater extent than plasma and 
the stimulatory effect of plasma was higher in platelet rich plasma 
compared with platelet poor plasma. Thus, platelet derived factors 
appear to be important in the stimulation of prostacyclin release. In 
addition, these authors showed that isolated degranulated platelets 
released factors which caused the stimulation of prostacyclin release. 
These studies were preceeded by the work of Coughlin et al (1980) who 
demonstrated platelet dependent stimulation of prostacyclin synthesis 
caused by platelet derived growth factor. Ritter et al (1982 & 1983) 
also described a serum factor formed during coagulation which 
stimulated the release of prostacyclin from rat aortic rings. However, 
their factor did not appear to be platelet derived and they suggested 
that it could be a small fragment cleaved from a coagulation factor 
such as factor VIII or IX. 
In addition to stimulatory factors, serum also contains 
platelet factors which may be used as substrate in the formation of 
prostacyclin. As mentioned previously, it appears that endothelial 
cells must obtain substrate from an exogenous supply (Spector et al 
1981, 1983; Sivarjaan et al 1984). Platelets are capable of providing 
arachidonic acid and/or endoperoxides for this purpose (Bunting et al 
1976; Moncada et al 1977; Marcus et al 1980; Chesterman et al 1986). 
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Thus the stimulation of prostacyclin release caused by serum may also 
be due to the provision of substrate in the form of platelet 
endoperoxides. 
The stimulatory effects of platelets, by the provision of 
arachidonic acid, may be important in vivo, at sites of vascular 
damage. Following endothelial cell damage, platelets adhere to the 
exposed subendothelium, aggregate and release various factors or 
provide arachidonic acid. Hence, the stimulation of prostacyclin 
release by local endothelium may occur in response to these 
degranulated platelets, thus inhibiting further aggregation of 
platelets and limiting thrombus formation. 
4.3.4.3 Variation of prostacyclin release from cultured human 
umbilical vein endothelial cells derived from different 
umbilical cords 
In this study, large variations in the release of prostacyclin 
were observed from human umbilical vein endothelial cells derived from 
different umbilical cords. For example a 5-6 fold difference in the 
stimUlation of prostacyclin release by aliquots of a standard AB human 
serum was observed in experiments performed to study the effects of 
sera from patients with systemic sclerosis on the release of 
prostacyclin (see later). These variations in prostacyclin synthesis 
are in agreement with the observations of several other authors 
working with endothelial cells in a variety of culture systems (Levin 
1984). For example, Eldor et al (1983) found a greater than five fold 
variation in the synthesis of prostacyclin by bovine aortic endo-
thelial cells. 
Several factors may contribute to this variability. For 
instance, the maternal smoking habits of umbilical cord donors may 
influence the production of prostacyclin from cultured human umbilical 
130 
vein endothelial cells. Busacca et al (1984) reported a marked 
reduction in the capacity of cultured human umbilical vein endothelial 
cells to produce prostacyclin in cells derived from mild and heavy 
smokers. In addition, these cells were less able to grow and reach 
confluence. Smoking during pregnancy thus appears to induce 
modifications in the enzymes of the prostacyclin synthesis pathway, 
which persist when they are cultured in vitro. In addition, 
experiments in animals have demonstrated that exposure of aortic rings 
to nicotine results in diminished prostacyclin synthesis (Bull et al 
1985). Since the age, and particularly, the smoking habits of 
umbilical cord donors could not be monitored in this study, it is 
likely that the variability in prostacyclin release from different 
cultures of human umbilical vein endothelial cells may be thus 
explained. 
Prostacyclin production has been shown to diminish with 
increased passaging of cells in vitro (Ager et al 1979). However, in 
this study, all experiments were performed on human umbilical vein 
endothelial cells at first passage, and therefore this factor cannot 
account for the variation in prostacyclin release observed in this 
study. 
Mechanical trauma, such as that occurring when growth medium is 
changed, may provide a stimulus for prostacyclin production. In this 
study the intra-assay variations were much lower than those observed 
between assays performed on different cultures of human umbilical vein 
endothelial cells. Thus it is unlikely that the variation in 
prostacyclin was due to mechanical trauma since this would be the same 
between different assays and within an individual experiment. 
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Finally, the administration of drugs to pregnant mothers and 
maternal anaesthesia were not recorded and may be a further source of 
variability between different cultures of human umbilical vein cells. 
For example, aspirin is known to have a marked inhibitory effect on 
prostacyclin synthesis (Roth et al 1975). 
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4.4 Errect or sera rrom patients with syste~c sclerosis on 
4.4.1 
prostacyclin release from cultured human umbilical vein 
endothelial Cells 
Introduction 
The various immunological abnormalities, such as immune 
complexes, antiendothelial cell and anticardiolipin antibodies, 
detected in the sera of patients with systemic sclerosis, may be 
capable of causing damage to the vascular endothelium. This could 
cause alterations in the production and release of prostacyclin 
(Goldsmith et al 1984). Thus, evidence of a prostacyclin imbalance 
may serve as an important indicator of altered endothelial cell 
function. The effect of sera from patients with systemic sclerosis on 
the release of prostacyclin from cuI tured human umbilical vein 
endothelial cells was therefore examined, during both short term (15 
minutes) and long term (72 hours) exposures. 
4.4.2 Materials and methods 
4.4.2.1 Patients and Controls 
Sera obtained from 28 patients with systemic sclerosis (24 
women 4 men· mean age 52.3 + 15.3 years), were compared with sera 
" --
obtained from 30 normal laboratory controls (22 women, 8 men; mean age 
37.3 + 12.5 years). An AB "standard" serum was also obtained from a 
single bleed of a normal donor, for use in the calculation of 
stimulation indices. 
4.4.2.2 Endothelial prostacyclin release during exposure to 20~ serum 
ror 15 minutes 
To determine the effect of sera from patients with systemic 
sclerosis, on the synthesis of prostacyclin from cultured human 
umbilical vein endothelial cells, during 15 minutes exposure, cells 
were incubated with 20% test or control serum. Since the mechanical 
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trauma arising from the washing of cells may stimulate the production 
of prostacyclin, a basal level of prostacyclin release, occurring in 
the presence of M199 alone, was first determined to quantify the 
basal prostacyclin release. Thus, endothelial cells were allowed to 
reach a steady state of prostacyclin release prior to the addition of 
test sera. The basal prostacyclin release was subsequently subtracted 
from the amount of prostacyclin released following 15 minute 
incubation with 20% test or control sera. 
Human umbilical vein endothelial cells were seeded at a 
concentration of 105 cells I well into 24 well tissue culture plates. 
The cells were incubated at 37°C for 48 hours, by which time they were 
confluent and ready for use in prostacyclin assays. 
Endothelial cells were washed once with M199, and 1ml M199 was 
then added to each well. After a 15 minute incubation at 370 C in a 
humidified atmosphere of 5% C02/95% air, 250pl was removed from each 
well and stored at -40oC prior to determination of the basal 
6-keto-PGF1~release. Immediately following the removal of this basal 
sample, 250yl of stimulatory agent was added to each well, the agent 
consisting of 200pl patient or control serum and 50pl M199, ie final 
concentration 20% serum. All tests were performed in triplicate. 
Following a further 15 minute incubation at 37oC, the entire contents 
of each well were retained for analysis of 6-keto-PGF1~content. 
The 6-keto-PGF1~ content of the 20% serum samples used as 
stimulatory agents were also determined, and the values thus obtained 
were subtracted from the 6-keto-PGF1~ levels in cell supernatants 
following the 15 minute incubations. 
In addition to 20% patient and control sera, human umbilical 
vein endothelial cells were also incubated with 20% normal human AB 
serum. This serum was obtained from a single batch, and the values 
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obtained for prostacyclin release following incubation with aliquots 
of this human "AB standard" serum were used to determine "stimulation 
indices". All manipulations between consecutive wells were performed 
with a standard time interval of 15 seconds per well. 
Calculation of Prostacyclin Release 
where:-
Prostacyclin Release = A - [ B + C ] 
A= 6-keto PGF1~release following 15 minute stimulation 
B= basal 6-keto-PGF1~release x 0.75 
C= 6-keto-PGF1~content in diluted test sera x 0.25 
Calculation of stimulation index 
prostacyclin release with test or control sera 
Stimulation Index = 
prostacyclin release with "AB Standard" 
4.4.2.3 Endothelial prostacyclin release during exposure to 20S serum 
for 72 hours 
Primary cultures of human umbilical vein endothelial cells were 
passaged as previously described, washed and seeded into gelatin 
coated 24 well plates at a density of 2 x 10 4 cells per well. The 
cells were allowed to adhere overnight and then the spent culture 
medium was removed and replaced with 0.5 ml M199 containing 20% 
patient or control sera. Within each assay, an additional control of 
0.5 ml M199 containing 20% human AB serum as a standard, was also 
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performed. All tests were performed in triplicate. After 72 hours 
incubation at 37 0 C in a humidified atmosphere of 5% C02, the medium 
was removed and stored at -40oC prior to the determination of 6-
keto- PGF 1()(. content. The remaining cells were fixed in methanol and 
stained by the Giemsa method. The stained endothelial cells in each 
well were then counted in triplicate, using an overhead microscope and 
1mm square graticule, and the results expressed as a mean for all 3 
wells. 6-keto-PGF1~release over 72 hours was then expressed per cell 
and stimulation indices calculated as previously described. 
4.4.2.4 Statistical analysis of data 
All results are expressed as the mean + SEM. Comparison between 
patient and control group responses was made using the Wilcoxon-
Mann-Whitney test. 
4.4.3 Results 
4.4.3.1 Endothelial prostacyclin release during exposure to 20S serum 
f'or 15 minutes 
Basal prostacyclin release 
The mean value obtained for the basal prostacyclin release was 
1.729 + 0.4340 nmol/l (n=11 experiments). While there was relatively 
little intra-assay variation between individual wells (coefficient of 
variation = 12-26%), the inter-assay variation was much greater, with 
human umbilical vein endothelial cells derived from different 
umbilical cords showing differing capacities to synthesize 
prostacyclin (coefficient of variation = 78%). However, there was 
little difference in the values of intra assay variation obtained for 
different plates of endothelial cells derived from the same umbilical 
cord (18.83% & 18.97%; 15.54% & 16.77%; 21.61% & 18.46%). 
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15 minute exposure with 20% "standard AB" serum and M199 alone 
The prostacyclin release following 15 minute incubation with the 
20% human "standard AB" serum and M199 alone are shown in table 8 and 
fig 28. 
Culture prostacyclin release 
medium (nmol/l) (mean + SEM) n (experiments) 
M199 0.1582 + 0.0513 11 
20% Human 0.4355 + 0.0591 11 
AB serum 
Table 8 
The prostacyclin release (mean + SEM) from human umbilical vein 
endothelial cells in response to exposure to 20% standard AB serum or 
M199 alone for 15 minute periods. 
Thus, the prostacyclin release following stimulation with 20% 
human serum was greater than that following a 15 minute incubation 
with M199 alone (p < 0.01, student's t test). 
As with the results for the basal prostacyclin release, the 
release following exposure to 20% human AB serum or M199 alone showed 
large fluctuations when human umbilical vein endothelial cells were 
derived from different umbilical cords (coefficient of variation = 
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Figure 28 
The prostacyclin release from human umbilical vein endothelial 
cells in response to exposure to 20% standard AB serum or M199 alone 
for 15 minute periods. 
64%) . 
Endothelial prostacyclin release during 15 minute exposure to 
20% serum from patients with systemic sclerosis and controls 
As large variations were found in prostacyclin release from 
endothelial cells derived from different cords, direct comparisons of 
different assays could not easily be made. To compensate for this 
variability, the stimulation index was derived (as previously 
described). The results obtained showed no significant difference 
between patient and control groups. (table 9; fig 29) 
Group 
studied 
Systemic sclerosis 
Controls 
Table 9 
Stimulation index 
(mean + SEM) 
1.6698 + 0.2921 
1.5452 + 0.1601 
n 
26 
25 
The prostacyclin release from human umbilical vein endothelial 
cells (mean + SEM) in response to exposure to 20% serum from patients 
with systemic sclerosis and normal controls for 15 minute periods, 
expressed as a ratio (stimulation index) of that produced by aliquots 
of a standard 20% AB serum. 
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The prostacyclin release from human umbilical vein endothelial 
cells in response to exposure to 20% serum from patients with systemic 
sclerosis and normal controls for 15 minute periods, expressed as a 
ratio (stimulation index) of that produced by aliquots of a standard 
20% AB serum. 
4.4.3.2 Endothelial prostacyclin release during exposure to 20S serum 
rrom patients with systemic sclerosis ror 72 hours 
As large variations in prostacyclin release from different 
cultures of human umbilical vein endothelial cells were again 
observed, stimulation indices were once more calculated. As with the 
results of 15 minute exposure experiments, no significant difference 
was observed between patient and control groups (Table 10; Fig 30). 
Group Stimulation index 
studied (mean + SEM) n 
Systemic sclerosis 1.3234 + 0.1438 28 
Controls 1.8268 + 0.2813 30 
Table 10 
The prostacyclin release from human umbilical vein endothelial 
( SEM) " e to exposure to 20% serum from patients cells mean + ln respons 
" d no~mal controls for 72 hours, expressed as with systemic sclerosls an L 
( "l"ndex) of that p~oduced by aliquots of a standard a ratio stimulatlon L 
20% AB serum. 
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Figure 30 The prostacyclin release from human umbilical vein endothelial 
cells in response to exposure to 20% serum from patients with systemic 
sclerosis and normal controls for 72 hours, expressed as a ratio 
(stimulation index) of that produced by aliquots of a standard 20% AB 
serum. 
4.-.3.3 Prostacyclin levels in sera from patients and controls 
The levels of 6-keto PGF1~in serum samples used in 15 minute 
exposure experiments showed no significant difference between patient 
and controls (p = NS, student's t test). Table 11; fig 31. 
Group 
studied 
Systemic sclerosis 
Controls 
Table 11 
Concentration of 6-keto-PGF~1 
nmol/L (mean + SEM) 
0.9722 + 0.1043 
0.7773 + 0.0846 
n 
20 
24 
The levels of 6-keto-PGF1~(mean + SEM) present in serum from 
patients with systemic sclerosis and normal controls. (Sera from 6 
patients and 1 contol contained levels of 6-Keto-PGF1~below the lower 
limit of detection) 
Comment 
No difference was observed in the release of prostacyclin from 
human umbilical vein endothelial cells during 15 minute and 72 hour 
exposure to sera from patients with systemic sclerosis and normal 
controls. In addition, the serum levels of prostacyclin did not 
differ in the 2 groups. 
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The levels of 6-keto-PGFb<, present in serum from patients with 
systemic sclerosis and normal controls. 
4.4.4 Discussion 
4.4.4.1 Effects of sera from patients with syste~c sclerosis on the 
release of prostacyclin from cultured human umbilical vein 
endothelial cells 
The results obtained in these experiments clearly demonstrate 
that serum obtained from patients with systemic sclerosis does not 
alter the release of prostacyclin from cultured human umbilical vein 
endothelial cells, during both 15 minute and 72 hour exposure. There 
have been two previous reports on the effects of serum from patients 
with systemic sclerosis on prostacyclin production by vascular 
endothelial cells. A preliminary study by Evans et al (1984) also 
showed no difference between control (n=4) and systemic sclerosis 
(n=4) sera, in their effects on endothelial cell prostacyclin 
production of 6-keto-PGF 10(. However, a later study by Rustin et al 
(1987a) published during the course of the present study, showed a 
dose dependent inhibition of prostacyclin production from stimulated 
human umbilical vein endothelial cells produced by 13 sera from 
patients with systemic sclerosis. However, the differences between the 
findings of Rustin's study and this investigation may be more apparent 
than real, as the consequence of exposure to tes t serum may be 
impairment of a subsequent agonist response, even though no effect is 
produced during the period of exposure. 
In addition, the variability in prostacyclin release from 
endothelial cells derived from different umbilical cords observed in 
this study, and has also been demonstrated by other authors, may be a 
factor accounting for the conflicting observations of Rustin et al 
(1987a) and those of the present study. The conversion of data to a 
stimulation index (as used in this study) could help to compensate for 
this variability. 
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A further factor that might also help to reduce the variability 
in prostacyclin release observed in different endothelial cell 
cultures would be the use of a stimulatory agent as used by Rustin et 
al (1987a). However, the calcium ionophore used by these authors is 
unphysiological and may even result in endothelial cell damage as 
demonstrated in some preliminary experiments carried out in this 
laboratory. Further studies might well consider the use of thrombin 
and perhaps bradykinin, both of which are more physiological 
stimulators of prostacyclin release. 
Such future studies must also consider whether serum is the most 
appropriate test medium to use in investigations of patient effects 
on prostacyclin release by cultured endothelium. As mentioned 
previously, serum contains platelet derived factors that may stimulate 
prostacyclin release (Coughlin et al 1980) and in addition, platelet 
endoperoxides released during the clotting process may be used by 
endothelial cells in the synthesis of prostacyclin (Bunting et al 
1976; Moncada et al 1977; Marcus et al 1980; Chesterman et al 1986). 
Thus, any inhibitory factors acting on the release of prostacyclin 
occurring in vivo would be masked by the stimulation produced by such 
factors present in serum. Platelet poor plasma is more relevant to in 
vivo situations and therefore should be used in future studies on the 
effect of prostacyclin release from cultured endothelial cells. 
Thus, although the results obtained in this study did not 
demonstrate a serum effect from patients with systemic sclerosis on 
endothelial cell prostacyclin production, further studies employing 
platelet poor plasma and possibly a stimulated prostacyclin response, 
are required in order to clarify the discrepant findings of the 
present study and those obtained by Rustin et al (1987a). 
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4.4.4.2 Serum levels of 6-keto-PGF1~in patients and controls 
This study has also demonstrated that the serum levels of 
6-keto-PGF1~in patients with systemic sclerosis are not significantly 
different to the levels in normal control sera. These results are in 
agreement with the findings of Evans et al (1984) who also measured 
the levels of 6-keto-PGF1~by radio-immunoassay, in 18 patients with 
systemic sclerosis and 12 normal controls, and found no significant 
difference between the two groups. 
However, in contrast to these observations, Belch et al (1984) 
reported elevated plasma levels of 6-keto-PGF1~ in patients with 
systemic sclerosis. The determinations of Belch and co-workers were 
derived from plasma samples, in contrast to the serum samples used by 
both Evans et al (1984) and in this study. These differences may be 
partly responsible for the discrepancies but also methodological 
problems in the determination of plasma 6-keto-PGF1~levels have been 
described (Morris et al 1981; Greaves and Preston 1982). In addition, 
differences in the extent and severity of the systemic sclerosis in 
the various subgroups of patients studied, could be a further factor 
responsible for the conflicting results obtained to date. 
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CHAPTER 5 
MEASUREMENT OF VON WILLEBRAND FACTOR ANTIGEN, 
ANTI CARDIOLIPIN ANTIBODIES AND IMMUNE COMPLEXES 
IN PATIENTS WITH SYSTEMIC SCLEROSIS 
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5.1 Measurement of Factor VIII complex in patients with systemic 
sclerosis 
5.1.1 Introduction 
There is widespread evidence for the presence of vascular and 
endothelial cell abnormalities in patients with systemic sclerosis. 
Von Willebrand factor antigen and its functional activity, which is 
measured as ristocetin co-factor, are manufactured by the endothelium 
and are known to be elevated in various diseases characterised by 
endothelial cell injury, for example, diabetes mellitus with 
proliferative retinopathy; atherosclerosis and renal failure (Coller 
et al 1978; Green et al 1978; Warrel et al 1979). 
In this study, therefore, patients with systemic sclerosis were 
investigated for evidence of endothelial damage by measurement of von 
Willebrand factor antigen and ristocetin co-factor. However, as von 
Willebrand factor antigen has been described as participating in acute 
phase responses, parallel measurements of both factor VIII coagulant 
and C reactive protein were also carried out. 
5.1.2 Materials and methods 
Patients 
For this part of the investigation, 28 patients with systemic 
sclerosis were studied (24 women, 4 men; mean (+ SD) age 52.8 + 14.7 
years). 
The extent (and severity) of the visceral involvement produced 
by the disease was defined by a standard investigative protocol which 
enabled points to be awarded for cutaneous and visceral involvement 
and so produce a "disease score" for each patient (see table 2.) 
Patients were thus divided into categories of "severe" (disease score 
~ 6) and "mild" disease (disease score ,5) 
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Von Willebrand factor antigen 
Von Willebrand factor antigen was determined by an enzyme-linked 
immunosorbent assay as described by Short et al (1982) (reference 
range 0.5-1.5 u/ml) 
Factor VIII coagulant 
Factor VIII coagulant was assayed by a 2-stage technique based 
upon the thromboplastin generation test (Biggs et al 1955) [reference 
range 0.5-1.5 u/mIJ. 
Ristocetin co-factor 
The ristocetin co-factor was measured using fixed washed 
platelets and a platelet counting technique (Evans & Austen 1977) 
[reference range 0.5-1.5 u/mIJ. 
C-reactive protein 
C-reactive protein was measured by single radial immunodiffusion 
(Milford-Ward 1986). Monospecific antiserum to human C-reactive 
protein was obtained from PRU Central Antiserum Purchasing Unit, 
Sheffield. Standardization of the assay was in relation to the WHO 
International Standard for C-reactive protein 1986 (NIBSC 85/506) 
[reference range 0-10 mg/IJ. 
All reference ranges were based on determinations made in 40 
normal, healthy laboratory staff. 
Statistical methods 
Comparison of factor VIII complex levels in "severe" and "mild" 
patient subgroups was by Student's t test while the relationship 
between disease score and factor VIII complex levels was examined by 
regression analysis. 
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5.1.3 Results 
Von Willebrand factor antigen 
Elevated levels of von Willebrand factor antigen were found in 
12 patients with systemic sclerosis, 10 of whom showed severe 
extensive visceral disease. There was a positive correlation (r=0.60 
p=<0.001) between the extent of visceral involvement (ie severity of 
disease) and plasma levels of von Willebrand factor antigen (fig 32). 
16 patients with severe disease had von Willebrand factor antigen 
levels of 1.73 + 0.57 u/ml, whereas those with mild disease had levels 
of 1.03 + 0.38 u/ml (p<0.001). 
Factor VIII coagulant 
By contrast, plasma levels of factor VIII coagulant were 
elevated in only 3 patients with raised von Willebrand factor antigen 
and in only 5 patients overall. The general failure of factor VIII 
coagulant to parallel increases in von Willebrand factor antigen was 
illustrated by a lack of correlation between factor VIII coagulant 
levels and disease score (r = 0.30; NS). 
Ristocetin co-factor 
Again, levels of ristocetin co-factor also failed to parallel 
the increases in von Willebrand factor antigen and so also failed to 
show any correlation with disease score (r = 0.14; NS). 
C-reactive protein 
Elevated levels of C-reactive protein were found in only 3 
patients, 2 of whom were in the "severe disease" group. 
5.1.~ Discussion 
This study has shown that patients with systemic sclerosis have 
elevated levels of circulating von Willebrand factor antigen. This 
observation is in agreement with the smaller studies of Kahaleh et al 
(1982) and Lee et al (1985), who also showed increased levels of von 
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Figure 32 
The correlation between the extent of visceral disease (disease 
score) and von Willebrand factor antigen in 28 patients with systemic 
sclerosis. r = 0.60; p < 0.001. 
Willebrand factor antigen in patients with systemic sclerosis. These 
authors, however, failed to fully exclude an acute phase response by 
carrying out parallel determinations of all components of the factor 
VIII complex as well as C-reactive protein. 
The results obtained in this study indicate that the rise in von 
Wille brand factor antigen is in fact due to in vivo endothelial cell 
damage rather than an acute phase response, since if this were the 
case, parallel rises would be shown by factor VIII coagulant and 
C-reactive protein. 
The present study has also shown that ristocetin co-factor fails 
to parallel the rise in von Willebrand factor antigen, in patients 
with systemic sclerosis. The failure of the functional component of 
the factor VIII complex to parallel von Willebrand factor antigen 
levels provides further confirmation that the elevated levels of von 
Willebrand factor antigen are due to endothelial cell injury with the 
release of functionally abnormal or incomplete molecules (Carvalho et 
al 1982). 
This study has reported a marked association between elevated 
levels of von Willebrand factor antigen and extensive visceral 
disease, confirming the previous smaller study of Lee et al (1985). 
This relationship is probably a reflection of the more widespread and 
extensive vascular pathology present in patients with visceral 
disease. Pulmonary involvement was present in all patients with 
severe and extensive visceral disease, and damage to the rich vascular 
bed present in the lungs, is likely to account for the elevated levels 
of von Willebrand factor antigen. 
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5.2 Measurement of anti cardiolipin antibodies in patients with 
systemic sclerosis 
5.2.1 Introduction 
Various immunological abnormalities, such as autoantibodies and 
circulating immune complexes, which occur in SLE have also been 
described in patients with systemic sclerosis (Bernstein et al 1984; 
Catoggio et al 1983; Pisko et al 1979; Hughes et al 1983; and Seibold 
et al 1982). The presence of anticardiolipin antibodies in patients 
with SLE is particularly interesting in view of the association of 
these autoantibodies with a thrombotic tendency, through their 
possible interaction with endothelial cells and platelets (Harris et 
al 1983). It was felt that it would be potentially relevant, 
therefore, to look for these autoantibodies in patients with systemic 
sclerosis, especially in view of the evidence for endothelial cell 
damage and the vascular pathology occurring in the disease (Norton & 
Nardo 1970). 
5.2.2. Materials and methods 
The same 28 patients who were studied in relation to altered 
levels of the factor VIII complex were also investigated for the 
presence of anticardiolipin antibodies. 
Plasma levels of anticardiolipin antibodies were determined by 
ELISA. 30JlI of cardiolipin in ethanol (50pg of cardiolipin/ml) was 
added to each well of a rigid 96 well microtitre plate. The 
cardiolipin was evaporated overnight at 40 C and the plate was washed 3 
times with PBS. 75pl/well of 10% adult bovine serum was added to each 
well and incubated at room temperature for 1 hour. The adult bovine 
serum was discarded and the plate washed once with PBS. 50 pI of 
either a standard or test plasma diluted in 10% adult bovine serum 
were added to each well and incubated at room temperature for 3 hours. 
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The wells were washed 3 times with PBS after which 50ul of a 1/1000 
dilution of alkaline phosphatase conjugated goat antiserum was added 
to each well and the plates left for 1.5 hours. The plates were 
washed 3 times in PBS and 50pl of well mixed freshly prepared p-
nitrophenyl phosphate solution (1pg/ml in diethanolamine buffer pH 
9.8) was added to each well. After incubating for 30 + 15 minutes in 
the dark at 37 0 C in a "wet box" the absorbance was measured at 405nm 
using a Titertek Multiscan. Results were expressed as anticardiolipin 
units calculated against IgG and IgM anticardiolipin standards kindly 
donated by Dr. N. Harris, the Rayne Insti tute, London, to gi ve 
reference ranges of 0-5.2 u and 0-4.4 u for IgG and IgM antibodies, 
respectively, based on determinations (mean + 2 SD) in 40 normal 
laboratory staff and blood donors. The specificity for cardiolipin 
was confirmed by the absence of any consistent reactivity of the assay 
with sera containing either high titre rheumatoid factors or myeloma 
paraproteins. 
5.2.3 Results 
The titres of anticardiolipin antibodies in the total group of 
patients with systemic sclerosis and in the mildly and severely 
affected subgroups are shown in Table 12. While the mean value in all 
the patient categories fell within the limits (mean + 2 SD) of the 
normal reference range, 7 patients had elevated levels of IgG and/or 
IgM anticardiolipin antibodies (Table 13). 5 of these 7 cases were in 
severely affected patients, including all 3 cases with the highest 
titre of anticardiolipin antibody. By contrast, only 2 of the mildly 
affected subgroup had elevated levels of anticardiolipin antibody 
(Table 13) 
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Table 12 
Anticardiolipin antibodies in patients with systemic sclerosis 
(SS) • 
Anticardiolipin antibodies 
(mean + SD) 
IgG (Ref. range 0-5.2 u) 
IgM (Ref. range 0-4.4 u) 
Total SS 
(n = 28) 
2.10+2.04 
Patient groups 
Mild SS 
(n = 12) 
2.70+1.75 
1.85+1.49 
Severe SS 
(n = 16) 
Table 13 
Titres of anticardiolipin antibodies (SD above mean value of 
reference range) in relation to the severity of disease in 28 patients 
with systemic sclerosis (SS) 
Anticardiolipin antibodies 
(IgG/lgM) (n = 28) 
> 2 SD 
> 3 SD 
> 5 SD 
Total SS 
(n = 16) 
7 
4 
3 
Patient groups 
Severe SS 
(n = 12) 
5 
3 
3 
Mild SS 
2 
1 
o 
5.2.4 Discussion 
This investigation has demonstrated the occurrence of raised 
levels of anticardiolipin antibodies in 20-25% of patients with 
systemic sclerosis, and is the most comprehensive study to date, 
enlarging on preliminary reports of occasional and generally low titre 
anticardiolipin antibodies in these patients (McHugh et al 1987; 
Baguley et al 1987b). 
In the severely affected subgroup of patients, 4 of 5 patients 
with anticardiolipin antibodies also showed elevated levels of von 
Willebrand factor antigen. These associations suggest that anti-
cardiolipin antibodies may somehow be involved in the pathogenesis of 
systemic sclerosis. Although non of the patients had a history of 
major thrombosis, the possibility that anticardiolipin antibodies may 
be capable of causing vascular damage by other means than the 
thrombotic tendency associated with their presence in SLE, has to be 
considered. While experiments suggesting that the anticardiolipin 
antibodies found in patients with SLE may inhibit prostacyclin 
production by vascular endothelium (Carreras and Vermylen 1982; 
Schorer and Watson 1987) have not been uniformaly reproducible (Rustin 
et al 1987b; Petraiuolo et al 1987) there is evidence that these 
autoantibodies can react with phospholipid antigens in platelets 
(Cortelazzio et al 1987; Khamashta et al 1987). Such a reaction could 
lead to the release of platelet products, such as p thromboglobulin, 
transforming growth factor f3 and serotonin, which can either have an 
inhibitory effect on vascular endothelium (Heimark et al 1986) and/or 
stimulatory effects on fibroblasts with the resulting development of 
both vascular lesions and perivascular collagen deposition which are 
prominent features of systemic sclerosis. 
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5.3 Measurement of inamme complexes m- t - t -th pa 1en s W1 systemic 
sclerosis 
5.3.1 Introduction 
The presence of elevated levels of immune complexes in patients 
with systemic sclerosis is well described with, however, a highly 
variable incidence (Pisko et al 1979; Swierczynska et al 1984; 
Cunningham et al 1980; Hughes et al 1983). In this study, immune 
complexes were determined by the method of C1q binding, and the 
results correlated with severity of disease in patients with systemic 
sclerosis. 
5.3.2 Materials and methods 
Patients 
The previous 28 patients with systemic sclerosis were also 
investigated for the presence of immune complexes. 
C1q binding assay 
Immune complexes were detected using the C1q binding assay, 
based on the method of Zubler & Lambert (1976). C1q was prepared from 
fresh normal human serum and iodinated by lactoperoxidase. The method 
was modified by the use of 4% polyethylene glycol to precipitate 
macromolecular-bound C1q, used heat aggregated (63 0 C for 30 minutes) 
Cohn fraction II to construct standard curves (0.1 mg/ml to 3.0 mg/ml) 
and gave a reference range of 0.8-13.8%, based on determinations made 
in 40 normal healthy laboratory staff. 
5.2.3 Results 
The results for C1q binding activity in the total group of 
patients with systemic sclerosis and in the mildly and severely 
affected subgroups are summarized in table 14. Increased C1q binding 
activity was found in 7 patients with systemic sclerosis, the 
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Table 14 
C1q binding activity in patients with systemic sclerosis (SS) 
C1q-binding (mean+SD) 
(Ref range 0.8-13.8%) 
Total SS 
(n = 28) 
12.27+14.18 
Patient groups 
Mild SS 
(n = 12) 
6.25+2.73 
Severe SS 
(n = 16) 
17.44+17.84 
increases being confined to patients severely affected by the disease 
who had mean levels of 17.44 + 17.84% in contrast to the 6.25 + 2.73% 
of the mildly affected subgroup (p(0.05, student's t test) 
5.2.4 Discussion 
This study has reported the occurrence of elevated levels of 
immune complexes in 7 of 28 patients with systemic sclerosis and 
further emphasizes earlier reports suggesting that systemic sclerosis 
is a disease characterised by immune complexes (Pisko et al 1979; 
Hughes et al 1983). In addition, immune complexes were found to be 
associated with extensive visceral disease as previously reported by 
these authors. 
In patients with extensive visceral involvement, 4 of the 5 
patients with anticardiolipin antibodies also had elevated levels of 
von Willebrand factor antigen, including the 3 patients with the 
highest titre of anticardiolipin antibodies. In addition, elevated 
C1q binding activity and/or anticardiolipin antibodies occurred in 7 
of the 10 patients with elevated levels of von Willebrand factor 
antigen. 
Such a correlation between immune complexes, anticardiolipin 
antibodies and elevated levels of von Willebrand factor antigen, 
occurring in severely affected patients, emphasizes the multifactorial 
pathogenesis of systemic sclerosis, which is further discussed in the 
following chapter. 
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CHAPTER 6 
FINAL DISCUSSION 
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6.1 Summary and conclusions 
Al though the pathogenesis of systemic sclerosis remained 
uncertain for many years, the last fifteen years has seen a steady 
accumulation of evidence in support of the concept of vascular 
involvement (Campbell and LeRoy 1975). Marked vascular lesions are a 
prominent feature of systemic sclerosis with Raynaud's phenomenon, 
digital ischaemia and telangiectasia occurring as characteristic 
features of the disease, while pathologically, a specific arterial 
lesion is a distinctive feature of visceral lesions (Norton & Nardo 
1970). 
In addition, it has over the same period been realized that 
marked immunological abnormalities are found in patients with systemic 
sclerosis, including a very high incidence of autoantibodies and 
immune complexes (Bernstein et al 1982; Hughes et al 1983). These 
findings begin to suggest that systemic sclerosis, like the related 
connective tissue disease of SLE, could also have an autoimmune 
aetiology. In SLE, pathological processes produced by the circulating 
immune complexes and various autoantibodies have been much more 
clearly defined than in systemic sclerosis. However, the clinical 
association and the occurrence in both, of autoantibodies, immune 
complexes and abnormalities of the cellular immune system, suggest 
very strongly that systemic sclerosis may also be an autoimmune 
disease (Tuffanelli & Winkelmann 1962). 
The findings of this study provide further support for the 
occurrence of vascular injury in systemic sclerosis and more 
interestingly, suggest that such damage may be immunologically 
mediated. In addition to the in vitro demonstration of ADCC of 
vascular endothelial cells, produced by sera from approximately 20% of 
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patients with systemic sclerosis, in vivo evidence of endothelial 
injury has been provided by the detection of elevated plasma levels of 
von Willebrand factor antigen. The presence of immune complexes and 
anti-cardiolipin antibodies in patients with systemic sclerosis are 
additional important findings of this study. Such immunological 
abnormali ties have the potential to cause vascular damage by 
mechanisms additional to ADCC and therefore it is probable that 
systemic sclerosis has a multifactorial pathogenesis similar to SLE. 
No fully satisfactory in vivo model of systemic sclerosis is 
available to study the development of the vascular lesion. The models 
which do exist include experimentally induced graft versus host 
disease in the rat as described by Stastny et al (1963). However, 
although chronic graft versus host disease displays many of the 
pathological features of systemic sclerosis, several features not seen 
in human systemic sclerosis are also observed, including haemolytic 
anaemia, thrombocytopenia and polyarthritis (Stastny et al 1963). In 
addition, the vascular lesions, when present in the graft versus host 
disease model, differ from those occurring in patients with systemic 
sclerosis (Jimenez 1987). ThUS, this system does not provide an ideal 
model to investigate the vascular lesions which occur in systemic 
sclerosis. 
The avian model of systemic sclerosis described by Gershwin et 
al (1981) is probably the best in vivo model so far described. 
However, the vascular lesions once more differ from those seen in 
human systemic sclerosis (Jimenez 1987). Another model, the tight 
skin mouse, although demonstrating the accumulation of collagen seen 
in systemic sclerosis, fails to show the inflammatory and 
immunological features of the disease (Green et al 1976). 
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Hence, in the present study, an in vitro system was adopted to 
investigate the vascular injury occurring in systemic sclerosis. ADCC 
of the vascular endothelium is a pathogenic mechanism which may well 
account for some of the vascular lesions which are seen in patients 
with this disease. The endothelium is an obvious primary target cell 
since it is in direct contact with circulating autoantibodies and 
peripheral blood effector cells which are thus ideally placed to 
interact and produce vascular damage by the mechanism of ADCC. 
However, in spite of this, ADCC has not been widely investigated as a 
pathogenic mechanism in systemic sclerosis, the only previous study 
being that of Penning et al (1983; 1984b). The advantages of the in 
vitro assay used in the present study is that it provides a totally 
homologous human system, in contrast to previously investigated assays 
where various transformed cell lines and chicken red blood cells have 
been used as target cells. Thus, heterologous systems have previously 
been employed despite the requirement for an entirely human system in 
which the mechanism of ADCC can be investigated. 
The present study has demonstrated the occurrence of ADCC 
against cultured venous endothelial cells by sera from approximately 
20% of patients with systemic sclerosis, following co-culture with 
normal human peripheral blood mononuclear cells. These results confirm 
the earlier study by Penning et al (1984b) who reported a similar 
incidence of ADCC caused by sera from these patients. In addition, 
this study has demonstrated, as a new finding, the occurrence of ADCC 
against human arterial endothelial target cells. This finding 
strengthens the view that ADCC is a pathogenic mechanism in systemic 
sclerosis, in view of the prevalence of arterial lesions in systemic 
sclerosis (Campbell and LeRoy 1975). 
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This study has also shed further light on the nature of the 
serum factor capable of causing cytotoxicity of vascular endothelium. 
Preincubation of target cells with serum has revealed that the 
responsible factor is able to bind to and presensitize vascular 
endothelial cells. This finding suggests that an antiendothelial cell 
antibody may be the ADCC inducing factor, and it was further supported 
by evidence obtained following column chromatography of serum. IgG 
prepared by both ion exchange and affinity chromatography, revealed 
that IgG was in fact the responsible cytotoxic factor in the majority 
of cases. In addition, gel filtration chromatography of sera with 
ULTROGEL provided further evidence that ADCC inducing activity of sera 
was restricted to monomeric 7S IgG fractions. These observations 
suggest that antiendothelial cell antibodies may be responsible for 
mediating ADCC against vascular endothelium and have been further 
supported by recent studies which have used an ELISA technique to 
demonstrate the presence of antiendothelial cell antibodies in 
patients with systemic sclerosis. It is also interesting to note that 
the incidence of these antibodies, as detected by ELISA, was similar 
to the incidence of ADCC described in this study (Hashemi et al 1987; 
Baguley et al 1987a; Byron et al 1987). 
A further observation made in this study was that, in the 
majority of cases, sera from patients with systemic sclerosis and SLE 
maintained the ability to mediate ADCC of vascular endothelial cells, 
when investigated serially over a period of two years. Thus, it is 
likely that damage to the vascular endothelium by ADCC is an important 
pathological mechanism occurring throughout the duration of these 
diseases, and may be one of the initial events contributing to the 
fibrosis which is such a characteristic feature of systemic sclerosis. 
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Antiendothelial cell antibodies, which may be responsible for 
the vascular damage observed in systemic sclerosis, have previously 
been described in patients undergoing renal allograft rejection, where 
they may be important in mediating endothelial cell damage (Cerilli et 
al 1977). In addition, antiendothelial cell antibodies have also been 
described in patients with SLE (Cines et al 1984; Shingu and Hurd 1981 
and Le Roux et al 1986). The occurrence of ADCC of vascular 
endothelium by sera from 7 of 49 patients with SLE was also observed 
in this study, and further analysis of these positive sera produced 
findings similar to those obtained with scleroderma sera. Thus, 
antiendothelial cell antibodies appear to mediate ADCC in patients 
with both systemic sclerosis and SLE, although it should be stressed, 
with a much lower incidence in the latter disease. 
In contrast to the ability of sera to presensitize target 
cells, the ability to presensitize effector cells only occurred with 
serum from one patient. Thus, in the majority of sera capable of 
mediating ADCC, "arming" of effector cells as described by Greenberg & 
Shen (1973) did not occur. However, sera from one patient which 
consistently demonstrated ADCC following preincubation of effector 
cells, may be capable of this effector cell "arming", an effect which 
could well be due to the presence of small sized immune complexes. 
Alternatively, a cytokine could cause the activation of effector cells 
to induce endothelial cell cytotoxicity such as occurs with lymphokine 
activated killer cells (Miltenburg et al 1987). It has actually been 
suggested that various cytokines may be involved in the pathogenesis 
of systemic sclerosis. For example, interleukin 1 is capable of 
enhancing fibroblast proliferation (Schmidt et al 1982). Interleukin 2 
may cause the activation of killer cells which could then be an 
additional factor in inducing endothelial cell damage. However 
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induced, endothelial damage would lead to exposure of the underlying 
collagen, with resulting platelet activation and the release of 
various platelet products, such as Transforming growth factor)?, 
serotonin, platelet derived growth factor and pthromboglobulin, which 
would then exert their effects on fibroblasts, as described later 
(Miltenberg et al 1987). 
The occurrence of ADCC against vascular endothelial cells 
demonstrated in this study tended to occur in patients with mild 
rather than extensive visceral involvement. This indicates that ADCC 
could be important in the initial stages of systemic sclerosis. It is 
likely that vascular injury occurs as a primary event (Campbell and 
LeRoy 1975; Norton and Nardo 1970) with fibrosis occurring after the 
initial vascular lesion. Thus ADCC is potentially an important 
pathogenic mechanism in the development of systemic sclerosis. 
In addition to the direct demonstration of vascular damage in 
vitro produced by ADCC, further evidence of endothelial cell injury in 
vivo, has also been provided by the occurrence of elevated plasma 
levels of von Willebrand factor antigen in patients with systemic 
sclerosis. Von Willebrand factor antigen has previously been reported 
as elevated in patients with various diseases characterised by 
vascular damage, for example diabetes, atherosclerosis and renal 
failure (Coller et al 1978; Green et al 1978; Warrel et al 1979). The 
findings described in this study confirm and extend the previous work 
of Kahaleh et al(1981); Pagono et al (1986); and Lee et al (1985) who 
also demonstrated elevated levels of von Willebrand factor antigen in 
patients with systemic sclerosis. However, these earlier studies 
failed to measure all three components of the factor VIII complex (von 
Willebrand factor antigen, factor VIII coagulant and ristocetin 
co-factor) simultaneously. The findings of the present study imply 
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that the elevated levels of von Willebrand factor antigen result from 
endothelial cell damage rather than an acute phase response, since 
factor VIII coagulant levels failed to show a parallel increase. In 
addition, the absence of C reactive protein response in most of the 
patients adds further support that the increase in von Willebrand 
factor antigen is not an acute phase response. Finally, this study 
has shown that ristocetin co-factor activity also fails to parallel 
von Willebrand factor antigen elevation, a finding which provides 
additional support for the view that in vivo endothelial damage occurs 
in patients with systemic sclerosis. 
4 of 10 patients who demonstrated "excess % specific 
cytotoxicity" of )10% also had elevated plasma levels of von 
Willebrand factor antigen. 3 of these patients had the highest disease 
scores in the group of patients capable of mediating ADCC against 
vascular endothelium, and were in the "severe disease" subset of 
patients. Thus the occurrence of both ADCC of vascular endothelial 
cells and the in vivo finding of elevated plasma levels of von 
Willebrand factor antigen appears to define patients characterized by 
extensive visceral involvement. In patients where a correlation was 
not observed between elevated levels of von Willebrand factor antigen 
and ADCC of vascular endothelium, the extent and severity of the 
vascular involvement in these patients may not be sufficient to cause 
increased levels of von Willebrand factor antigen, thus reflecting the 
sensitivity of ADCC as an indicator of vascular damage. 
In add it i on to th e autoimmune mechanism of ADCC which has been 
demonstrated by this study, in 20% of patients with systemic 
sclerosis, various other immunological abnormalities have also been 
detected in these patients. 
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The demonstration of anticardiolipin antibodies in 20-25% of 
patients with systemic sclerosis confirms and extends the results of 
earlier and smaller studies (McHugh et al 1987; Baguley et al 1987b). 
Anticardiolipin antibodies have previously been described in patients 
with SLE, where they distinguish a subset of patients characterised by 
a thrombotic tendency (Harris et al 1983). Although thrombosis is not 
a common feature of systemic sclerosis, it is possible that these 
antiphospholipid antibodies could play a pathogenic role in systemic 
sclerosis and may be responsible, at least in part, for the vascular 
lesions present in patients with this disease, via a mechanism 
different to that occurring in SLE. Such a view is supported by the 
interesting association between the presence of these antibodies, 
severe vascular damage and elevated plasma levels of von Willebrand 
factor antigen, as revealed by this investigation. Another interesting 
finding was the occurrence of anticardiolipin antibodies in 4 of 5 
patients with SLE who also demonstrated ADCC of vascular endothelial 
cells. This association strongly suggests the importance of these 
antibodies in mediating ADCC of vascular endothelial cells and is 
supported by the recent observation of Vismara and co-workers who 
showed that affinity purified anticardiolipin antibodies were able to 
react with intact human endothelial cells (Vismara et al 1988). 
Other mechanisms by which anticardiolipin antibodies could 
mediate vascular injury in systemic sclerosis include damage via 
complement activation (Norberg et al 1987). Even more important, 
anticardiolipin antibodies are capable of reacting with phospholipid 
antigens in platelets, the resulting platelet activation being 
followed by the release of platelet derived products (Cortelazzio et 
al 1987; Khamashta et al 1987). These platelet products would then be 
available to exert their effects on boththe endothelium and underlying 
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vascular and connective tissue. For example, transforming growth 
factor, has been shown to inhi bit endothelial cell prolife ra t i on and 
angiogenesis in vitro (Heimark et al 1986; Takehara et al 1987; Muller 
et al 1987; Frater-Schroder et al 1986).;8 thromboglobulin may also be 
important, in that it causes an inhibition of prostacyclin release 
(Hope 1979) and has been shown to be elevated in systemic sclerosis 
(Kahaleh et al 1982). Transforming growth factor:p also exerts 
effects on fibroblasts and may alter the phenotypic expression of 
these cells to produce more collagen (LeRoy 1987). The recent study by 
Falanga et al (1987) which demonstrated a selective increase in 
glycosaminoglycan synthesis by cultures of fibroblasts obtained from 
patients with systemic sclerosis, is thus potentially relevant. 
In addition, anticardiolipin antibody containing sera have been 
shown to inhibit the release of prostacyclin from cultured endothelial 
cells (Carreras and Vermylen 1982; Schorer and Watson 1987) although 
other studies have failed to confirm these observations (Rustin et al 
1987b; Pet raillolo et al 1987). Thus further work is required in 
this area to clarify these discrepant observations. 
This study has also confirmed previous reports demonstrating the 
occurrence of immune complexes in the sera of patients with systemic 
sclerosis and has reemphasized the association of these immune 
complexes with extensive visceral disease. The formation of immune 
complexes is likely to result from the interaction of autoantibodies 
found in patients with systemic sclerosis, with cellular antigens 
released following cell breakdown. Although there is no direct proof 
that these immune complexes are pathogenic in systemic sclerosis, 
immune complexes occurring in other diseases are known to be capable 
of causing lesions. For example, in SLE, immune complexes are 
frequently found deposited in vessel walls and in the kidney where 
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they give ris e to vas culi t is and lupus nephritis. Immune complexes 
have also been described deposited in the kidneys of patients with 
systemic sclerosis (McGiven et al 1971) where they may give rise to 
vascular injury by various mechanisms. For instance, by interaction 
with components of the complement system, a chemotactic stimulus for 
neutrophils can be produced with resulting tissue and endothelial cell 
damage (Weiss et al 1981). In addition, immune complexes could 
interact with Fc receptors on lymphocytes and produce the effector 
cell arming described by Greenberg and Shen (1973) resulting in 
further vascular damage by the mechanism of ADCC (Penning et al 
1984c). However, in this study, only two patients with systemic 
sclerosis capable of causing ADCC of vascular endothelial cells showed 
elevated levels of immune complexes by the method of C1q binding. 
Although serum from one patient observed in this study was capable of 
such arming of effector cells, with subsequent vascular endothelial 
cell damage, and small sized immune complexes could well be 
responsible for this observation. Finally, immune complexes are also 
capable of reacting with platelet Fc receptors (Penttinen 1977) 
resulting in platelet activation and subsequent release of platelet 
derived products as previously described. In addition, a disturbance 
of prostacyclin release may occur following platelet activation. Thus 
various mechanisms may be initiated by immune complexes, all of which 
could be important in the pathogenesis of systemic sclerosis. 
One of the aims of this study was to investigate patients with 
systemic sclerosis, for the presence of serum factors capable of 
either damaging the vascular endothelium directly, or else capable of 
altering the interaction between platelets and endothelial cells. 
Hence, the production of prostacyclin by endothelial cells during 
incubation with control and scleroderma serum was investigated. A 
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recent study by Rustin et al (1987a) reported diminished agonist 
stimulated prostacyclin release by cultured endothelial cells 
following incubation with sera from patients with systemic sclerosis. 
However, in contrast to these findings, the experiments performed in 
this study failed to demonstrate such an inhibition, an observation 
which was also made in the preliminary study of Evans et al (1984). 
However, prostacyclin is likely to playa key role in the 
pa thogenesis of systemic sclerosis. 
occurring in systemic sclerosis, 
Endothelial cell injury, 
whether it is mediated 
immunologically via antiendothelial cell antibodies, anticardiolipin 
anti bodies and immune complexes, may well resul t in al tered 
prostacyclin release either directly, or via platelet effects 
occurring as a result of endothelial cell injury. Altered 
prostacyclin release may exert further effects on the aggregation of 
platelets resulting in the release of various platelet products. 
It is likely that the failure to detect any alterations in 
prostacyclin release observed in this study, may be due to the large 
variability in endothelial cell cultures derived from different 
umbilical cords. In addition, serum may produce a masking effect by 
supplying exogenous arachidonic acid for the synthesis of 
prostacyclin. The apparently differing results of the present study 
and those of Rustin et al (1987a) may not in fact be conflicting since 
in the study of Rustin et al (1987a) the release of prostacyclin was 
not measured during incubation with sera, but in a subsequent agonist 
stimulated release. It is possible that the prolonged stimulation of 
prostacyclin release, or even an independent cytotoxic effect, 
occurring in the presence of test sera, may cause a decrease in the 
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subsequent ability of these cells to respond to an agonist. Thus 
further studies are required in order to characterize any prostacyclin 
inbalance which may occur in systemic sclerosis. 
Finally, perhaps the single most important conclusion produced 
in this study is that multiple pathogenic mechanisms are likely to be 
involved in the pathogenesis of systemic sclerosis. Thus, of all the 
patients investigated, 75% exhibited abnormalities such as ADCC of 
endothelium, the presence of circulating immune complexes and elevated 
levels of von Wille brand factor antigen and the occurrence of 
anticardiolipin antibodies which could well be capable of causing 
vascular damage. All these immunological abnormalities are also 
present to varying degrees in the related connective tissue disease 
of SLE, in which it is known that multiple autoimmune mechanisms are 
responsible for the differing disease manifestations. 
This study has produced clear evidence in support of a vascular 
pathogenesis for systemic sclerosis, which arises as a result of 
autoimmune mechanisms. These observations carry a therapeutic 
implication as well as stimulating further investigations of the 
multiple mechanisms responsible for this highly complex disease. 
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6.2 Further work 
The work described in this thesis provides a basis for further 
investigation, which is discussed below. 
Evidence has been presented that antiendothelial cell antibodies 
may be responsible for some of the vascular pathology seen in patients 
with systemic sclerosis. Further evidence to confirm the role of 
these antibodies could be provided by using the ELISA technique 
recently described (Hashemi et al 1987; Baguley et al 1987a; Byron et 
al 1987). Final proof could then be obtained by affinity 
chromatography. The ability of the purified antibody to produce ADCC 
of vascular endothelial cells could then be tested and fully 
confirmed. In addition, the antibody subclass of the involved 
antiendothelial antibodies should also be defined, using purification 
techniques. 
The antigenic determinants present on endothelial cells which 
are recognised by specific antibodies also require elucidation. 
Immunoblotting techniques using solubilized cultured endothelial cells 
and antiendothelial cell antibody containing sera could provide 
information of this nature. 
The mechanism of ADCC, in particular, the nature of the 
responsible effector cells and the Fc receptors involved in mediating 
the reaction, also require further investigation. Various monoclonal 
antibodies directed against the different Fc receptors exist, and 
these could be used to eliminate or block the action of corresponding 
effector cell populations. In addition to peripheral blood 
mononuclear cells, other effector cell populations, for example 
neutrophils, have been shown to mediate ADCC (Shen et al 1987). These 
cells could be isolated and used in ADCC reactions against endothelial 
cells. In addition, neutrophils may produce endothelial damage via 
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oxygen radicals (Weiss et al 1981; Varani et al 1985; Sacks et al 
1978). This phenomenon should also be investigated as a possible 
pathogenic mechanism in systemic sclerosis. 
Cytokines have been shown to enhance ADCC (Ralph 1984). Since 
altered levels of Interleukin 1 have been reported in patients with 
systemic sclerosis, the possible involvement of this factor in ADCC 
reactions would be an interesting study. In addition, various growth 
factors, including platelet release products such as transforming 
growth factor f> and f thromboglobulin exert effects on the vascular 
endothelium (Heimark et al 1986; Takehara et al 1987; Hope et al 
1979). These and other factors require further investigation to 
determine the precise mechanisms involved in their actions on 
endothelial cells. 
Other diseases which feature a vascular pathology should be 
investigated for the occurrence of ADCC against endothelial cells. 
Although an earlier study failed to show any cytotoxicity of 
endothelium in patients with atherosclerosis (Penning 198~, ADCC of 
vascular endothelium is also produced in SLE, although to a lesser 
extent than in systemic sclerosis, and may well be found in a variety 
of other autoimmune and connective tissue diseases, in particular 
rheumatoid arthritis. A recent report by Fattorossi et al (1988) 
demonstrated the occurrence of antiendothelial cell antibodies in 
patients with autoimmune hypoparathyroidism, therefore sera from 
patients with this disease should also be examined for the occurrence 
of ADCC of vascular endothelial cells. 
In addition to the use of human umbilical vein and arterial 
endothelial cells, there is a need to investigate microvascular target 
cells in ADCC reactions, especially as the vascular lesion occurring 
in systemic sclerosis is prominent in the microcirculation (Kahaleh 
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and LeRoy 1988). Human capillaries have been isolated from various 
sites, including the skin and foreskin (Folkman et al 1979; Sherer et 
al 1980; Davison et al 1980, 1981; Marks 1985). However, at the 
present time, human capillary endothelial cell culture is in its 
infancy, and improved techniques for the isolation and growth of these 
cells will be necessary to obtain the numbers necessary for their use 
as target cells in ADCC assays. Nevertheless, large vessel endothelial 
cells from human adult tissue, for example the lung, could perhaps be 
used to provide a more relevant target cell compared with those 
derived from umbilical cords. 
The effect, on endothelial cells, of the anticardiolipin 
antibodies detected in this investigation also requires further 
investigation. Anticardiolipin antibodies can be affinity purified by 
absorption to cardiolipin liposomes followed by elution with 1M sodium 
iodide (Alving and Richards 1977). Antibodies purified in this way 
could then be tested in ADCC and other cytotoxicity assays and perhaps 
also studied for their effects on prostacyclin production by 
endothelium. Such experiments on prostacyclin production could be 
combined with further studies on the effect of platelet poor plasma on 
endothelium in order to minimize the effect of platelet derived 
arachidonic acid, on the synthesis of prostacyclin. In addition, the 
effect on stimulated prostacyclin release could be investigated, as 
used in the study by Rustin et al (1987a) using, however, more 
physiologically relevant agonists, such as thrombin and bradykinin, 
rather than the calcium ionophore originally used by Rustin et al 
( 1987a) • 
There is, therefore, a vast amount of further work to be carried 
out in order to unfold the complex mechanisms involved in the 
pathogenesis of systemic sclerosis. 
169 
APPENDICES 
170 
APPENDIX I 
Double j 1IIIIIJnodif'f'usion (Ochter lony ) 
This technique was used for the qualitative determination of 
immunoglobulins 
Principle 
In this technique, antigen and antibody are allowed to migrate 
towards each other through a gel and a line of precipitation occurs 
where they meet. The precipitate is soluble in excess antigen, hence 
a sharp line is formed at equivalence, the position of which is 
determined by the concentration of antigen and antibody in the agar. 
Procedure 
Plates were coated with 1% agar in PBS and allowed to set at 
40 c. Wells were punched into the agar using a 5pl borer attached to a 
suction pump. Antiserum was added to the centre well and samples 
placed in the outer wells. The plate was then left overnight at room 
temperature in a wet box. A single line of precipitation occured at 
the sight of antigen and antibody interaction. 
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APPENDIX II 
Radial j nwunodif'f'usion (Mancini ) 
This technique was used for the quantitative determination of 
immunoglobulins. 
Principle 
Single radial immunodiffusion is a diffusion in gel reaction in 
which antiserum is incorporated into a thin layer of agar on a plate. 
Antigen is then placed into wells cut into the plate. As the antigen 
diffuses radially, a precipitation ring forms around the well and 
moves outwards. At equi valence, the ring becomes stationary. The 
diameter of this ring is equivalent to the antibody concentration. A 
standard curve is constructed using known antibody concentrations and 
thus the unknown concentration can be determined by reference to this 
standard curve. 
Procedure 
Antisera was added to 6% PEG in PBS, which had been heated to 
56 0 C. This was mixed with an equal volume of 2% agarose in PBS also 
at 56 0 C. The mixture was then poured onto a level plate which had 
previously been precoated with 0.5% agar. The coated plate was then 
allowed to cool at 40 C in a wet box. 16 wells were evenly punched 
into the gel using a 5pl borer. 
IgG standards and dilutions of test samples were added to the 
wells, and the plate was then incubated in a covered wet box at room 
temperature for 3-4 days. Following incubation, the plate was soaked 
in 0.9% saline over night, then rinsed in water, and allowed to dry. 
Plates were then stained and the ring diameters were read using a 
vernier micrometer. Immunoglobulin concentrations were determined by 
plotting the diameter on a linear scale, against the log of the 
antigen concentration. 
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APPENDIX III 
Lowry Method of Protein Determination 
Principle 
The assay used for the determination of protein content was 
adopted from the method of Lowry (1951). The method involves a 
two-step process in which protein is first reduced with an alkaline 
copper compound and then causes the reduction of a 
phosphomolybdic-phosphotungstic reagent. Protein is then quantified 
colorimetrically by measurement of changes in absorbance at 750nm. 
Procedure 
Human umbilical vein endothelial cells were hydrolysed overnight 
in situ with 1N sodium hydroxide. 100ul distilled water was added to 
100pl test sample. A reference standard curve, ranging from 0-100 pg 
protein, was prepared with bovine serum albumin as the standard. 
Standard were diluted to 100pl with distilled water and the volume 
adjusted to 200pl with 1N sodium hydroxide. Each test and standard 
was reformed in duplicate. 1ml solution A was added to each test and 
standard and allowed to stand at room temperature for 10 minutes. 
100pl solution B was then added, the samples mixed and left for a 
further 30 minutes. Optical density was read at 750nm in a Gilford 
spectrophotometer. 
Solution A 
Solution B 
100ml 2% sodium carbonate 
1ml 2% sodium potassium tartarate 
1ml 2% copper carbonate (CUS04.5H20) 
1:1 v:v Folins reagent:distilled water 
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APPENDIX IV 
Pattern of visceral involvement in patients with systemic sclerosis 
who were examined for cytotoxicity of vascular endothelium. 
Age Sex Visceral involvement Disease (years) score 
Severe Disease 
61 M Skin, oesophagus, lung, small bowel, 17 
heart, polymyositis 
39 F Skin, oesophagus, lung, heart, kidney 14 
68 F Skin, oesophagus, lung, heart, kidney 14 
36 M Skin, oesophagus, lung, heart, polymyositis 14 
73 F Skin, oesophagus, lung, heart 11 
74 F Skin, oesophagus, lung, arthritis 11 
17 F Skin, oesophagus, lung, small bowel 1 1 
64 F Skin, oesophagus, lung, small bowel 11 
79 F Skin, oesophagus, lung 8 
30 F Skin, oesophagus, lung 8 
68 M Skin, oesophagus, lung 8 
F Skin, oesophagus, lung 8 
78 F Skin, oesophagus, lung 8 
46 F Skin, oesophagus, lung 8 
53 F Skin, oesophagus, lung 8 
77 F Skin, oesophagus, lung 8 
69 M Skin, oesophagus, lung 8 
49 F Skin, oesophagus, lung 8 
59 F Skin, oesophagus, kidney 8 
66 F Skin, lung, heart 8 
60 M Skin, oesophagus, lung 7 
50 F Skin, lung 6 
41 F Skin, oesophagus 6 
Mild disease 
43 F Skin, oesophagus 5 
76 F Skin, oesophagus 5 
70 F Skin, oesophagus 5 
53 M Skin, oesophagus 5 
66 F Skin, oesophagus 5 
62 F Skin, oesophagus 5 
63 F Skin, oesophagus 5 
66 F Skin, oesophagus 5 
48 F Skin, oesophagus 5 
39 M Skin, oesophagus 5 
63 F Skin, oesophagus 5 
34 F Skin 3 
49 F Skin 2 
54 F Skin 2 
2 63 F Skin 2 60 F Skin 2 29 F Skin 2 67 F Skin 
2 40 F Skin 
2 43 F Skin 2 43 F Skin 2 49 F Skin 
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APPENDIX V 
Pattern of system involvement in patients with SLE who were examined 
for cytotoxicity of vascular endothelium. 
Age 
(years) 
49 
26 
45 
38 
41 
75 
47 
57 
31 
37 
52 
44 
23 
50 
57 
24 
64 
63 
32 
46 
34 
34 
42 
43 
41 
56 
21 
58 
61 
29 
41 
30 
43 
45 
65 
22 
57 
40 
49 
Sex 
F 
F 
F 
F 
F 
M 
M 
F 
F 
F 
F 
F 
F 
F 
F 
F 
M 
F 
F 
F 
F 
M 
M 
F 
F 
F 
F 
M 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
F 
Visceral involvement 
Joints, lung, heart, gut 
Joints, cerebral, skin 
Joints, cerebral, renal 
Joints, renal 
Joints, skin 
Joints, renal, splenomegaly 
Joints, lung 
Joints, splenomegaly, polymyositis 
Cerebral, renal, skin 
Joints, lung, skin 
Joints, lung, heart 
Joints, lung, heart 
Joints, lung 
Lung, heart, cerebral 
Renal, skin 
Joints, lung 
Heart, skin, haemolysis 
Joints, splenomegaly, anaemia 
Lung, neuropathy 
Cerebral 
Lung, cerebral, DVTs 
Joints, lung, heart 
Joints, lung 
Joints, heart, skin 
Joints, lung, heart, renal 
Joints, cerebral, DVTs 
Joints, heart, neuropathy 
Skin, DVTs 
Joints, lung, cerebral, thrombocytopenia 
Abortion 
Joints, lung, gut, skin 
Lung, renal, skin 
Joints, skin 
Joints, skin, myopathy 
Joints, cerebral 
Renal, skin 
Joints, skin 
Splenomegaly, optic neuritis, arthritis 
Cerebral, gut, arthritis 
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APPENDIX VI 
List of suppliers 
Tissue culture 
Minimum essential medium (MEM) 
Medium 199 
HEPES 
Sodium bicarbonate 
Penicillin 
Streptomycin sulphate 
Fungizone 
L-glutamine 
Gelatin 
Collagenase 
Typsin 
EDTA 
Foetal calf serum 
Thyoglycolate 
T25 & T75 flasks (Nunclon) 
96 well microtitre plates (Nunclon) 
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Flow laboratories 
Rickmansworth 
Hertfordshire 
England 
Flow laboratories 
Boehringer-Mannheim 
Lewes 
E Sussex 
England 
BDH 
Poole 
England 
Glaxo laboratories 
Greenford 
England 
Glaxo laboratories 
ER Sqibb & sons 
Princeton 
USA 
Flow laboratories 
Sigma chemical 
Poole 
England 
Sigma chemical 
Sigma chemical 
Sigma chemical 
Gibco 
Paisley 
Scotland 
Oxoid 
Basingstoke 
Hampshire 
England 
Gibco 
Gibco 
Co 
Co 
Co 
Co 
24 well plates (Falcon) 
Staining 
Coverslips (13mm round) 
Peroxidase labelled anti-human 
von Willebrand factor antigen 
Peroxidase labelled rabbit 
anti-mouse immunoglobulin 
DAB 
Hydrogen peroxide 
DPX mountant (microscopical reagent) 
Trypan blue 
Haemalin 
Giemsa 
6-keto-PGF1~ radio-immunoassay 
Tritiated 6-keto-PGF1~ 
6-keto-PGF1~ antibody 
Tris hydrochloric acid 
Bovine serum albumin 
dextran T70 
Norit A charcoal 
Optiphase safe scintillant 
1 
Beckton & Dickinson 
Cowley 
England 
Miles scientific 
Naperville 
USA 
Dakopatts 
Glostrup 
Denmark 
Dakopatts 
Sigma chemical Co 
Sigma chemical Co 
BDH 
BDH 
BDH 
BDH 
NEN 
Dupont (UK) Ltd. 
Stevenage 
Hertfordshire 
England 
Dr M Greaves 
Dept Haematology 
Hallamshire Hospital 
Sheffield 
England 
Sigma chemical Co 
Sigma chemical Co 
Pharmacia LKB 
Milton Keynes 
England 
BDH 
Pharmacia LKB 
Column chromatography 
ULTROGEL 
DEAE-Sepharose 
Staphylococcal Protein A-sepharose 
Cytotoxicity assays 
Sodium chromate - 51Cr 
Saponin (biochemicals) 
Lymphoprep 
Nycodenz monocytes 
Carbonyl iron powder 
Formic acid 
Heparin 
Biochemicals 
Pharmacia-LKB 
Whatman chromatography 
services 
Wirral 
Cheshire 
England 
Bio-processing Ltd 
Consett 
England 
NEN & 
Amersham Internatinal 
Amersham 
England 
BDH 
Nycomed (UK) Ltd 
Sheldon 
Birmingham 
England 
Nycomed 
GAF (GB) Ltd 
Wythenshawe 
Manchester 
England 
BDH 
CP Pharmaceuticals Ltd 
Wrexham 
England 
Biochemicals for buffers etc were obtained from BDH, and were ANALAR 
grade 
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